{
  "letters": 1041538,
  "pages": 229,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "AstraZeneca",
    "major_industry": "Pharmaceuticals",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 1,
          "title": "AstraZeneca Annual Report and Form 20-F Information 2022",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca"
            },
            {
              "key": "Report Type",
              "value": "Annual Report"
            },
            {
              "key": "Form",
              "value": "20-F"
            },
            {
              "key": "Year",
              "value": "2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 6,
          "title": "AstraZeneca at a Glance",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$44.4bn"
            },
            {
              "key": "Oncology Revenue",
              "value": "35%"
            },
            {
              "key": "BioPharmaceuticals Revenue",
              "value": "45%"
            },
            {
              "key": "Rare Disease Revenue",
              "value": "16%"
            },
            {
              "key": "Other Medicines Revenue",
              "value": "4%"
            },
            {
              "key": "US Revenue",
              "value": "40%"
            },
            {
              "key": "Emerging Markets Revenue",
              "value": "26%"
            },
            {
              "key": "Europe Revenue",
              "value": "20%"
            },
            {
              "key": "Established Rest of World Revenue",
              "value": "13%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 11,
          "title": "Healthcare in a Changing World",
          "data": [
            {
              "key": "Global pharmaceutical sales growth",
              "value": "8.4% in 2022"
            },
            {
              "key": "Expected annual healthcare spending growth (2021-2026)",
              "value": "5.7%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 20,
          "title": "Therapy Area Review",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca"
            },
            {
              "key": "Segment",
              "value": "Oncology"
            },
            {
              "key": "Strategic Focus",
              "value": "Redefine cancer care through science"
            },
            {
              "key": "Goals",
              "value": "Discover, develop and deliver life-changing treatments to transform outcomes"
            },
            {
              "key": "Key Area",
              "value": "Epigenetic modulation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 25,
          "title": "Financial Performance Overview",
          "data": [
            {
              "key": "Total Revenue Cardiovascular, Renal & Metabolism 2021",
              "value": "$8,103m"
            },
            {
              "key": "Total Revenue Cardiovascular, Renal & Metabolism 2020",
              "value": "$7,139m"
            },
            {
              "key": "Total Revenue growth Cardiovascular, Renal & Metabolism",
              "value": "up 13% (19% at CER)"
            },
            {
              "key": "Total Revenue Respiratory & Immunology 2021",
              "value": "$6,049m"
            },
            {
              "key": "Total Revenue Respiratory & Immunology 2020",
              "value": "$5,375m"
            },
            {
              "key": "Total Revenue growth Respiratory & Immunology",
              "value": "down 1% (up 3% at CER)"
            },
            {
              "key": "Total Revenue Vaccines & Immune Therapies 2021",
              "value": "$4,779m"
            },
            {
              "key": "Total Revenue Vaccines & Immune Therapies 2020",
              "value": "$669m"
            },
            {
              "key": "Total Revenue growth Vaccines & Immune Therapies",
              "value": "up 1% (8% at CER)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 32,
          "title": "Acquisition of Alexion Pharmaceuticals",
          "data": [
            {
              "key": "Acquisition Date",
              "value": "21 July 2021"
            },
            {
              "key": "Acquirer",
              "value": "AstraZeneca"
            },
            {
              "key": "Acquired",
              "value": "Alexion Pharmaceuticals, Inc."
            },
            {
              "key": "Reporting Year",
              "value": "2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 33,
          "title": "Strategic Report Total Revenue",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$7,053m up 4% (10% at CER)"
            },
            {
              "key": "2021 Revenue",
              "value": "$3,110m"
            },
            {
              "key": "2020 Revenue",
              "value": "$38m"
            },
            {
              "key": "Growth Rates Note",
              "value": "Growth rates for medicines acquired with Alexion have been calculated on a pro forma basis compared with the corresponding period in the prior year."
            },
            {
              "key": "Koselugo Revenue Change",
              "value": "Included within Rare Disease for 2022 reporting, previously within Oncology."
            },
            {
              "key": "Andexxa Revenue Change",
              "value": "Included within BioPharmaceuticals: Cardiovascular, Renal & Metabolism for 2022 reporting, previously within Rare Disease."
            },
            {
              "key": "C5 Franchise Growth",
              "value": "Sustained growth in C5 franchise including conversion to Ultomiris in PNH and aHUS."
            },
            {
              "key": "Ultomiris Launch Note",
              "value": "Launch of Ultomiris in gMG in the US, Japan and EU."
            },
            {
              "key": "Koselugo Approval Note",
              "value": "Koselugo approved in Japan for pediatric patients with plexiform neurofibromas."
            },
            {
              "key": "Ultomiris Phase III Trial Note",
              "value": "Ultomiris met the primary endpoint in CHAMPION-NMOSD Phase III trial."
            },
            {
              "key": "Acquisition Note",
              "value": "Acquired LogicBio Therapeutics, Inc."
            },
            {
              "key": "Rare Disease Market Note",
              "value": "400 million people affected; 5% have approved treatments."
            },
            {
              "key": "Annual Worldwide Market Value Source",
              "value": "IQVIA."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 33,
          "title": "Rare Disease Medications Performance Summary",
          "data": [
            {
              "key": "Soliris (eculizumab) Sales",
              "value": "$3,762m, down 11% (5% at CER)"
            },
            {
              "key": "Ultomiris (avulizumab) Sales",
              "value": "$1,965m, up 34% (42% at CER)"
            },
            {
              "key": "Strensiq (asfotase alfa) Sales",
              "value": "$95m, up 16% (18% at CER)"
            },
            {
              "key": "Koselugo (selumetinib) Sales",
              "value": "$208m, up 93% (96% at CER)"
            },
            {
              "key": "Kanuma (sebelipase alfa) Sales",
              "value": "$160m, up 16% (19% at CER)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 36,
          "title": "Business Review and R&D Focus",
          "data": [
            {
              "key": "Description",
              "value": "A business review page focusing on strategic priorities in R&D and commercial functions, emphasizing the delivery of life-changing medicines through innovation."
            },
            {
              "key": "Strategic Focus",
              "value": "Reinforcement of science and innovation from discovery through development and life-cycle management."
            },
            {
              "key": "Therapy Areas",
              "value": "Oncology, BioPharmaceuticals (CVRM, R&I, V&I), and Rare Disease."
            },
            {
              "key": "Performance Summary",
              "value": "Summary and performance indicators related to R&D, commercial strategy, and new medicines development."
            },
            {
              "key": "Commitment",
              "value": "Strengthening commitment to people, sustainability, and a focus on ethical practices."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 44,
          "title": "AstraZeneca Operations and Supply Chain Overview",
          "data": [
            {
              "key": "Business Continuity",
              "value": "Activated business continuity plans to maintain supply of medicines and mitigate disruption."
            },
            {
              "key": "Supply Chain Finance Program",
              "value": "Supports cash flow for suppliers, managed by Taulia Inc."
            },
            {
              "key": "Audits Conducted",
              "value": "42 audits on high-risk commercial suppliers."
            },
            {
              "key": "Market Launches",
              "value": "Delivered 198 successful market launches in 2022."
            },
            {
              "key": "Manufacturing Site Developments",
              "value": "Announced intention to build new inhalation site in Qingdao, China."
            },
            {
              "key": "Site Reduction",
              "value": "Ceasing activities in Reims, France, and sold Ohio site to National Resilience, Inc."
            },
            {
              "key": "Employment Transition",
              "value": "Continued employment for over 500 people post-site sale."
            },
            {
              "key": "Regulatory Approvals",
              "value": "Approval for new drug substance facility in Athlone."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 45,
          "title": "Acquisitions and Strategic Partnerships",
          "data": [
            {
              "key": "Acquisition of CinCor Pharma, Inc.",
              "value": "AstraZeneca will pay $26 per share plus $10 per share contingent on specific regulatory events, totaling approximately $1.8 billion."
            },
            {
              "key": "Acquisition of Neogene Therapeutics, Inc.",
              "value": "Initial payment of $200 million with up to $120 million in additional contingent considerations."
            },
            {
              "key": "Acquisition of TeneoTwo",
              "value": "Acquired for an upfront payment of $100 million with additional contingent milestone payments."
            },
            {
              "key": "Licensing agreement with Neurimmune AG for NI006",
              "value": "Upfront payment of $30 million with potential additional payments of up to $730 million."
            },
            {
              "key": "Licensing transaction with RQ Biotechnology Limited",
              "value": "Transaction for pre-clinical mAbs against SARS-CoV2."
            },
            {
              "key": "Strategic research collaboration with Illumina",
              "value": "Collaboration to improve efficiency in drug target discovery."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 72,
          "title": "Business combinations",
          "data": [
            {
              "key": "Acquisition Target",
              "value": "LogicBio Therapeutics, Inc."
            },
            {
              "key": "Location",
              "value": "Lexington, MA, US"
            },
            {
              "key": "Total Consideration",
              "value": "$72 million"
            },
            {
              "key": "Cash Paid on Completion",
              "value": "$68 million"
            },
            {
              "key": "Outstanding Options",
              "value": "$4 million"
            },
            {
              "key": "Acquisition Date",
              "value": "16 November 2022"
            },
            {
              "key": "Acquisition Method",
              "value": "Acquisition method of accounting in accordance with IFRS 3"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 72,
          "title": "Previous Acquisition",
          "data": [
            {
              "key": "Acquisition Target",
              "value": "Alexion"
            },
            {
              "key": "Consideration",
              "value": "$41,058 million"
            },
            {
              "key": "Acquisition Date",
              "value": "21 July 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 79,
          "title": "Corporate Governance Overview",
          "data": [
            {
              "key": "Document Title",
              "value": "AstraZeneca Annual Report & Form 20-F Information 2022"
            },
            {
              "key": "Description",
              "value": "A compilation of corporate imagery featuring a dominant scientific visualization of DNA strands in pink and purple colors, accompanied by smaller supporting images showing laboratory settings and digital health technology. A table of contents is visible on the left side listing various corporate governance sections including Board Reports, Committee Reports, and Remuneration information."
            },
            {
              "key": "Document Type",
              "value": "Corporate Annual Report"
            },
            {
              "key": "Visual Elements",
              "value": "DNA visualization, Laboratory scene, Digital health device, Table of contents"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 99,
          "title": "Committee overview and composition",
          "data": [
            {
              "key": "Committee Name",
              "value": "Audit Committee"
            },
            {
              "key": "Purpose",
              "value": "Monitor integrity of financial reporting, review internal controls and risk management systems."
            },
            {
              "key": "Key Responsibilities",
              "value": "Financial performance oversight, internal and external audit processes oversight."
            },
            {
              "key": "Key Risks Identified",
              "value": "Impact of Ukraine conflict, IT and cybersecurity risks."
            },
            {
              "key": "Members Qualifications",
              "value": "Recent relevant financial experience, independent as per governance codes."
            },
            {
              "key": "Recent Discussions",
              "value": "Valuation of pension arrangements, impairment of intangible assets, financial reporting considerations for significant transactions."
            },
            {
              "key": "Assurance Provided By",
              "value": "Stress test analyses of profitability, liquidity, and funding metrics."
            },
            {
              "key": "New Risks",
              "value": "Active and emerging risks discussed quarterly."
            },
            {
              "key": "Impact of External Factors",
              "value": "Increased significance of cyber risk and economic pressures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 139,
          "title": "Responsibilities for the Financial Statements and the Audit",
          "data": [
            {
              "key": "Directors' Responsibilities",
              "value": "Responsible for the preparation of the financial statements in accordance with the applicable framework and internal control."
            },
            {
              "key": "Evaluation Procedures",
              "value": "Evaluation and testing of the design and operating effectiveness of management’s controls."
            },
            {
              "key": "Responsibilities for Audit",
              "value": "Obtaining reasonable assurance that financial statements are free from material misstatement."
            },
            {
              "key": "Audit Appointment",
              "value": "Appointed on 27 April 2017 to audit the financial statements for the year ended 31 December 2017."
            },
            {
              "key": "Irregularities",
              "value": "Instances of non-compliance with laws and regulations, and audits to detect material misstatements including fraud."
            },
            {
              "key": "Audit Assessment",
              "value": "Identified principal risks of non-compliance related to patent protection, product safety, anti-bribery laws, and tax legislation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 146,
          "title": "Group Accounting Policies",
          "data": [
            {
              "key": "Cost of Sales",
              "value": "Costs recognized as revenue is recognized, including manufacturing costs, royalties, provisions for inventories, and foreign exchange gains/losses."
            },
            {
              "key": "Research and Development",
              "value": "Research expenditure charged to profit and loss in the year incurred; internal development capitalized if recognition criteria are met."
            },
            {
              "key": "Intangible Assets",
              "value": "Stated at cost, less amortisation and impairments; subject to annual impairment testing."
            },
            {
              "key": "Employee Benefits",
              "value": "Accounts for pensions under IAS 19; obligations measured based on projected unit credit method."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 147,
          "title": "Taxation, Leases, and Property, Plant and Equipment",
          "data": [
            {
              "key": "Surplus recognised asset",
              "value": "Limited to present value of available future refunds from the plan."
            },
            {
              "key": "Taxable profit",
              "value": "Differs from reported profit due to exclusions from taxation."
            },
            {
              "key": "Deferred tax",
              "value": "Provided using balance sheet liability method for temporary differences."
            },
            {
              "key": "Uncertain tax positions",
              "value": "Liabilities require management judgement of potential tax audit exposures."
            },
            {
              "key": "Group’s lease arrangements",
              "value": "Principally for property and global car fleet."
            },
            {
              "key": "Right-of-use asset",
              "value": "Measured at cost, including initial lease liabilities."
            },
            {
              "key": "Property, plant and equipment policy",
              "value": "Depreciated over estimated useful life on straight-line basis."
            },
            {
              "key": "Estimated useful life of assets",
              "value": "Ranges from 10 to 50 years for buildings, and 3 to 15 years for equipment."
            },
            {
              "key": "Impairment testing",
              "value": "Conducted when indications of non-recoverable carrying values are present."
            },
            {
              "key": "Discount rate for lease payments",
              "value": "Based on incremental borrowing rates due to implicit rates not being identifiable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 148,
          "title": "Group Accounting Policies and Business Combinations",
          "data": [
            {
              "key": "Incremental Borrowing Rate",
              "value": "Risk-free interest rate adjusted for credit risk."
            },
            {
              "key": "Lease Payments",
              "value": "Allocated between principal and finance cost."
            },
            {
              "key": "Short-term Leases",
              "value": "Leases with a term of 12 months or less, recognised as an expense."
            },
            {
              "key": "Low-value Leases",
              "value": "Assets valued at $5,000 or less."
            },
            {
              "key": "Acquisition Assessment",
              "value": "Management assesses if acquired assets are a business or an asset."
            },
            {
              "key": "Fair Value Attributions",
              "value": "Fair values are attributed to identifiable assets and liabilities."
            },
            {
              "key": "Contingent Liabilities",
              "value": "Recorded at fair value unless reliably measured."
            },
            {
              "key": "Goodwill Calculation",
              "value": "Difference between fair value of consideration and net assets."
            },
            {
              "key": "Control Definition",
              "value": "Exposure to variable returns combined with power to affect returns."
            },
            {
              "key": "Inventory Valuation",
              "value": "Stated at lower of cost and net realisable value."
            },
            {
              "key": "Assets Held for Sale",
              "value": "Classified when recovery through sale is highly probable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 152,
          "title": "Collaboration Revenue",
          "data": [
            {
              "key": "Enhertu: alliance revenue'",
              "value": "2022 $m: 519, 2021 $m: 193, 2020 $m: 94"
            },
            {
              "key": "Tezspire: alliance revenue'",
              "value": "2022 $m: 79, 2021 $m: -, 2020 $m: -"
            },
            {
              "key": "Roxadustat: alliance revenue!",
              "value": "2022 $m: 5, 2021 $m: 6, 2020 $m: 30"
            },
            {
              "key": "Lynparza/Koselugo (MSD) - regulatory milestones",
              "value": "2022 $m: 355, 2021 $m: -, 2020 $m: 160"
            },
            {
              "key": "Lynparza/Koselugo (MSD) - sales-related milestones",
              "value": "2022 $m: -, 2021 $m: 400, 2020 $m: 300"
            },
            {
              "key": "Tralokinumab: sales milestone",
              "value": "2022 $m: 110, 2021 $m: -, 2020 $m: -"
            },
            {
              "key": "Vaxzevria: royalties",
              "value": "2022 $m: 76, 2021 $m: 64, 2020 $m: -"
            },
            {
              "key": "Other royalty income",
              "value": "2022 $m: 72, 2021 $m: 74, 2020 $m: 62"
            },
            {
              "key": "Nexium: sale of rights",
              "value": "2022 $m: 62, 2021 $m: 75, 2020 $m: -"
            },
            {
              "key": "Other Collaboration Revenue",
              "value": "2022 $m: 1353, 2021 $m: 876, 2020 $m: 727"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 155,
          "title": "Tax Breakdown Statement",
          "data": [
            {
              "key": "Current tax - Current year",
              "value": "1,823"
            },
            {
              "key": "Current tax - Adjustment to prior years",
              "value": "(187)"
            },
            {
              "key": "Current tax - Total",
              "value": "1,636"
            },
            {
              "key": "Deferred tax - Origination and reversal of temporary differences",
              "value": "(2,563)"
            },
            {
              "key": "Deferred tax - Adjustment to prior years",
              "value": "135"
            },
            {
              "key": "Deferred tax - Total",
              "value": "(2,428)"
            },
            {
              "key": "Taxation (charge)/credit recognised in profit",
              "value": "(792)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 155,
          "title": "Current and deferred tax",
          "data": [
            {
              "key": "Items that will not be reclassified to profit or loss - Total",
              "value": "36"
            },
            {
              "key": "Remeasurement of the defined benefit liability - Total",
              "value": "(231)"
            },
            {
              "key": "Equity investments at fair value - Total",
              "value": "15"
            },
            {
              "key": "Movement in deferred taxes - Total",
              "value": "-"
            },
            {
              "key": "Taxation (charge)/credit recognised in Other comprehensive income",
              "value": "(143)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 162,
          "title": "Lease Liabilities and Asset Values Overview",
          "data": [
            {
              "key": "Period",
              "value": "2022 Total Lease Liabilities"
            },
            {
              "key": "Within one year",
              "value": "-228"
            },
            {
              "key": "Later than one year and not later than five years",
              "value": "-549"
            },
            {
              "key": "Later than five years",
              "value": "-176"
            },
            {
              "key": "Total lease liabilities",
              "value": "-953"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 162,
          "title": "Asset Cost, Depreciation and Net Book Value Summary",
          "data": [
            {
              "key": "At 1 January 2020",
              "value": "851"
            },
            {
              "key": "At 31 December 2020",
              "value": "666"
            },
            {
              "key": "At 31 December 2021",
              "value": "988"
            },
            {
              "key": "At 31 December 2022",
              "value": "942"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 163,
          "title": "Goodwill and Amortization Schedule",
          "data": [
            {
              "key": "Cost At 1 January",
              "value": "2022: 20311, 2021: 12164, 2020: 11982"
            },
            {
              "key": "Additions through business combinations (Note 27)",
              "value": "2022: 15, 2021: 8287, 2020: 0"
            },
            {
              "key": "Exchange and other adjustments",
              "value": "2022: -195, 2021: -140, 2020: 182"
            },
            {
              "key": "At 31 December",
              "value": "2022: 20131, 2021: 20311, 2020: 12164"
            },
            {
              "key": "At 1 January",
              "value": "2022: 314, 2021: 319, 2020: 314"
            },
            {
              "key": "Exchange and other adjustments (Amortisation)",
              "value": "2022: -3, 2021: -6, 2020: 5"
            },
            {
              "key": "At 31 December (Amortisation)",
              "value": "2022: 311, 2021: 314, 2020: 319"
            },
            {
              "key": "Net book value at 31 December",
              "value": "2022: 19820, 2021: 19997, 2020: 11845"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 163,
          "title": "Asset Cost and Amortization Schedule",
          "data": [
            {
              "key": "Cost At 1 January 2020",
              "value": "col1: 40654, col2: 2649, col3: 1781, total: 45084"
            },
            {
              "key": "Additions — separately acquired",
              "value": "col1: 1454, col2: 2, col3: 136, total: 1592"
            },
            {
              "key": "At 31 December 2022",
              "value": "col1: 66785, col2: 2442, col3: 1395, total: 70622"
            },
            {
              "key": "Net book value at 31 December 2021",
              "value": "col1: 41314, col2: 748, col3: 430, total: 42492"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 167,
          "title": "Investment Portfolio Breakdown",
          "data": [
            {
              "key": "Non-current investments",
              "value": "N/A"
            },
            {
              "key": "Equity securities at fair value through Other comprehensive income",
              "value": "1056"
            },
            {
              "key": "Fixed income securities at fair value through profit and loss",
              "value": "10"
            },
            {
              "key": "Total",
              "value": "1066"
            },
            {
              "key": "Current investments",
              "value": "N/A"
            },
            {
              "key": "Fixed income securities at fair value through profit and loss",
              "value": "13"
            },
            {
              "key": "Cash collateral pledged to counterparties",
              "value": "162"
            },
            {
              "key": "Fixed deposits",
              "value": "64"
            },
            {
              "key": "Total",
              "value": "239"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 167,
          "title": "Investment Fair Value Hierarchy",
          "data": [
            {
              "key": "Level 1 (2022 FVPL)",
              "value": "13"
            },
            {
              "key": "Level 1 (2022 FVOCI)",
              "value": "880"
            },
            {
              "key": "Level 2 (2022 FVPL)",
              "value": "0"
            },
            {
              "key": "Level 2 (2022 FVOCI)",
              "value": "0"
            },
            {
              "key": "Level 3 (2022 FVPL)",
              "value": "10"
            },
            {
              "key": "Level 3 (2022 FVOCI)",
              "value": "176"
            },
            {
              "key": "Total (2022 FVPL)",
              "value": "23"
            },
            {
              "key": "Total (2022 FVOCI)",
              "value": "1056"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 167,
          "title": "Movements in Level 3 Investments",
          "data": [
            {
              "key": "At 1 January (FVPL $m)",
              "value": "0"
            },
            {
              "key": "At 1 January (Fvocl $m)",
              "value": "104"
            },
            {
              "key": "At 1 January (FVOcI $m)",
              "value": "217"
            },
            {
              "key": "At 31 December (FVPL $m)",
              "value": "10"
            },
            {
              "key": "At 31 December (Fvocl $m)",
              "value": "176"
            },
            {
              "key": "At 31 December (FVOcI $m)",
              "value": "104"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 169,
          "title": "Inventories Summary",
          "data": [
            {
              "key": "Total Inventory Value",
              "value": "8983"
            },
            {
              "key": "Peak Period for Inventory Value",
              "value": "Period 2"
            },
            {
              "key": "Inventory Write-offs",
              "value": "$479m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 169,
          "title": "Trade and Other Receivables",
          "data": [
            {
              "key": "Total Trade Receivables",
              "value": "$10521"
            },
            {
              "key": "Trade Receivables Growth (2020-2022)",
              "value": "$7,022m to $10,521m"
            },
            {
              "key": "Increase in Expected Credit Loss Provision (2022)",
              "value": "$59m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 169,
          "title": "Cash and Cash Equivalents",
          "data": [
            {
              "key": "Total Cash and Cash Equivalents",
              "value": "$6,166"
            },
            {
              "key": "Decline in Cash Position (2020-2022)",
              "value": "$7,832m to $6,166m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 169,
          "title": "Non-Cash and Other Movements",
          "data": [
            {
              "key": "Total Operating Activities Non-Cash Movements",
              "value": "-692"
            },
            {
              "key": "Significant Item - Share-based Payments",
              "value": "$619"
            },
            {
              "key": "Notable Variation in Foreign Exchange Movements",
              "value": "-590"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 179,
          "title": "Fair Value of Scheme Assets by Region and Type",
          "data": [
            {
              "key": "Total scheme assets",
              "value": "$10,564 million"
            },
            {
              "key": "UK region share",
              "value": "$7,333 million"
            },
            {
              "key": "Major investment categories",
              "value": "Government bonds, Investment funds with absolute return/multi strategy, Corporate bonds/credit funds"
            },
            {
              "key": "Total fair value of scheme assets - 2022",
              "value": "$7,030 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 179,
          "title": "Present value of scheme obligations",
          "data": [
            {
              "key": "UK total obligations",
              "value": "$4,801 million"
            },
            {
              "key": "Sweden total obligations",
              "value": "$1,312 million"
            },
            {
              "key": "Pensioners liabilities",
              "value": "$5,079 million"
            },
            {
              "key": "Total obligations",
              "value": "$8,108 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 181,
          "title": "Pension Financial Statement Components",
          "data": [
            {
              "key": "Operating profit Current service cost UK",
              "value": "-14"
            },
            {
              "key": "Operating profit Current service cost US",
              "value": "-1"
            },
            {
              "key": "Operating profit Current service cost Sweden",
              "value": "-35"
            },
            {
              "key": "Operating profit Current service cost Rest_of_Group",
              "value": "-38"
            },
            {
              "key": "Operating profit Current service cost Total",
              "value": "-88"
            },
            {
              "key": "Operating profit Past service (cost)/credit UK",
              "value": "-5"
            },
            {
              "key": "Operating profit Past service (cost)/credit US",
              "value": "0"
            },
            {
              "key": "Operating profit Past service (cost)/credit Sweden",
              "value": "-4"
            },
            {
              "key": "Operating profit Past service (cost)/credit Rest_of_Group",
              "value": "3"
            },
            {
              "key": "Operating profit Past service (cost)/credit Total",
              "value": "-6"
            },
            {
              "key": "Finance expense Interest income on scheme assets UK",
              "value": "123"
            },
            {
              "key": "Finance expense Interest income on scheme assets US",
              "value": "29"
            },
            {
              "key": "Finance expense Interest income on scheme assets Sweden",
              "value": "18"
            },
            {
              "key": "Finance expense Interest income on scheme assets Rest_of_Group",
              "value": "5"
            },
            {
              "key": "Finance expense Interest income on scheme assets Total",
              "value": "175"
            },
            {
              "key": "Other comprehensive income Remeasurement of the defined benefit liability UK",
              "value": "279"
            },
            {
              "key": "Other comprehensive income Remeasurement of the defined benefit liability US",
              "value": "-27"
            },
            {
              "key": "Other comprehensive income Remeasurement of the defined benefit liability Sweden",
              "value": "653"
            },
            {
              "key": "Other comprehensive income Remeasurement of the defined benefit liability Rest_of_Group",
              "value": "213"
            },
            {
              "key": "Other comprehensive income Remeasurement of the defined benefit liability Total",
              "value": "1118"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Acquisitions of business operations",
          "data": [
            {
              "key": "AstraZeneca acquisition of LogicBio Therapeutics",
              "value": "Completed on 16 November 2022 for $72m, including $68m cash."
            },
            {
              "key": "Goodwill from LogicBio acquisition",
              "value": "$15m"
            },
            {
              "key": "Total assets from LogicBio acquisition",
              "value": "$82m"
            },
            {
              "key": "Liabilities from LogicBio acquisition",
              "value": "$25m"
            },
            {
              "key": "AstraZeneca acquisition of Alexion Pharmaceuticals",
              "value": "Completed on 21 July 2021 for $41,058m, including cash and AstraZeneca shares."
            },
            {
              "key": "Goodwill from Alexion acquisition",
              "value": "$8,287m"
            },
            {
              "key": "Net cash outflow from Alexion acquisition",
              "value": "$9,263m"
            },
            {
              "key": "Total fair value of equity consideration for Alexion",
              "value": "$27,196m"
            },
            {
              "key": "Intangible assets from Alexion acquisition",
              "value": "$26,855m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 185,
          "title": "Fair Value and Useful Lives of Intangible Assets",
          "data": [
            {
              "key": "Fair value of intangible assets",
              "value": "$26,955m"
            },
            {
              "key": "Intellectual property rights over launched products",
              "value": "$23,695m"
            },
            {
              "key": "Products under development",
              "value": "$2,760m"
            },
            {
              "key": "Fair value of inventory",
              "value": "$6,769m"
            },
            {
              "key": "Carrying value prior to acquisition uplift",
              "value": "$5,635m"
            },
            {
              "key": "Estimated fair value of property, plant and equipment",
              "value": "$1,135m"
            },
            {
              "key": "Fair value adjustment for contingent liabilities",
              "value": "$76m"
            },
            {
              "key": "Estimated fair value of trade receivables",
              "value": "$2,096m"
            },
            {
              "key": "Deferred tax adjustment",
              "value": "$5,215m"
            },
            {
              "key": "Goodwill on acquisition",
              "value": "$8,287m"
            },
            {
              "key": "Non-controlling interests in Caelum Biosciences",
              "value": "$150m"
            },
            {
              "key": "Acquisition closing date",
              "value": "5 October 2021"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 194,
          "title": "Commitments, contingent liabilities and contingent assets",
          "data": [
            {
              "key": "Contracts placed for future capital expenditure on Property, plant and equipment and software development costs not provided for in these financial statements",
              "value": "2022: $502m, 2021: $388m, 2020: $689m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 194,
          "title": "Future Milestone Payments Breakdown",
          "data": [
            {
              "key": "Future potential research and development milestone payments",
              "value": "Total: $11,729M, Under 1 year: $1,320M, Years 1 and 2: $2,662M, Years 3 and 4: $2,698M, 5 years and greater: $5,049M"
            },
            {
              "key": "Future potential revenue milestone payments",
              "value": "Total: $17,499M, Under 1 year: $65M, Years 1 and 2: $368M, Years 3 and 4: $1,859M, 5 years and greater: $15,207M"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 200,
          "title": "Acquisition of CinCor Pharma, Inc.",
          "data": [
            {
              "key": "Announcement Date",
              "value": "09 January 2023"
            },
            {
              "key": "Target Company",
              "value": "CinCor Pharma, Inc."
            },
            {
              "key": "Focus",
              "value": "Developing novel treatments for resistant and uncontrolled hypertension and chronic kidney disease"
            },
            {
              "key": "Tender Offer Initiated",
              "value": "23 January 2023"
            },
            {
              "key": "Offer Price",
              "value": "$26 per share upfront, plus $10 contingent value right"
            },
            {
              "key": "Transaction Value (Maximum Potential)",
              "value": "Approximately $1.8bn"
            },
            {
              "key": "Cash and Marketable Securities of CinCor",
              "value": "Approximately $522m as of 30 September 2022"
            },
            {
              "key": "Expected Closing Date",
              "value": "First quarter of 2023"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 200,
          "title": "Acquisition of Neogene Therapeutics Inc.",
          "data": [
            {
              "key": "Completion Date",
              "value": "16 January 2023"
            },
            {
              "key": "Total Consideration",
              "value": "Up to $320m"
            },
            {
              "key": "Initial Payment",
              "value": "$200m"
            },
            {
              "key": "Further Potential Consideration",
              "value": "Up to $120m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 200,
          "title": "Sale of West Chester Site",
          "data": [
            {
              "key": "Completion Date",
              "value": "30 January 2023"
            },
            {
              "key": "Buyer",
              "value": "National Resilience, Inc."
            },
            {
              "key": "Assets Disposed",
              "value": "Property, plant and equipment assets valued at $150m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 200,
          "title": "New Bank Facilities",
          "data": [
            {
              "key": "Date Entered",
              "value": "02 February 2023"
            },
            {
              "key": "Facility Amount",
              "value": "$2.0bn"
            },
            {
              "key": "Term",
              "value": "Two-year committed bank facilities"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "Group Interest Details at 31 December 2022",
          "data": [
            {
              "key": "Location",
              "value": "Denmark"
            },
            {
              "key": "Company",
              "value": "AstraZeneca A/S"
            },
            {
              "key": "Address",
              "value": "World Trade Center Ballerup, Borupvang DK- 2750 Ballerup, Denmark"
            },
            {
              "key": "Group Interest",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "AstraZeneca Subsidiaries in Finland and France",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca OY."
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Address",
              "value": "Itsehallintokuja 4, Espoo, 02600, Finland"
            },
            {
              "key": "Country",
              "value": "Finland"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "AstraZeneca Subsidiary Companies and Ownership Structure",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca Kft"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Address",
              "value": "1st floor, 4 building B, Aliz str., Budapest, 1117, Hungary"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "Company Ownership Structure",
          "data": [
            {
              "key": "Company",
              "value": "Simesa SpA"
            },
            {
              "key": "Ownership",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "AstraZeneca Hong Kong Limited Details",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca Hong Kong Limited"
            },
            {
              "key": "Ownership",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "AstraZeneca Asia-Pacific Business",
          "data": [
            {
              "key": "Entity",
              "value": "Services Sdn Bhd"
            },
            {
              "key": "Ownership",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "The Netherlands",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca B.V."
            },
            {
              "key": "Ownership",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 203,
          "title": "AstraZeneca Group Subsidiaries and Interests as of 31 December 2022",
          "data": [
            {
              "key": "Location",
              "value": "New Zealand"
            },
            {
              "key": "Company",
              "value": "AstraZeneca Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Address",
              "value": "58 Richard Pearse Drive, Mangere, Auckland, 1142, New Zealand"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 203,
          "title": "AstraZeneca Subsidiary Ownership Structure",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca Produtos Farmaceuticos Lda"
            },
            {
              "key": "Ownership",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 203,
          "title": "At 31 December 2022 Group Subsidiary Companies and Their Interests",
          "data": [
            {
              "key": "Location",
              "value": "Russia"
            },
            {
              "key": "Company",
              "value": "AstraZeneca Industries, LLC"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Address",
              "value": "8 1st Vostochniy lane, Dobrino village, Borovskiy district, Kaluga region 249006, Russian Federation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 203,
          "title": "AstraZeneca Swedish Subsidiary Ownership Structure",
          "data": [
            {
              "key": "Company",
              "value": "Astra Export & Trading Aktiebolag"
            },
            {
              "key": "Ownership",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 204,
          "title": "Group Subsidiaries and Holdings continued",
          "data": [
            {
              "key": "Entity",
              "value": "United Kingdom"
            },
            {
              "key": "Interest",
              "value": ""
            },
            {
              "key": "Entity",
              "value": "Ardea Biosciences Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "Arrow Therapeutics Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "Astra Pharmaceuticals Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraPharm"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca China UK Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Death In Service Trustee Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Employee Share Trust Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Finance Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Intermediate Holdings Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Investments Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Japan Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Nominees Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Quest Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Share Trust Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Sweden Investments Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca Treasury Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca UK Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AstraZeneca US Investments Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AZENCO2 Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "AZENCO4 Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "Cambridge Antibody Technology Group Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "KuDOS Horsham Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "KuDOS Pharmaceuticals Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "Zenco (No. 8) Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "Zeneca Finance (Netherlands) Company"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "MedImmune Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "MedImmune U.K. Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "Syntimmune Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "Alexion Pharma UK Limited"
            },
            {
              "key": "Interest",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "Portola Pharma UK Limited (in liquidation)"
            },
            {
              "key": "Interest",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 204,
          "title": "United States Subsidiaries",
          "data": [
            {
              "key": "Company Name",
              "value": "Amylin Ohio LLC"
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Amylin Pharmaceuticals, LLC"
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Collaboration Ventures, LLC"
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Pharmaceuticals LP"
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Atkemix Nine Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Atkemix Ten Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "BMS Holdco, Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Corpus Christi Holdings Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Omthera Pharmaceuticals, Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Optein, Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Stauffer Management Company LLC"
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Zeneca Holdings Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Zeneca Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Zeneca Wilmington Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Finance LLC"
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Finance and Holdings Inc."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            },
            {
              "key": "Company Name",
              "value": "Namor Merger Sub, Inc"
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 204,
          "title": "Subsidiary Ownership Structure",
          "data": [
            {
              "key": "Subsidiary",
              "value": "Achillion Pharmaceuticals Inc"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "Alexion Delaware Holding LLC"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "Alexion Pharma LLC"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "Alexion Pharmaceuticals, Inc."
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "Syntimmune, Inc."
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "Alexion US1 LLC"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "Savoy Therapeutics Corp"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "Nilson Therapeutics USA, Inc."
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "feneoTwo, Inc"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Subsidiary",
              "value": "_ogicBio Therapeutics, Inc"
            },
            {
              "key": "Ownership",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 204,
          "title": "AstraZeneca Uruguay Entity Details",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca S.A."
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Address Line 1",
              "value": "Jaguarón 1407 of 1205, 11.100"
            },
            {
              "key": "Address Line 2",
              "value": "Montevideo, Uruguay"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 204,
          "title": "Ownership Structure",
          "data": [
            {
              "key": "Entity",
              "value": "Jedimmune, LLC"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Entity",
              "value": "fedimmune Ventures, Inc."
            },
            {
              "key": "Ownership",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 204,
          "title": "Company Registration Details",
          "data": [
            {
              "key": "Company Name",
              "value": "AstraZeneca Vietnam Company Limited"
            },
            {
              "key": "Ownership",
              "value": "100%"
            },
            {
              "key": "Address Line 1",
              "value": "18th Floor, A&B Tower, 76 Le Lai, Ben Thanh"
            },
            {
              "key": "Address Line 2",
              "value": "Ward, District 1, Ho Chi Minh City, Vietnam"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 204,
          "title": "Gotland Pharma S.A.",
          "data": [
            {
              "key": "Company",
              "value": "Gotland Pharma S.A."
            },
            {
              "key": "Ownership Percentage",
              "value": "100%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 205,
          "title": "Group Subsidiaries and Holdings",
          "data": [
            {
              "key": "Subsidiary Name",
              "value": "Namor Merger Sub Inc."
            },
            {
              "key": "Status",
              "value": "Merged into Neogene Therapeutics, Inc."
            },
            {
              "key": "Surviving Corporation",
              "value": "Neogene Therapeutics, Inc."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 210,
          "title": "Notes to the Company Financial Statements",
          "data": [
            {
              "key": "Fixed asset investments",
              "value": "Investments in subsidiaries"
            },
            {
              "key": "Loans to subsidiaries",
              "value": "Loans consist of bonds issued externally and are repayable on maturity."
            },
            {
              "key": "Total fixed asset investments",
              "value": "Increased significantly from $33,268M to $65,624M in 2021."
            },
            {
              "key": "Notable movements",
              "value": "Transfers to Group undertakings debtors -$1,249M in 2021 and -$1,531M in 2022."
            },
            {
              "key": "Loan recoverability assessment",
              "value": "Assessed in accordance with IFRS 9, with no impairment identified."
            },
            {
              "key": "Credit risk",
              "value": "Considered low due to timely payment."
            },
            {
              "key": "Other payables summary",
              "value": "Total payables across all categories sum to $230M."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 224,
          "title": "Glossary continued",
          "data": [
            {
              "key": "FDA",
              "value": "the US Food and Drug Administration, which is part of the US Department of Health and Human Services Agency, which is the regulatory authority for all pharmaceuticals (including biologics and vaccines) and medical devices in the US."
            },
            {
              "key": "FibroGen",
              "value": "FibroGen, Inc."
            },
            {
              "key": "FRC",
              "value": "the UK Financial Reporting Council."
            },
            {
              "key": "FX",
              "value": "foreign exchange."
            },
            {
              "key": "GAAP",
              "value": "Generally Accepted Accounting Principles."
            },
            {
              "key": "GHG",
              "value": "greenhouse gas."
            },
            {
              "key": "GIA",
              "value": "the Group’s Internal Audit function."
            },
            {
              "key": "Gilead",
              "value": "Gilead Sciences Ltd."
            },
            {
              "key": "GLP1",
              "value": "glucagon-like peptide-1."
            },
            {
              "key": "Gross margin",
              "value": "the margin, as a percentage, by which sales exceed the cost of sales, calculated by dividing the difference between the two by the sales figure."
            },
            {
              "key": "Group",
              "value": "AstraZeneca PLC and its subsidiaries."
            },
            {
              "key": "Grünenthal",
              "value": "Grünenthal Group."
            },
            {
              "key": "GSK",
              "value": "GlaxoSmithKline plc."
            },
            {
              "key": "GWP",
              "value": "Global Warming Potential."
            },
            {
              "key": "HCPs",
              "value": "healthcare practitioners."
            },
            {
              "key": "HF",
              "value": "heart failure."
            },
            {
              "key": "HK",
              "value": "hyperkalaemia."
            },
            {
              "key": "Honeywell",
              "value": "Honeywell International Inc."
            },
            {
              "key": "IAS",
              "value": "International Accounting Standards."
            },
            {
              "key": "IASB",
              "value": "International Accounting Standards Board."
            },
            {
              "key": "ICAEW",
              "value": "Institute of Chartered Accoutants in England and Wales."
            },
            {
              "key": "ICS",
              "value": "inhaled oral corticosteroid."
            },
            {
              "key": "IFPMA",
              "value": "International Federation of Pharmaceutical Manufacturers and Associations."
            },
            {
              "key": "IFRS",
              "value": "International Financial Reporting Standards or International Financial Reporting Standard, as the context requires."
            },
            {
              "key": "Innate Pharma",
              "value": "Innate Pharma S.A."
            },
            {
              "key": "IQVIA",
              "value": "IQVIA Solutions HQ Limited."
            },
            {
              "key": "Ironwood",
              "value": "Ironwood Pharmaceuticals, Inc."
            },
            {
              "key": "IS",
              "value": "information services."
            },
            {
              "key": "ISAs",
              "value": "International Standards on Auditing."
            },
            {
              "key": "IT",
              "value": "information technology."
            },
            {
              "key": "KPI",
              "value": "key performance indicator."
            },
            {
              "key": "krona or SEK",
              "value": "references to the currency of Sweden."
            },
            {
              "key": "LABA",
              "value": "long-acting beta2-agonist."
            },
            {
              "key": "LAMA",
              "value": "long-acting muscarinic antagonist."
            },
            {
              "key": "LCA",
              "value": "Life-Cycle Assessment."
            },
            {
              "key": "LCM projects",
              "value": "significant life-cycle management projects (as determined by potential revenue generation), or line extensions."
            },
            {
              "key": "Lilly",
              "value": "Eli Lilly and Company."
            },
            {
              "key": "LoE",
              "value": "Loss of Exclusivity."
            },
            {
              "key": "LMICs",
              "value": "low- and middle-income countries."
            },
            {
              "key": "mAb",
              "value": "monoclonal antibody, a biologic that is specific, meaning it binds to and attacks one particular antigen."
            },
            {
              "key": "major market",
              "value": "US, Europe, Japan and China."
            },
            {
              "key": "MAT",
              "value": "moving annual total."
            },
            {
              "key": "mCRPC",
              "value": "metastatic castration-resistant prostate cancer."
            },
            {
              "key": "MedImmune",
              "value": "MedImmune, LLC (formerly MedImmune, Inc.)."
            },
            {
              "key": "MET",
              "value": "tyrosine kinase receptor."
            },
            {
              "key": "MI",
              "value": "myocardial infarction."
            },
            {
              "key": "Moderna",
              "value": "Moderna Therapeutics, Inc."
            },
            {
              "key": "MSD",
              "value": "Merck & Co., Inc., which is known as Merck in the US and Canada, and MSD in other territories."
            },
            {
              "key": "n/m",
              "value": "not meaningful."
            },
            {
              "key": "Nasdaq",
              "value": "Nasdaq Global Select Market."
            },
            {
              "key": "Nasdaq Stockholm",
              "value": "previously the Stockholm Stock Exchange."
            },
            {
              "key": "Neogene",
              "value": "Neogene Therapeutics Inc."
            },
            {
              "key": "NME",
              "value": "new molecular entity."
            },
            {
              "key": "NMOSD",
              "value": "neuromyelitis optica spectrum disorder."
            },
            {
              "key": "Novartis",
              "value": "Novartis Pharma AG."
            },
            {
              "key": "NRDL",
              "value": "National Reimbursement Drug List, China."
            },
            {
              "key": "NSCLC",
              "value": "non-small cell lung cancer."
            },
            {
              "key": "NYSE",
              "value": "the New York Stock Exchange."
            },
            {
              "key": "OECD",
              "value": "the Organisation for Economic Co-operation and Development."
            },
            {
              "key": "operating profit",
              "value": "sales, less cost of sales, less operating costs, plus operating income."
            },
            {
              "key": "Ordinary Share",
              "value": "an ordinary share of $0.25 each in the share capital of the Company."
            },
            {
              "key": "Orphan Drug",
              "value": "a drug that has been approved for use in a relatively low-incidence indication (an orphan indication) and has been rewarded with a period of market exclusivity; the period of exclusivity and the available orphan indications vary between markets."
            },
            {
              "key": "Paediatric Exclusivity",
              "value": "in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug."
            },
            {
              "key": "PARP",
              "value": "an oral poly ADP-ribose polymerase."
            },
            {
              "key": "PD-L1",
              "value": "an anti-programmed death-ligand 1."
            },
            {
              "key": "Pearl Therapeutics",
              "value": "Pearl Therapeutics, Inc."
            },
            {
              "key": "Pfizer",
              "value": "Pfizer, Inc."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 8,
          "title": "Chair’s Statement",
          "data": [
            {
              "key": "Chair",
              "value": "Leif Johansson"
            },
            {
              "key": "Incoming Chair",
              "value": "Michel Demaré"
            },
            {
              "key": "CEO",
              "value": "Pascal Soriot"
            },
            {
              "key": "Tenure as Chair",
              "value": "Since June 2012"
            },
            {
              "key": "Announcement of stepping down",
              "value": "April 2022, conclusion of AGM"
            },
            {
              "key": "Achievements",
              "value": "Delivered strategic goals, scientific leadership, returning AstraZeneca to growth"
            },
            {
              "key": "Total Revenue",
              "value": "More than $44 billion in 2022"
            },
            {
              "key": "Total Dividends",
              "value": "Declared a total of $2.90 per share for the full year"
            },
            {
              "key": "Total Shareholder Return last decade",
              "value": "467% compared to FTSE100 (85%) and pharma peers (366%)"
            },
            {
              "key": "New Medicines Launched",
              "value": "20 new medicines in last 10 years, 3 in 2022"
            },
            {
              "key": "Blockbuster Medicines",
              "value": "14 blockbuster medicines with revenues over $1 billion in 2022"
            },
            {
              "key": "COVID-19 Response",
              "value": "Leading role in fighting the COVID-19 pandemic"
            },
            {
              "key": "Ambition Zero Carbon strategy",
              "value": "Contributing to the health of the planet"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 43,
          "title": "AstraZeneca Ethical Standards and Compliance",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$11,745 million"
            },
            {
              "key": "2021 Total Revenue",
              "value": "$12,281 million"
            },
            {
              "key": "Largest Company",
              "value": "AstraZeneca"
            },
            {
              "key": "Humanitarian Support",
              "value": "over $10 million"
            },
            {
              "key": "China Total Revenue 2022",
              "value": "$5,792 million"
            },
            {
              "key": "2021 China Total Revenue",
              "value": "$6,011 million"
            },
            {
              "key": "Employee and Third-Party Non-Compliance",
              "value": "2,872 instances"
            },
            {
              "key": "Number of Employees Removed",
              "value": "147"
            },
            {
              "key": "Number of Warnings Issued",
              "value": "3,326"
            },
            {
              "key": "Compliance Issues Recorded",
              "value": "10 confirmed external breaches"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "leadership_change",
          "page": 80,
          "title": "Chair’s Introduction",
          "data": [
            {
              "key": "Chair",
              "value": "Leif Johansson"
            },
            {
              "key": "New Chair",
              "value": "Michel Demaré"
            },
            {
              "key": "Date of Transition",
              "value": "At the conclusion of this year’s AGM"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 81,
          "title": "Corporate Governance Overview",
          "data": [
            {
              "key": "Directors",
              "value": "Leif Johansson, Pascal Soriot, Aradhana Sarin, Euan Ashley, Philip Broadley, Michel Demar, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg"
            },
            {
              "key": "Changes",
              "value": "Sheri McCoy became Chair of the Remuneration Committee on 1 December 2022; Michel Demaré stepped down as Chair effective 1 December 2022; Sheri McCoy was appointed as a member of the Nomination and Governance Committee on 1 December 2022."
            },
            {
              "key": "Board Structure",
              "value": "Board consists of Executive and Non-Executive Directors with delegated committees."
            },
            {
              "key": "Attendance Summary",
              "value": "All directors have perfect board attendance (6/6 meetings) in 2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 82,
          "title": "Board of Directors as at 31 December 2022",
          "data": [
            {
              "key": "Total Directors",
              "value": "13"
            },
            {
              "key": "Men",
              "value": "8"
            },
            {
              "key": "Women",
              "value": "5"
            },
            {
              "key": "Nationality - British",
              "value": "4"
            },
            {
              "key": "Nationality - American",
              "value": "3"
            },
            {
              "key": "Nationality - Swedish",
              "value": "2"
            },
            {
              "key": "Nationality - Belgian",
              "value": "1"
            },
            {
              "key": "Nationality - Canadian",
              "value": "1"
            },
            {
              "key": "Nationality - French",
              "value": "1"
            },
            {
              "key": "Nationality - German",
              "value": "1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 83,
          "title": "Executive Directors and Senior Management",
          "data": [
            {
              "key": "Director",
              "value": "Deborah DiSanzo"
            },
            {
              "key": "Skills and experience",
              "value": "Deborah has more than 30 years’ experience at the intersection of healthcare and technology. She is currently President of Best Buy Health for Best Buy Co. Inc. Best Buy Health provides digital health solutions in active aging, virtual care and consumer health. Deborah holds an appointment at the Harvard TH Chan School of Public Health teaching Artificial Intelligence in Health. Until December 2018, she served as General Manager of IBM Watson Health. Prior to IBM, until 2014, Deborah held multiple senior executive positions at Philips Healthcare where she also served as Chief Executive Officer. Deborah has been honoured by multiple organisations as a top health influencer. She holds an MBA from Babson College and is a Harvard University Advanced Leadership Initiative 2019 Fellow."
            },
            {
              "key": "Other appointments",
              "value": "Deborah is President of Best Buy Health for Best Buy Co. Inc."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 83,
          "title": "Executive Directors and Senior Management",
          "data": [
            {
              "key": "Director",
              "value": "Nazneen Rahman"
            },
            {
              "key": "Skills and experience",
              "value": "Nazneen has significant scientific, medical and data analysis experience in rare disease, cancer genomics and sustainable healthcare. She qualified in medicine from Oxford University, is an accredited specialist in medical genetics and has a PhD in molecular genetics. Nazneen was Professor of Genetics at the Institute of Cancer Research, Head of Cancer Genetics at the Royal Marsden NHS Foundation Trust, and founder and Director of the TGLclinical Genetic Testing Laboratory until 2018. In 2020, Nazneen founded YewMaker to build science-based sustainable healthcare solutions. Nazneen has a strong commitment to open science and has garnered numerous awards, including a CBE in recognition of her contribution to medical sciences."
            },
            {
              "key": "Other appointments",
              "value": "Nazneen is CEO of YewMaker and Director of the Sustainable Medicines Partnership."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 83,
          "title": "Executive Directors and Senior Management",
          "data": [
            {
              "key": "Director",
              "value": "Diana Layfield"
            },
            {
              "key": "Skills and experience",
              "value": "Diana has broad global business experience which began in the pharmaceutical and biotech sector. She has held senior leadership roles at Standard Chartered Bank, as the CEO of a start-up technology company, and in Healthcare and Life Sciences at McKinsey & Co. Until December 2020, Diana was a Non-Executive Director of Aggreko plc. She has a BA from Oxford University and an MA in Public Administration and International Economics from Harvard University."
            },
            {
              "key": "Other appointments",
              "value": "Diana is General Manager, International Search at Google, leading the development of Google Search internationally, including product and engineering. She was also President, EMEA Partnerships and Vice-President, ‘Next Billion Users’. She is the Chair of British International Investment plc (BII), the UK’s development finance institution, and a Council Member of the London School of Hygiene & Tropical Medicine."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 83,
          "title": "Executive Directors and Senior Management",
          "data": [
            {
              "key": "Director",
              "value": "Andreas Rummelt"
            },
            {
              "key": "Skills and experience",
              "value": "Andreas joined the Board following the acquisition of Alexion, where he had been a Director since 2010. Previously he was Group Head of Technical Operations and Quality at Novartis, and from 2006 until 2010 served on the Executive Committee. He was Global CEO of the Generics Division of Sandoz from 2004 to 2008, having originally joined in 1985. Andreas earned his PhD in pharmaceutical sciences from the University of Erlangen-Nuremberg and received his executive training in general management and leadership from IMD in Lausanne; INSEAD in Fontainebleau; and Harvard Business School."
            },
            {
              "key": "Other appointments",
              "value": "Andreas is Chairman and Managing Partner of InterPharmaLink AG and a Director of various privately-held biotech and pharmaceutical companies. He is a member of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 83,
          "title": "Executive Directors and Senior Management",
          "data": [
            {
              "key": "Director",
              "value": "Sheri McCoy"
            },
            {
              "key": "Skills and experience",
              "value": "Until February 2018, Sheri was CEO and a Director of Avon Products, Inc. Prior to joining them in 2012, she had a 30-year career at Johnson & Johnson, latterly serving as Vice-Chairman of the Executive Committee, responsible for the Pharmaceuticals and Consumer business segments. Sheri joined Johnson & Johnson as an R&D scientist and subsequently managed businesses in every major product sector, holding positions including Worldwide Chairman, Surgical Care Group and Division President, Consumer."
            },
            {
              "key": "Other appointments",
              "value": "Sheri serves on the boards of Stryker, Kimberly-Clark, and Laronde. She is also an industrial adviser for EQT, and in connection serves on the boards of Galderma and Parexel."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 83,
          "title": "Executive Directors and Senior Management",
          "data": [
            {
              "key": "Director",
              "value": "Tony Mok"
            },
            {
              "key": "Skills and experience",
              "value": "Tony is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. His work includes multiple aspects of lung cancer research, including biomarker and molecular targeted therapy in lung cancer. Tony is a former President of the International Association for the Study of Lung Cancer and a past Board member of the American Society of Clinical Oncology. His work has achieved numerous awards including the ESMO Lifetime Achievement Award in 2018 and Giant of Cancer Care in 2020."
            },
            {
              "key": "Other appointments",
              "value": "Tony is a Non-Executive Director of Hutchison China MediTech Limited (Chair of the Nomination Committee) and a member of the Scientific Advisory Board of Prenetics Global Limited."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 84,
          "title": "Senior Executive Team (SET) as at 31 December 2022",
          "data": [
            {
              "key": "CEO",
              "value": "Pascal Soriot"
            },
            {
              "key": "CFO",
              "value": "Aradhana Sarin"
            },
            {
              "key": "Executive Vice-President, BioPharmaceuticals Business Unit",
              "value": "Ruud Dobber"
            },
            {
              "key": "CEO, Alexion and Chief Strategy Officer, AstraZeneca",
              "value": "Marc Dunoyer"
            },
            {
              "key": "Executive Vice-President, Oncology R&D",
              "value": "Susan Galbraith"
            },
            {
              "key": "Executive Vice-President, BioPharmaceuticals R&D",
              "value": "Menelas (Mene) Pangalos"
            },
            {
              "key": "Executive Vice-President, Vaccines & Immune Therapies",
              "value": "Iskra Reic"
            },
            {
              "key": "Executive Vice-President, International and China President",
              "value": "Leon Wang"
            },
            {
              "key": "Executive Vice-President, Operations, Information Technology and Sustainability",
              "value": "Pam Cheng"
            },
            {
              "key": "Executive Vice-President, Oncology Business Unit",
              "value": "David Fredrickson"
            },
            {
              "key": "Chief Compliance Officer, Chief Human Resources Officer and General Counsel",
              "value": "Jeff Pott"
            },
            {
              "key": "Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca AB Sweden",
              "value": "Katarina Ageborg"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 85,
          "title": "Chair's Tenure and Board Composition",
          "data": [
            {
              "key": "Chair",
              "value": "Leif Johansson"
            },
            {
              "key": "Chair's Tenure Announcement",
              "value": "Mr Johansson intends to retire from the Board at the conclusion of the 2023 AGM."
            },
            {
              "key": "Independent Status at Appointment",
              "value": "Mr Johansson was considered to be independent on his appointment as Chair in June 2012."
            },
            {
              "key": "Board Independence",
              "value": "The majority of the Board consists of independent Non-Executive Directors."
            },
            {
              "key": "Directors' Independence Review",
              "value": "Directors’ independence is considered annually by the Board."
            },
            {
              "key": "Board Responsibilities",
              "value": "The Directors are collectively responsible for the success of the Group."
            },
            {
              "key": "Chair's Annual Evaluation",
              "value": "Further information about the Chair’s annual evaluation is included on page 91."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 86,
          "title": "Corporate Governance Report",
          "data": [
            {
              "key": "Senior independent Non-Executive Director",
              "value": "Philip Broadley"
            },
            {
              "key": "Appointment Date",
              "value": "1 March 2021"
            },
            {
              "key": "Nomination and Governance Committee Role",
              "value": "Review composition of the Board and succession planning."
            },
            {
              "key": "Time Commitment for Chair of the Board",
              "value": "40% of their time, equivalent to 90 days per annum."
            },
            {
              "key": "Board members' evaluation",
              "value": "Annually assessed as part of the Board’s performance evaluation."
            },
            {
              "key": "External appointments of Directors",
              "value": "Allowed subject to Board approval."
            },
            {
              "key": "Audit Committee Role",
              "value": "Responsible for reviewing relationship and independence of external auditor."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 88,
          "title": "Corporate Governance Report: Connecting with our stakeholders",
          "data": [
            {
              "key": "description",
              "value": "This image shows a title page or section header for a Corporate Governance Report focusing on stakeholder engagement. The page has a coral/pink gradient background with an artistic microscopic or underwater-like illustration featuring what appears to be coral-like structures or molecular formations in golden and pink hues."
            },
            {
              "key": "financial_impact",
              "value": "Stakeholder interests being fundamental to the group's strategy in 2022. AstraZeneca works closely with various stakeholders to optimize healthcare systems ensuring that the medicines and services developed have the greatest impact on lives."
            },
            {
              "key": "stakeholders",
              "value": "Patients, caregivers, patient advocacy organizations, payers, investor community, healthcare professionals, academic and R&D partners."
            },
            {
              "key": "engagement",
              "value": "Diverse insights gathered and incorporated throughout the drug development process to minimize patient burden and measure outcomes."
            },
            {
              "key": "interest",
              "value": "Financial performance, development of innovative medicines, pricing of medicines, ensuring safety and efficacy, and collaboration with stakeholders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 92,
          "title": "Corporate Governance Report",
          "data": [
            {
              "key": "Engagement Purpose",
              "value": "To ensure an environment where all employees are respected, with openness and diversity celebrated."
            },
            {
              "key": "Engagement Mechanisms",
              "value": "Various communication channels including Pulse surveys and engagement events."
            },
            {
              "key": "Workforce Survey Participation",
              "value": "91% of employees participated in November 2022 Pulse survey."
            },
            {
              "key": "Employee Sentiment",
              "value": "89% believe strongly in AstraZeneca's future direction."
            },
            {
              "key": "Site Visits",
              "value": "Directors visited various global sites including those in US and Europe."
            },
            {
              "key": "Wellbeing Updates",
              "value": "Regular updates on safe working environments and mental health support due to external factors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 93,
          "title": "Board performance evaluation",
          "data": [
            {
              "key": "Overview",
              "value": "Directors were asked to consider several areas during the Board performance evaluation."
            },
            {
              "key": "Areas of consideration",
              "value": "Board composition, Stakeholder oversight, Board dynamics, Board information, Board Committees, Strategic oversight, Risk oversight, Succession planning and people oversight, Priorities for change."
            },
            {
              "key": "Internal evaluation",
              "value": "The 2022 evaluation was carried out internally, with assistance from Lintstock Ltd."
            },
            {
              "key": "Results of evaluation",
              "value": "The evaluation emphasized in-person Board meetings and noted successful CFO and Chair succession plans."
            },
            {
              "key": "Focus areas for 2023",
              "value": "Board succession planning, CEO succession planning, overseeing SET succession plans."
            },
            {
              "key": "Geopolitical monitoring",
              "value": "The Board plans to monitor geopolitical developments affecting the business."
            },
            {
              "key": "Directors' training",
              "value": "Training needs are met via internal and external sessions."
            },
            {
              "key": "Diversity focus",
              "value": "The Nomination and Governance Committee reviews the Board composition for appropriate expertise and diversity."
            },
            {
              "key": "2022 outcomes",
              "value": "The Board operates effectively, with a focus on risk management and workforce engagement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 94,
          "title": "Nomination and Governance Committee Report",
          "data": [
            {
              "key": "Chair of the Board",
              "value": "Michel Demaré"
            },
            {
              "key": "Former Chair",
              "value": "Leif Johansson"
            },
            {
              "key": "Committee Members",
              "value": "Leif Johansson, Philip Broadley, Michel Demaré, Sheri McCoy, Nazneen Rahman"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 95,
          "title": "Gender Distribution in Board and Executive Management",
          "data": [
            {
              "key": "Category",
              "value": "Men"
            },
            {
              "key": "Number of Board members",
              "value": "8"
            },
            {
              "key": "Percentage of the Board",
              "value": "62%"
            },
            {
              "key": "positions on the Board",
              "value": "3"
            },
            {
              "key": "Number in executive management",
              "value": "8"
            },
            {
              "key": "Percentage of executive management",
              "value": "62%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 95,
          "title": "Gender Distribution in Board and Executive Management",
          "data": [
            {
              "key": "Category",
              "value": "Women"
            },
            {
              "key": "Number of Board members",
              "value": "5"
            },
            {
              "key": "Percentage of the Board",
              "value": "38%"
            },
            {
              "key": "positions on the Board",
              "value": "1"
            },
            {
              "key": "Number in executive management",
              "value": "5"
            },
            {
              "key": "Percentage of executive management",
              "value": "38%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 95,
          "title": "Gender Distribution in Board and Executive Management",
          "data": [
            {
              "key": "Category",
              "value": "Non-binary"
            },
            {
              "key": "Number of Board members",
              "value": "-"
            },
            {
              "key": "Percentage of the Board",
              "value": "-"
            },
            {
              "key": "positions on the Board",
              "value": "-"
            },
            {
              "key": "Number in executive management",
              "value": "-"
            },
            {
              "key": "Percentage of executive management",
              "value": "-"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 95,
          "title": "Gender Distribution in Board and Executive Management",
          "data": [
            {
              "key": "Category",
              "value": "Not specified/prefer not to say"
            },
            {
              "key": "Number of Board members",
              "value": ""
            },
            {
              "key": "Percentage of the Board",
              "value": ""
            },
            {
              "key": "positions on the Board",
              "value": ""
            },
            {
              "key": "Number in executive management",
              "value": ""
            },
            {
              "key": "Percentage of executive management",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 98,
          "title": "Audit Committee Report",
          "data": [
            {
              "key": "Routine attendees",
              "value": "CFO; Chief Human Resources Officer and General Counsel; EVP Sustainability and Chief Compliance Officer; VP Ethics & Transparency and Deputy Chief Compliance Officer; Deputy General Counsel, BioPharmaceuticals; VP, Group Internal Audit; SVP Finance, Group Controller & Head of Global Financial Services; the Company’s external auditor."
            },
            {
              "key": "Committee Responsibilities",
              "value": "Monitoring the integrity of financial reporting and formal announcements relating to financial performance, reviewing the effectiveness of internal controls and risk management systems, and overseeing the external and internal audit processes."
            },
            {
              "key": "Participants",
              "value": "CEO and other members of the SET attend when required by the Committee."
            },
            {
              "key": "Chair",
              "value": "Philip Broadley"
            },
            {
              "key": "Other Members",
              "value": "Michel Demaré, Deborah DiSanzo, Sheri McCoy"
            },
            {
              "key": "Focus Areas",
              "value": "Integration of Alexion into AstraZeneca's business, evaluating financial performance impacts due to the Ukraine conflict, and market environment understanding in China."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 144,
          "title": "Group Accounting Policies",
          "data": [
            {
              "key": "Basis of accounting",
              "value": "The Consolidated Financial Statements have been prepared under the historical cost convention, modified to include revaluation to fair value of certain financial instruments. They comply with UK-adopted International Accounting Standards and International Financial Reporting Standards."
            },
            {
              "key": "Functional currency",
              "value": "The financial statements are presented in US dollars."
            },
            {
              "key": "Financial resources",
              "value": "As at 31 December 2022, the Group has $11.1bn in financial resources."
            },
            {
              "key": "Borrowings",
              "value": "$5.5bn of borrowings due within one year."
            },
            {
              "key": "New bank facilities",
              "value": "On 2 February 2023, the Group entered into an additional $2.0bn of two-year committed bank facilities."
            },
            {
              "key": "Revenue streams",
              "value": "The Group anticipates new revenue streams from recently launched medicines and those in development."
            },
            {
              "key": "COVID-19 impact",
              "value": "No material accounting impacts relating to COVID-19 were recognized in the year."
            },
            {
              "key": "Climate risk assessment",
              "value": "The impact assessment was focused on valuation and useful lives of intangible assets."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "leadership_change",
          "page": 214,
          "title": "Additional Information",
          "data": [
            {
              "key": "Shareholder information",
              "value": "213"
            },
            {
              "key": "Directors’ report",
              "value": "215"
            },
            {
              "key": "Sustainability supplementary information",
              "value": "218"
            },
            {
              "key": "Trade Marks",
              "value": "219"
            },
            {
              "key": "Glossary",
              "value": "220"
            },
            {
              "key": "Cautionary statement regarding forward-looking statements",
              "value": "224"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 219,
          "title": "Gender Distribution in the Senior Executive Team",
          "data": [
            {
              "key": "Men",
              "value": "7 (58%)"
            },
            {
              "key": "Women",
              "value": "5 (42%)"
            },
            {
              "key": "Total",
              "value": "12"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 219,
          "title": "Company's Subsidiaries Gender Diversity",
          "data": [
            {
              "key": "Men",
              "value": "234 (62%)"
            },
            {
              "key": "Women",
              "value": "141 (38%)"
            },
            {
              "key": "Total",
              "value": "375"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 223,
          "title": "Abbreviations and Expressions in the Annual Report",
          "data": [
            {
              "key": "AbbVie",
              "value": "AbbVie Inc."
            },
            {
              "key": "Acerta Pharma",
              "value": "Acerta Pharma B.V."
            },
            {
              "key": "Actavis",
              "value": "Actavis plc."
            },
            {
              "key": "ADC",
              "value": "antibody drug conjugate(s)."
            },
            {
              "key": "ADRs",
              "value": "American Depositary Receipts."
            },
            {
              "key": "ADSs",
              "value": "American Depositary Shares."
            },
            {
              "key": "AGM",
              "value": "an Annual General Meeting of the Company."
            },
            {
              "key": "AI",
              "value": "artificial intelligence."
            },
            {
              "key": "Alexion",
              "value": "Alexion Pharmaceuticals, Inc."
            },
            {
              "key": "Allergan",
              "value": "Allergan Plc."
            },
            {
              "key": "Almirall",
              "value": "Almirall, S.A."
            },
            {
              "key": "Amgen",
              "value": "Amgen Inc."
            },
            {
              "key": "Amplimmune",
              "value": "Amplimmune, Inc."
            },
            {
              "key": "Annual Report",
              "value": "this Annual Report and Form 20-F Information 2022."
            },
            {
              "key": "API",
              "value": "active pharmaceutical ingredient."
            },
            {
              "key": "Ardea",
              "value": "Ardea Biosciences, Inc."
            },
            {
              "key": "Articles",
              "value": "the Articles of Association of the Company."
            },
            {
              "key": "Astellas",
              "value": "Astellas Pharma Inc."
            },
            {
              "key": "Astra",
              "value": "Astra AB, being the company with whom the Company merged in 1999."
            },
            {
              "key": "AstraZeneca",
              "value": "the Company and its subsidiaries."
            },
            {
              "key": "Atnahs",
              "value": "Atnahs Pharma UK Ltd."
            },
            {
              "key": "ATTR",
              "value": "Transthyretin amyloidosis."
            },
            {
              "key": "biologic(s)",
              "value": "a class of drugs that are produced in living cells."
            },
            {
              "key": "Baxter",
              "value": "Baxter International Inc."
            },
            {
              "key": "BMS",
              "value": "Bristol-Myers Squibb Company."
            },
            {
              "key": "Board",
              "value": "the Board of Directors of the Company."
            },
            {
              "key": "BRCA",
              "value": "BReast CAncer gene."
            },
            {
              "key": "BRCAm",
              "value": "BRCA-mutated."
            },
            {
              "key": "Bureau Veritas",
              "value": "Bureau Veritas UK Limited."
            },
            {
              "key": "CDP (formerly the Carbon Disclosure Project)",
              "value": "a not-for-profit organisation that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts."
            },
            {
              "key": "CEO",
              "value": "the Chief Executive Officer of the Company."
            },
            {
              "key": "CER",
              "value": "constant exchange rates."
            },
            {
              "key": "CFO",
              "value": "the Chief Financial Officer of the Company."
            },
            {
              "key": "Cheplapharm",
              "value": "Cheplapharm Arzneimittel GmbH."
            },
            {
              "key": "CKD",
              "value": "chronic kidney disease."
            },
            {
              "key": "CLL",
              "value": "chronic lymphocytic leukaemia."
            },
            {
              "key": "Code of Ethics",
              "value": "the Group’s Code of Ethics, see page 51."
            },
            {
              "key": "Company or Parent Company",
              "value": "AstraZeneca PLC (formerly Zeneca Group PLC (Zeneca))."
            },
            {
              "key": "COPD",
              "value": "chronic obstructive pulmonary disease."
            },
            {
              "key": "COVAX",
              "value": "the vaccines pillar of the Access to COVID-19 Tools (Act) Accelerator."
            },
            {
              "key": "COVID-19",
              "value": "the official WHO name for the disease caused by the 2019 novel coronavirus."
            },
            {
              "key": "CV",
              "value": "cardiovascular."
            },
            {
              "key": "CVRM",
              "value": "Cardiovascular, Renal & Metabolism."
            },
            {
              "key": "Daiichi Sankyo",
              "value": "Daiichi Sankyo, Inc. or a company within the Daiichi Sankyo group of companies."
            },
            {
              "key": "Director",
              "value": "a director of the Company."
            },
            {
              "key": "DTR",
              "value": "UK Disclosure Guidance and Transparency Rules."
            },
            {
              "key": "EBITDA",
              "value": "Reported Profit before tax plus net finance expense, share of after tax losses of joint ventures and associates and charges for depreciation, amortisation and impairment."
            },
            {
              "key": "EFPIA",
              "value": "European Federation of Pharmaceutical Industries and Associations."
            },
            {
              "key": "EGFR",
              "value": "epidermal growth factor receptor."
            },
            {
              "key": "EGFRm",
              "value": "EGFR-mutated."
            },
            {
              "key": "EPS",
              "value": "earnings per share: profit for the year after tax and non-controlling interests, divided by the weighted average number of Ordinary Shares in issue during the year."
            },
            {
              "key": "ESG",
              "value": "environmental, social and governance."
            },
            {
              "key": "ESMO",
              "value": "European Society for Medical Oncology."
            },
            {
              "key": "EVP",
              "value": "Executive Vice-President."
            },
            {
              "key": "EU",
              "value": "the European Union."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 228,
          "title": "Registered office and corporate headquarters",
          "data": [
            {
              "key": "Corporate Headquarters",
              "value": "AstraZeneca PLC"
            },
            {
              "key": "Address",
              "value": "1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK"
            },
            {
              "key": "Telephone",
              "value": "+44 (0)20 3749 5000"
            },
            {
              "key": "Website",
              "value": "www.astrazeneca.com/annualreport2022"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 47,
          "title": "People and Sustainability Overview",
          "data": [
            {
              "key": "Total job applications",
              "value": "793,000"
            },
            {
              "key": "Total employees hired",
              "value": "22,500"
            },
            {
              "key": "Internal hires",
              "value": "7,700"
            },
            {
              "key": "External hires",
              "value": "14,800"
            },
            {
              "key": "Hires from employee referral scheme",
              "value": "4,720"
            },
            {
              "key": "Apprentice, graduate and MBA hires",
              "value": "300"
            },
            {
              "key": "Voluntary employee turnover",
              "value": "11% (2021: 14%)"
            },
            {
              "key": "Employees promoted in 2022",
              "value": "9%"
            },
            {
              "key": "Alexion employees integrated into AstraZeneca",
              "value": "4,000"
            },
            {
              "key": "Performance development workshops conducted",
              "value": "555"
            },
            {
              "key": "Participants in workshops",
              "value": "16,500"
            },
            {
              "key": "Line managers attending workshops",
              "value": "8,000"
            },
            {
              "key": "Completion rate of year-end insights (employees)",
              "value": "95.5%"
            },
            {
              "key": "Completion rate of year-end insights (managers)",
              "value": "96.5%"
            },
            {
              "key": "Rewards given to employees",
              "value": "269,000"
            },
            {
              "key": "Employees receiving rewards",
              "value": "68%"
            },
            {
              "key": "Participation rate in global engagement survey",
              "value": "92%"
            },
            {
              "key": "Employees believing in AstraZeneca's future direction",
              "value": "89%"
            },
            {
              "key": "Employees having development discussions with managers",
              "value": "89%"
            },
            {
              "key": "Employees considering reemployment in exit interviews",
              "value": ">90%"
            },
            {
              "key": "Average Candidate Experience survey rating",
              "value": "4.6 out of 5"
            },
            {
              "key": "Investment in employee upskilling",
              "value": "$37.7 million"
            },
            {
              "key": "Average spend on upskilling per employee",
              "value": "$482"
            },
            {
              "key": "Total learning hours",
              "value": "2,348,892"
            },
            {
              "key": "Average learning hours per employee",
              "value": "20.6 hours"
            },
            {
              "key": "Employees accessing global learning platform",
              "value": "64%"
            },
            {
              "key": "Attendees across development experiences",
              "value": "3,994"
            },
            {
              "key": "Participants in Colleague Connexion Buddy Programme",
              "value": "2,350"
            },
            {
              "key": "Percentage of women in development programme",
              "value": "67%"
            },
            {
              "key": "Employees believing they've improved skills",
              "value": "89%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 49,
          "title": "Global Employee Distribution and Regional Breakdown",
          "data": [
            {
              "key": "Cambridge, UK",
              "value": "4,400"
            },
            {
              "key": "Boston, MA, US",
              "value": "1,000"
            },
            {
              "key": "Gaithersburg, MD, US",
              "value": "4,087"
            },
            {
              "key": "Gothenburg, Sweden",
              "value": "2,800"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 174,
          "title": "Provisions Movement Analysis 2020-2022",
          "data": [
            {
              "key": "period",
              "value": "At 1 January 2020"
            },
            {
              "key": "Severance $m",
              "value": "241"
            },
            {
              "key": "Environmental $m",
              "value": "96"
            },
            {
              "key": "ie eet ies benefits $m",
              "value": "130"
            },
            {
              "key": "Legal $m",
              "value": "642"
            },
            {
              "key": "provisions $m",
              "value": "455"
            },
            {
              "key": "Total $m",
              "value": "1564"
            },
            {
              "key": "period",
              "value": "At 31 December 2020"
            },
            {
              "key": "Severance $m",
              "value": "214"
            },
            {
              "key": "Environmental $m",
              "value": "100"
            },
            {
              "key": "ie eet ies benefits $m",
              "value": "128"
            },
            {
              "key": "Legal $m",
              "value": "348"
            },
            {
              "key": "provisions $m",
              "value": "770"
            },
            {
              "key": "Total $m",
              "value": "1560"
            },
            {
              "key": "period",
              "value": "At 31 December 2021"
            },
            {
              "key": "Severance $m",
              "value": "212"
            },
            {
              "key": "Environmental $m",
              "value": "90"
            },
            {
              "key": "ie eet ies benefits $m",
              "value": "195"
            },
            {
              "key": "Legal $m",
              "value": "239"
            },
            {
              "key": "provisions $m",
              "value": "988"
            },
            {
              "key": "Total $m",
              "value": "1724"
            },
            {
              "key": "period",
              "value": "At 31 December 2022"
            },
            {
              "key": "Severance $m",
              "value": "165"
            },
            {
              "key": "Environmental $m",
              "value": "131"
            },
            {
              "key": "ie eet ies benefits $m",
              "value": "143"
            },
            {
              "key": "Legal $m",
              "value": "161"
            },
            {
              "key": "provisions $m",
              "value": "1018"
            },
            {
              "key": "Total $m",
              "value": "1618"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 191,
          "title": "Employees by Region",
          "data": [
            {
              "key": "UK",
              "value": "9800"
            },
            {
              "key": "Rest of Europe",
              "value": "20600"
            },
            {
              "key": "The Americas",
              "value": "20900"
            },
            {
              "key": "Asia, Africa & Australasia",
              "value": "30700"
            },
            {
              "key": "Continuing operations",
              "value": "82000"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 218,
          "title": "Shareholder Ownership Disclosure and Holdings",
          "data": [
            {
              "key": "Shareholder",
              "value": "BlackRock, Inc."
            },
            {
              "key": "Date of the latest disclosure",
              "value": "4 December 2009"
            },
            {
              "key": "Number of Ordinary Shares",
              "value": "100,885,181"
            },
            {
              "key": "31 December 2020",
              "value": "7.69"
            },
            {
              "key": "31 December 2021",
              "value": "6.51"
            },
            {
              "key": "31 December 2022",
              "value": "6.51"
            },
            {
              "key": "31 January 2023",
              "value": "6.51"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 218,
          "title": "Directors’, officers’ and SET shareholdings",
          "data": [
            {
              "key": "Ordinary Shares",
              "value": "545,338"
            },
            {
              "key": "Percentage",
              "value": "0.04"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 218,
          "title": "Options to purchase securities from registrant or subsidiaries",
          "data": [
            {
              "key": "Options Outstanding",
              "value": "126,431"
            },
            {
              "key": "Subscription",
              "value": "3597-9064"
            },
            {
              "key": "Normal _",
              "value": "2023-2028"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 218,
          "title": "Distributions to shareholders – dividends for 2022",
          "data": [
            {
              "key": "Total Dividend Payment",
              "value": "$4,493 million"
            },
            {
              "key": "Dividend per Share",
              "value": "$2.90"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "layoff",
          "page": 218,
          "title": "Directors Share Options",
          "data": [
            {
              "key": "Number of shares",
              "value": "526"
            },
            {
              "key": "Subscription price(pence)",
              "value": "6839"
            },
            {
              "key": "Normal _expiry date",
              "value": "2024"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 7,
          "title": "Employee Statistics and Commitment",
          "data": [
            {
              "key": "Total Employees",
              "value": "83,500"
            },
            {
              "key": "Employees 2021",
              "value": "83,100"
            },
            {
              "key": "Employees 2020",
              "value": "76,100"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 7,
          "title": "Diversity in Leadership",
          "data": [
            {
              "key": "Women in Senior Roles",
              "value": "38% Europe"
            },
            {
              "key": "Women in Senior Roles",
              "value": "35% Emerging Markets"
            },
            {
              "key": "Women in Senior Roles",
              "value": "20% US"
            },
            {
              "key": "Women in Senior Roles",
              "value": "7% Rest of World"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 7,
          "title": "R&D Organization",
          "data": [
            {
              "key": "Total R&D Employees",
              "value": "More than 13,000"
            },
            {
              "key": "Global R&D Centers",
              "value": "Cambridge, UK; Boston, MA, US; Gaithersburg, MD, US; Gothenburg, Sweden"
            },
            {
              "key": "Other R&D Centers",
              "value": "7"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 10,
          "title": "AstraZeneca's Commitment to Patient Health and Sustainability",
          "data": [
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Achievement",
              "value": "Record-breaking five approvals for cancer treatments in one day"
            },
            {
              "key": "Total Approvals",
              "value": "12 medicine approvals"
            },
            {
              "key": "New Indications",
              "value": "8 new indication launches"
            },
            {
              "key": "Major Market Approvals",
              "value": "21 major market approvals"
            },
            {
              "key": "Impact",
              "value": "Vaxzevria saved more than six million lives in its first year"
            },
            {
              "key": "Cancer Treatment Availability",
              "value": "Alexion’s first medicine in China: Soliris"
            },
            {
              "key": "Health Program Expansion",
              "value": "Healthy Heart Africa launched in nine countries with more than 32 million screenings"
            },
            {
              "key": "Sustainability Strategy",
              "value": "59% reduction in Scope 1 and 2 greenhouse gas emissions by December 2022"
            },
            {
              "key": "New Chair",
              "value": "Michel Demaré"
            },
            {
              "key": "Departing Chairman",
              "value": "Leif Johansson"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 15,
          "title": "Strategic Report Overview",
          "data": [
            {
              "key": "Investment Focus",
              "value": "Investment in discovery, development, manufacturing and commercialization of prescription medicines."
            },
            {
              "key": "Revenue Generation",
              "value": "Revenue generation from Product Sales of existing and new medicines, collaboration activities."
            },
            {
              "key": "Reinvestment Strategy",
              "value": "Reinvest in next-generation innovative medicines and business for future revenue."
            },
            {
              "key": "Cycle Description",
              "value": "Reinvestment of returns cycle showing pharmaceutical development process."
            },
            {
              "key": "Research Duration",
              "value": "5-15 years for research and development phases."
            },
            {
              "key": "Launch Duration",
              "value": "5-15 years for launch phase."
            },
            {
              "key": "Post-Exclusivity Duration",
              "value": "20+ years after patent expiry."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 28,
          "title": "Respiratory Product Portfolio Performance",
          "data": [
            {
              "key": "Market Value",
              "value": "$82.4bn"
            },
            {
              "key": "Asthma Revenue",
              "value": "$24.8bn"
            },
            {
              "key": "COPD Revenue",
              "value": "$19.8bn"
            },
            {
              "key": "Other Revenue",
              "value": "$37.8bn"
            },
            {
              "key": "Symbicort Revenue",
              "value": "$2,538m, down 7% (2% at CER)"
            },
            {
              "key": "Fasenra Revenue",
              "value": "$1,396m, up 11% (15% at CER)"
            },
            {
              "key": "Breztri/Trixeo Revenue",
              "value": "up 96% (103% at CER)"
            },
            {
              "key": "Tezspire Revenue",
              "value": "$82m"
            },
            {
              "key": "Pulmicort Revenue",
              "value": "$645m, down 33% (31% at CER)"
            },
            {
              "key": "Daliresp/Daxas Revenue",
              "value": "$189m, down 17% (16% at CER)"
            },
            {
              "key": "Bevespi Revenue",
              "value": "$58m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 41,
          "title": "Regional Revenue and Growth Analysis",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$44,351 million"
            },
            {
              "key": "Total Revenue Growth",
              "value": "19% (25% at CER)"
            },
            {
              "key": "US Revenue",
              "value": "$17,920 million"
            },
            {
              "key": "US Revenue Growth",
              "value": "47%"
            },
            {
              "key": "Europe Revenue",
              "value": "$8,738 million"
            },
            {
              "key": "Europe Revenue Growth",
              "value": "9% (21% at CER)"
            },
            {
              "key": "Emerging Markets Revenue",
              "value": "$11,745 million"
            },
            {
              "key": "Emerging Markets Revenue Growth",
              "value": "-4% (1% at CER)"
            },
            {
              "key": "Number of Market Launches",
              "value": "198"
            },
            {
              "key": "Total Employees in Commercial Teams",
              "value": "44,790"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 87,
          "title": "Executive Remuneration Policy",
          "data": [
            {
              "key": "Description",
              "value": "The Remuneration Committee reviews the Directors’ Remuneration Policy and arrangements to support the delivery of long-term strategy."
            },
            {
              "key": "Independent Judgement",
              "value": "The Committee considers a range of data, including business and individual performance, while maintaining independent judgment."
            },
            {
              "key": "Directors' Appointments",
              "value": "Mr Johansson has served as Chair and will retire in 2023; Michel Demaré appointed Chair-designate."
            },
            {
              "key": "Non-Executive Directors Independence",
              "value": "Most Non-Executive Directors are independent except Marcus Wallenberg due to his long tenure and relationship with a significant shareholder."
            },
            {
              "key": "Global Compliance Overview",
              "value": "Global Compliance ensures adherence to priorities and ethical conduct across the organization."
            },
            {
              "key": "GIA's Role",
              "value": "Internal Audit reviews governance, risk management, and control processes and reports findings to the Board."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Directors’ Remuneration Report",
          "data": [
            {
              "key": "Report Year",
              "value": "2022"
            },
            {
              "key": "Three-year TSR",
              "value": "58%"
            },
            {
              "key": "Vote in favour of 2021 Report",
              "value": "92%"
            },
            {
              "key": "Chair of Remuneration Committee",
              "value": "Sheri McCoy"
            },
            {
              "key": "Base pay adjustment for inflation",
              "value": "Approved in high inflation countries"
            },
            {
              "key": "One-off cost of living payment in UK",
              "value": "£1,500"
            },
            {
              "key": "Long-term incentive eligibility improvement",
              "value": "Global basis"
            },
            {
              "key": "Percentage of workforce in share-based incentive schemes",
              "value": "35%"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 108,
          "title": "Directors’ Remuneration Report continued",
          "data": [
            {
              "key": "Annual bonus",
              "value": "92% of maximum"
            },
            {
              "key": "Mr Soriot's bonus",
              "value": "228.75% of base pay"
            },
            {
              "key": "Dr Sarin's bonus",
              "value": "183% of base pay"
            },
            {
              "key": "LTI award vesting",
              "value": "97% of maximum"
            },
            {
              "key": "Chair fee increase effective May 2023",
              "value": "£800,000 per annum"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 108,
          "title": "Performance Metrics Achievement",
          "data": [
            {
              "key": "Science and Innovation: Annual pipeline progression achievement",
              "value": "72%"
            },
            {
              "key": "Growth and Therapy Area Leadership achievement",
              "value": "100%"
            },
            {
              "key": "Achieve Group Financial Targets achievement",
              "value": "100%"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 108,
          "title": "Science and Innovation: First approvals and NME volume over three years",
          "data": [
            {
              "key": "Science and Innovation first approvals achievement",
              "value": "100%"
            },
            {
              "key": "Growth and Therapy Area Leadership achievement",
              "value": "100%"
            },
            {
              "key": "Achieve Group Financial Targets achievement",
              "value": "100%"
            },
            {
              "key": "Relative TSR achievement",
              "value": "84%"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 109,
          "title": "Market positioning of Executive Directors’ on-target remuneration for 2022",
          "data": [
            {
              "key": "European pharma peers",
              "value": "£6.60m"
            },
            {
              "key": "Global pharma peers",
              "value": "£3.99m"
            },
            {
              "key": "Current position CFO",
              "value": "£5.93m"
            },
            {
              "key": "Current position European pharma peers",
              "value": "£4.68m"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 110,
          "title": "Executive Directors' remuneration for 2023",
          "data": [
            {
              "key": "Position",
              "value": "CEO"
            },
            {
              "key": "Name",
              "value": "Pascal Soriot"
            },
            {
              "key": "Base Pay",
              "value": "£1,428,517"
            },
            {
              "key": "Benefits Fund",
              "value": "£157,137"
            },
            {
              "key": "Benefits Percentage",
              "value": "11% of base pay"
            },
            {
              "key": "Annual Bonus Maximum",
              "value": "250% base pay"
            },
            {
              "key": "Annual Bonus Target",
              "value": "125% base pay"
            },
            {
              "key": "Annual Bonus Deferral",
              "value": "50% for three years"
            },
            {
              "key": "Long Term Incentives Maximum",
              "value": "650% base pay"
            },
            {
              "key": "Long Term Incentives Performance Period",
              "value": "three years"
            },
            {
              "key": "Long Term Incentives Holding Period",
              "value": "two years"
            },
            {
              "key": "Shareholding Requirement",
              "value": "650% base pay"
            },
            {
              "key": "Post-Cessation Shares",
              "value": "shares up to 650% base pay for two years"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 110,
          "title": "Executive Directors' remuneration for 2023",
          "data": [
            {
              "key": "Position",
              "value": "CFO"
            },
            {
              "key": "Name",
              "value": "Aradhana Sarin"
            },
            {
              "key": "Base Pay",
              "value": "£914,888"
            },
            {
              "key": "Benefits Fund",
              "value": "£100,638"
            },
            {
              "key": "Benefits Percentage",
              "value": "11% of base pay"
            },
            {
              "key": "Annual Bonus Maximum",
              "value": "200% base pay"
            },
            {
              "key": "Annual Bonus Target",
              "value": "100% base pay"
            },
            {
              "key": "Annual Bonus Deferral",
              "value": "50% for three years"
            },
            {
              "key": "Long Term Incentives Maximum",
              "value": "450% base pay"
            },
            {
              "key": "Long Term Incentives Performance Period",
              "value": "three years"
            },
            {
              "key": "Long Term Incentives Holding Period",
              "value": "two years"
            },
            {
              "key": "Shareholding Requirement",
              "value": "450% base pay"
            },
            {
              "key": "Post-Cessation Shares",
              "value": "shares up to 450% base pay for two years"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 111,
          "title": "How our performance measures for 2023 support the delivery of our strategy",
          "data": [
            {
              "key": "Incentives",
              "value": "Short and long term bonuses linked to science, financial and ESG measures."
            },
            {
              "key": "Performance Measures",
              "value": "Cash flow, Total Revenue, science indices, Core EPS, regulatory submissions and approvals."
            },
            {
              "key": "Strategic Priorities",
              "value": "Aligns with patient-centric culture and sustainable growth."
            },
            {
              "key": "Ambition Zero Carbon",
              "value": "Targets for elimination of Scope 1 and Scope 2 GHG emissions by 2025."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 112,
          "title": "Executive Directors’ Bonuses and Performance Assessment Process",
          "data": [
            {
              "key": "2023 Targets Assessment",
              "value": "Targets are stretching and require performance above prior year outturns and industry average expectations."
            },
            {
              "key": "Review Process",
              "value": "The Remuneration Committee reviews proposed targets with input from Science and Sustainability Committees."
            },
            {
              "key": "Financial Metrics",
              "value": "Measured against budget rates of exchange and compared year-on-year."
            },
            {
              "key": "Performance Assessment Cycle",
              "value": "Involves multiple stages, including review of targets, performance outcomes, and final bonus determination."
            },
            {
              "key": "Incentivizing Collaborative Performance",
              "value": "Targets include ESG metrics and long-term sustainable value creation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Executive Compensation Summary (in £'000)",
          "data": [
            {
              "key": "Executive Director",
              "value": "Pascal Soriot"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Base Pay",
              "value": "£1,367,000"
            },
            {
              "key": "Taxable Benefits",
              "value": "£136,000"
            },
            {
              "key": "Pension",
              "value": "£150,000"
            },
            {
              "key": "Total Fixed Compensation",
              "value": "£1,653,000"
            },
            {
              "key": "Annual Bonus",
              "value": "£3,127,000"
            },
            {
              "key": "Long-Term Incentives",
              "value": "£10,543,000"
            },
            {
              "key": "Total Variable Compensation",
              "value": "£13,670,000"
            },
            {
              "key": "Single Total Figure",
              "value": "£15,323,000"
            },
            {
              "key": "Appreciation Percentage",
              "value": "20%"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Executive Compensation Summary (in £'000)",
          "data": [
            {
              "key": "Executive Director",
              "value": "Pascal Soriot"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Base Pay",
              "value": "£1,327,000"
            },
            {
              "key": "Taxable Benefits",
              "value": "£123,000"
            },
            {
              "key": "Pension",
              "value": "£146,000"
            },
            {
              "key": "Total Fixed Compensation",
              "value": "£1,596,000"
            },
            {
              "key": "Annual Bonus",
              "value": "£3,152,000"
            },
            {
              "key": "Long-Term Incentives",
              "value": "£10,993,000"
            },
            {
              "key": "Total Variable Compensation",
              "value": "£14,145,000"
            },
            {
              "key": "Single Total Figure",
              "value": "£15,740,000"
            },
            {
              "key": "Appreciation Percentage",
              "value": "27%"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Executive Compensation Summary (in £'000)",
          "data": [
            {
              "key": "Executive Director",
              "value": "Aradhana Sarin"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Base Pay",
              "value": "£876,000"
            },
            {
              "key": "Taxable Benefits",
              "value": "£161,000"
            },
            {
              "key": "Pension",
              "value": "£96,000"
            },
            {
              "key": "Total Fixed Compensation",
              "value": "£1,133,000"
            },
            {
              "key": "Annual Bonus",
              "value": "£1,602,000"
            },
            {
              "key": "Long-Term Incentives",
              "value": "£0"
            },
            {
              "key": "Total Variable Compensation",
              "value": "£1,602,000"
            },
            {
              "key": "Single Total Figure",
              "value": "£2,735,000"
            },
            {
              "key": "Appreciation Percentage",
              "value": "-"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Executive Compensation Summary (in £'000)",
          "data": [
            {
              "key": "Executive Director",
              "value": "Aradhana Sarin"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Base Pay",
              "value": "£354,000"
            },
            {
              "key": "Taxable Benefits",
              "value": "£6,000"
            },
            {
              "key": "Pension",
              "value": "£39,000"
            },
            {
              "key": "Total Fixed Compensation",
              "value": "£2,418,000"
            },
            {
              "key": "Annual Bonus",
              "value": "£595,000"
            },
            {
              "key": "Long-Term Incentives",
              "value": "£0"
            },
            {
              "key": "Total Variable Compensation",
              "value": "£595,000"
            },
            {
              "key": "Single Total Figure",
              "value": "£3,013,000"
            },
            {
              "key": "Appreciation Percentage",
              "value": "-"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 114,
          "title": "Base Pay and Increases for Executive Directors",
          "data": [
            {
              "key": "Executive Director",
              "value": "Pascal Soriot"
            },
            {
              "key": "Change from 2021",
              "value": "3%"
            },
            {
              "key": "2022 Base pay",
              "value": "1,367"
            },
            {
              "key": "Change from 2022",
              "value": "4.5%"
            },
            {
              "key": "2023 Base pay",
              "value": "1,429"
            },
            {
              "key": "Executive Director",
              "value": "Aradhana Sarin"
            },
            {
              "key": "Change from 2021",
              "value": "3%"
            },
            {
              "key": "2022 Base pay",
              "value": "876"
            },
            {
              "key": "Change from 2022",
              "value": "4.5%"
            },
            {
              "key": "2023 Base pay",
              "value": "915"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 114,
          "title": "Taxable Benefits for Executive Directors",
          "data": [
            {
              "key": "Executive Director",
              "value": "Pascal Soriot"
            },
            {
              "key": "2022 Total taxable benefits",
              "value": "136"
            },
            {
              "key": "2023 Taxable benefits",
              "value": "Inline with 2022"
            },
            {
              "key": "Executive Director",
              "value": "Aradhana Sarin"
            },
            {
              "key": "2022 Total taxable benefits",
              "value": "161"
            },
            {
              "key": "2023 Taxable benefits",
              "value": "Lower than 2022"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Executive Pension Arrangements",
          "data": [
            {
              "key": "Pascal Soriot - Pensionable Base Pay",
              "value": "£1,367,000"
            },
            {
              "key": "Pascal Soriot - Pension Allowance 2022",
              "value": "11% of base pay"
            },
            {
              "key": "Pascal Soriot - Cash in Lieu 2022",
              "value": "£150,000"
            },
            {
              "key": "Pascal Soriot - Pension Allowance 2023",
              "value": "1% of base pay"
            },
            {
              "key": "Aradhana Sarin - Pensionable Base Pay",
              "value": "£876,000"
            },
            {
              "key": "Aradhana Sarin - Pension Allowance 2022",
              "value": "11% of base pay"
            },
            {
              "key": "Aradhana Sarin - Cash in Lieu 2022",
              "value": "£96,000"
            },
            {
              "key": "Aradhana Sarin - Pension Allowance 2023",
              "value": "1% of base pay"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Bonus Structure and Awards",
          "data": [
            {
              "key": "Pascal Soriot - Bonus Potential Target",
              "value": "125%"
            },
            {
              "key": "Pascal Soriot - Bonus Potential Maximum",
              "value": "250%"
            },
            {
              "key": "Pascal Soriot - Bonus Payable in Cash",
              "value": "1,563"
            },
            {
              "key": "Pascal Soriot - Bonus Deferred into Shares",
              "value": "1,564"
            },
            {
              "key": "Pascal Soriot - Total Bonus Awarded",
              "value": "3,127 92%"
            },
            {
              "key": "Aradhana Sarin - Bonus Potential Target",
              "value": "100%"
            },
            {
              "key": "Aradhana Sarin - Bonus Potential Maximum",
              "value": "200%"
            },
            {
              "key": "Aradhana Sarin - Bonus Payable in Cash",
              "value": "801"
            },
            {
              "key": "Aradhana Sarin - Bonus Deferred into Shares",
              "value": "801"
            },
            {
              "key": "Aradhana Sarin - Total Bonus Awarded",
              "value": "1,602 92% max"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 116,
          "title": "2022 Group scorecard performance measures and metrics",
          "data": [
            {
              "key": "category",
              "value": "Science and Innovation measures"
            },
            {
              "key": "metric",
              "value": "Pipeline progression events"
            },
            {
              "key": "weighting",
              "value": "15%"
            },
            {
              "key": "maximum",
              "value": "30"
            },
            {
              "key": "outcome",
              "value": "25"
            },
            {
              "key": "formulaic_outcome",
              "value": "23%"
            },
            {
              "key": "category",
              "value": "Science and Innovation measures"
            },
            {
              "key": "metric",
              "value": "Regulatory events"
            },
            {
              "key": "weighting",
              "value": "15%"
            },
            {
              "key": "maximum",
              "value": "59"
            },
            {
              "key": "outcome",
              "value": "50"
            },
            {
              "key": "formulaic_outcome",
              "value": "20%"
            },
            {
              "key": "category",
              "value": "Science and Innovation measures"
            },
            {
              "key": "metric",
              "value": "Subtotal"
            },
            {
              "key": "weighting",
              "value": "30%"
            },
            {
              "key": "formulaic_outcome",
              "value": "43%"
            },
            {
              "key": "category",
              "value": "Financial measures"
            },
            {
              "key": "metric",
              "value": "Total Revenue"
            },
            {
              "key": "weighting",
              "value": "30%"
            },
            {
              "key": "outcome",
              "value": "46.3"
            },
            {
              "key": "formulaic_outcome",
              "value": "60%"
            },
            {
              "key": "category",
              "value": "Financial measures"
            },
            {
              "key": "metric",
              "value": "Core EPS"
            },
            {
              "key": "weighting",
              "value": "20%"
            },
            {
              "key": "outcome",
              "value": "7.04"
            },
            {
              "key": "formulaic_outcome",
              "value": "40%"
            },
            {
              "key": "category",
              "value": "Financial measures"
            },
            {
              "key": "metric",
              "value": "Subtotal"
            },
            {
              "key": "weighting",
              "value": "70%"
            },
            {
              "key": "formulaic_outcome",
              "value": "140%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 117,
          "title": "Executive Director Performance Assessment 2022 - Pascal Soriot",
          "data": [
            {
              "key": "Overall Performance",
              "value": "Pascal Soriot led AstraZeneca to double-digit growth across all therapy areas in 2022, with pipeline delivery recognized among the strongest in industry. Total Shareholder Return was 32% for 2022."
            },
            {
              "key": "Global Leadership",
              "value": "Over 20 external engagements with world leaders, including attendance at COP27, AACR Award ceremony, and engagement with Chinese officials on rare disease centre development."
            },
            {
              "key": "ESG Performance",
              "value": "Led SMI Health Systems task force with HM King Charles III for healthcare decarbonisation, Achieved CDP double A listing for climate change and water security, Developed collaboration with Honeywell for eco-friendly inhalers, Delivered UN General Assembly address on COVID-19 response, Expanded Healthy Heart Africa program to new regions, Improved Access to Medicines Index ranking from 7th to 3rd."
            },
            {
              "key": "Workplace Excellence",
              "value": "Launched refreshed Global Inclusion & Diversity strategy, Achieved multiple diversity recognitions and awards, Implemented extensive learning initiatives with 78% employee participation, Launched 'AZ Together' employee support fund."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 118,
          "title": "Executive Directors' Bonus and Share Grants Overview",
          "data": [
            {
              "key": "Bonus outturn for Executive Directors",
              "value": "183% of target (or 92% of maximum)"
            },
            {
              "key": "Deferred Bonus Plan (DBP)",
              "value": "A proportion of each Executive Director’s pre-tax annual bonus is compulsorily deferred."
            },
            {
              "key": "Pascal Soriot shares granted",
              "value": "17216 shares granted on 4 March 2022 at 9154 pence/share."
            },
            {
              "key": "Aradhana Sarin shares granted",
              "value": "3249 shares granted on 4 March 2022 at 9154 pence/share."
            },
            {
              "key": "Audited 2022 grant for Pascal Soriot",
              "value": "1576"
            },
            {
              "key": "Audited 2022 grant for Aradhana Sarin",
              "value": "297"
            },
            {
              "key": "2023 grant from 2022 bonus for Pascal Soriot",
              "value": "1564"
            },
            {
              "key": "2023 grant from 2022 bonus for Aradhana Sarin",
              "value": "801"
            },
            {
              "key": "Grant price description",
              "value": "Average closing share price over the three dealing days preceding grant."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 119,
          "title": "Long-term incentive awards with performance periods ended 31 December 2022",
          "data": [
            {
              "key": "Name",
              "value": "Pascal Soriot"
            },
            {
              "key": "Award Type",
              "value": "2020 PSP"
            },
            {
              "key": "Ordinary Shares Granted",
              "value": "96080"
            },
            {
              "key": "Performance Outcome",
              "value": "97%"
            },
            {
              "key": "Face Value at Grant (£)",
              "value": "6874"
            },
            {
              "key": "Value due to Share Price Appreciation (£)",
              "value": "3057"
            },
            {
              "key": "Dividend Equivalent Accrued (£)",
              "value": "612"
            },
            {
              "key": "Total Value (£)",
              "value": "10543"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 119,
          "title": "PSP performance measures and metrics - Science and Innovation: First approvals and NME volume over three years (2020)",
          "data": [
            {
              "key": "NME Phase III/registrational volume",
              "value": "18"
            },
            {
              "key": "Regulatory events",
              "value": "29"
            },
            {
              "key": "Innovative Science Subtotal Payout",
              "value": "30%"
            },
            {
              "key": "Growth and Therapy Area Leadership ($bn) Payout",
              "value": "25%"
            },
            {
              "key": "Cash flow ($bn) Outcome",
              "value": "20.0"
            },
            {
              "key": "Total Shareholder Return Outcome",
              "value": "5th"
            },
            {
              "key": "Overall Payout Percentage",
              "value": "97%"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 120,
          "title": "Share Grant Details",
          "data": [
            {
              "key": "Name",
              "value": "Pascal Soriot"
            },
            {
              "key": "Ordinary Shares granted",
              "value": "97,066"
            },
            {
              "key": "Grant date",
              "value": "4 March 2022"
            },
            {
              "key": "Grant price",
              "value": "9154"
            },
            {
              "key": "Face value £7000",
              "value": "8,885"
            },
            {
              "key": "End of performance period",
              "value": "31 December 2024"
            },
            {
              "key": "End of holding period",
              "value": "4 March 2027"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 120,
          "title": "Share Grant Details",
          "data": [
            {
              "key": "Name",
              "value": "Aradhana Sarin"
            },
            {
              "key": "Ordinary Shares granted",
              "value": "43,038"
            },
            {
              "key": "Grant date",
              "value": "4 March 2022"
            },
            {
              "key": "Grant price",
              "value": "9154"
            },
            {
              "key": "Face value £7000",
              "value": "3,940"
            },
            {
              "key": "End of performance period",
              "value": "31 December 2024"
            },
            {
              "key": "End of holding period",
              "value": "4 March 2027"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 122,
          "title": "Board Members Compensation 2021-2022",
          "data": [
            {
              "key": "Total Compensation 2021",
              "value": "£1,905,000"
            },
            {
              "key": "Total Compensation 2022",
              "value": "£2,049,000"
            },
            {
              "key": "Top paid director 2022",
              "value": "Leif Johansson"
            },
            {
              "key": "Fees structure for 2023",
              "value": "Chair of the Board: £800,000; Basic Non-Executive Director: £95,000; Senior independent Non-Executive Director: £40,000; Audit Committee Member: £25,000; Audit Committee Chair: £45,000; Remuneration Committee Member: £20,000; Remuneration Committee Chair: £40,000; Sustainability Committee Member: £15,000; Sustainability Committee Chair: £30,000; Science Committee Member: £15,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 123,
          "title": "Share Ownership and Minimum Shareholding Requirements",
          "data": [
            {
              "key": "Pascal Soriot",
              "value": "248855 beneficially owned shares, 42894 shares in deferral, 1197% MSR of base pay"
            },
            {
              "key": "Aradhana Sarin",
              "value": "70154 beneficially owned shares, 39112 shares in deferral, 1149% MSR of base pay"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 123,
          "title": "Directors' Share Holdings",
          "data": [
            {
              "key": "Pascal Soriot",
              "value": "Ordinary Shares at 31 December 2021: 293439"
            },
            {
              "key": "Aradhana Sarin",
              "value": "Ordinary Shares at 31 December 2021: 27957"
            },
            {
              "key": "Leif Johansson",
              "value": "Ordinary Shares at 31 December 2021: 39009"
            },
            {
              "key": "Euan Ashley",
              "value": "Ordinary Shares at 31 December 2021: 1150"
            },
            {
              "key": "Philip Broadley",
              "value": "Ordinary Shares at 31 December 2021: 7045"
            },
            {
              "key": "Michel Demaré",
              "value": "Ordinary Shares at 31 December 2021: 2000"
            },
            {
              "key": "Deborah DiSanzo",
              "value": "Ordinary Shares at 31 December 2021: 1000"
            },
            {
              "key": "Diana Layfield",
              "value": "Ordinary Shares at 31 December 2021: 1400"
            },
            {
              "key": "Sheri McCoy",
              "value": "Ordinary Shares at 31 December 2021: 1736"
            },
            {
              "key": "Tony Mok",
              "value": "Ordinary Shares at 31 December 2021: 2000"
            },
            {
              "key": "Nazneen Rahman",
              "value": "Ordinary Shares at 31 December 2021: 1017"
            },
            {
              "key": "Andreas Rummelt",
              "value": "Ordinary Shares at 31 December 2021: 34790"
            },
            {
              "key": "Marcus Wallenberg",
              "value": "Ordinary Shares at 31 December 2021: 60028"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 124,
          "title": "Share Scheme Interests Summary",
          "data": [
            {
              "key": "scheme",
              "value": "DBP"
            },
            {
              "key": "grant_dates",
              "value": "08/03/2019, 06/03/2020, 05/03/2021, 04/03/2022"
            },
            {
              "key": "total_shares_granted",
              "value": "17216"
            },
            {
              "key": "total_shares_released",
              "value": "9849"
            },
            {
              "key": "total_shares_outstanding",
              "value": "42894"
            },
            {
              "key": "scheme",
              "value": "PSP"
            },
            {
              "key": "grant_dates",
              "value": "24/03/2017, 23/03/2018, 08/03/2019, 06/03/2020, 21/05/2020, 05/03/2021, 14/05/2021, 04/03/2022"
            },
            {
              "key": "total_shares_granted",
              "value": "97066"
            },
            {
              "key": "total_shares_released",
              "value": "121258"
            },
            {
              "key": "total_shares_lapsed",
              "value": "5124"
            },
            {
              "key": "shares_subject_to_performance",
              "value": "319192"
            },
            {
              "key": "scheme",
              "value": "AZIP"
            },
            {
              "key": "grant_dates",
              "value": "28/03/2014, 27/03/2015, 24/03/2016"
            },
            {
              "key": "total_shares_released",
              "value": "20677"
            },
            {
              "key": "total_shares_outstanding",
              "value": "23904"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 125,
          "title": "Directors' Remuneration Policy Summary",
          "data": [
            {
              "key": "Ownership Percentage",
              "value": "No director or senior executive owns or has options over 1% or more of the issued share capital."
            },
            {
              "key": "Payments to Former Directors",
              "value": "Marc Dunoyer's 2020 PSP award will result in 97% vesting, equating to 21,246 shares."
            },
            {
              "key": "Loss of Office Payments",
              "value": "No payments made in 2022."
            },
            {
              "key": "Engagement with Workforce",
              "value": "The Board values workforce engagement in remuneration decisions."
            },
            {
              "key": "Factors Considered in Decisions",
              "value": "Annual Group scorecard, employee feedback, workforce remuneration data."
            },
            {
              "key": "Priorities and Feedback Mechanisms",
              "value": "Active engagement with employee representative groups for workforce remuneration changes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 126,
          "title": "Comparison of Workforce and Executive Remuneration Policies",
          "data": [
            {
              "key": "Base pay",
              "value": "Our base pay is the basis for a competitive total reward package for all employees, and we review base pay annually. This review takes account of country budget, relevant market comparators, the skills, capabilities, knowledge and experience of each individual, relative to peers within the Company and individual contribution. In setting the budget each year, we consider affordability as well as assessing how employee base pay is currently positioned relative to inflation, market rates, forecasts of any further market increases and turnover."
            },
            {
              "key": "Pensions and benefits",
              "value": "We offer market-aligned wellbeing benefit packages reflecting market practice in each country in which we operate. Where appropriate, we offer elements of personal benefit choice to our employees."
            },
            {
              "key": "Annual bonus",
              "value": "With the exception of our sales representatives receiving sales-related incentives, our global workforce participates in the same annual cash bonus plan as the Executive Directors and SET, with the same Group scorecard performance measures outlined on page 114. Achievement against the scorecard creates a bonus pool from which all awards are made. For employees within our commercial organisation, the country-level share of the global bonus pool also takes into account country performance against KPIs. Individual outcomes are based on manager assessment of contribution against individual objectives and peers. Awards are based on a 0-200% target range."
            },
            {
              "key": "Long-term incentives",
              "value": "The PSP is operated with a three-year performance period for employees at Vice-President and Senior Vice-President level, with the same performance measures that apply to Executive Director and SET PSP awards (outlined on pages 117 to 119). A proportion of our workforce below Vice-President level is eligible to be considered for other long-term incentive awards, such as restricted stock awards. 35% of our global employee population are eligible to receive an award under our Long-term incentive plans."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 127,
          "title": "Compensation and Benefits Summary",
          "data": [
            {
              "key": "Executive Directors",
              "value": "Details on compensation structures for Executive Directors including names and compensation details."
            },
            {
              "key": "Pascal Soriot - period1",
              "value": "Base Pay: 3.0, Benefits: 10.5, Bonus: -0.8"
            },
            {
              "key": "Pascal Soriot - period2",
              "value": "Base Pay: 3.0, Benefits: 14.0, Bonus: 35.9"
            },
            {
              "key": "Pascal Soriot - period3",
              "value": "Base Pay: 0.0, Benefits: -2.7, Bonus: 20.0"
            },
            {
              "key": "Aradhana Sarin - period1",
              "value": "Base Pay: 147.2, Benefits: 2753.2, Bonus: 169.3"
            },
            {
              "key": "Non-Executive Directors",
              "value": "Details on compensation structures for Non-Executive Directors."
            },
            {
              "key": "Leif Johansson - period1",
              "value": "Base Pay: 0.0, Benefits: -6.4, Bonus: null"
            },
            {
              "key": "Leif Johansson - period2",
              "value": "Base Pay: 0.0, Benefits: 1.4, Bonus: null"
            },
            {
              "key": "Leif Johansson - period3",
              "value": "Base Pay: 0.0, Benefits: 1.4, Bonus: null"
            },
            {
              "key": "Euan Ashley - period1",
              "value": "Base Pay: 6.8, Benefits: null, Bonus: null"
            },
            {
              "key": "Euan Ashley - period2",
              "value": "Base Pay: 300.0, Benefits: null, Bonus: null"
            },
            {
              "key": "Employees",
              "value": "Compensation details for employees across periods."
            },
            {
              "key": "Employees - period1",
              "value": "Base Pay: 6.0, Benefits: 6.0, Bonus: 19.3"
            },
            {
              "key": "Employees - period2",
              "value": "Base Pay: 49.0, Benefits: 4.9, Bonus: 44.4"
            },
            {
              "key": "Employees - period3",
              "value": "Base Pay: 44.0, Benefits: 44.0, Bonus: -11.6"
            },
            {
              "key": "Summary",
              "value": "Compensation data across groups shows significant variation in bonuses, particularly for Pascal Soriot, and highlights high benefits for Aradhana Sarin."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 128,
          "title": "CEO and employee pay ratios",
          "data": [
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Option",
              "value": "OptionA"
            },
            {
              "key": "Ratio1 (CEO:Lower quartile)",
              "value": "230:1"
            },
            {
              "key": "Ratio2 (CEO:Median)",
              "value": "1591"
            },
            {
              "key": "Ratio3 (CEO:Upper quartile)",
              "value": "107:1"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Option",
              "value": "Option A"
            },
            {
              "key": "Ratio1 (CEO:Lower quartile)",
              "value": "240:1"
            },
            {
              "key": "Ratio2 (CEO:Median)",
              "value": "162:1"
            },
            {
              "key": "Ratio3 (CEO:Upper quartile)",
              "value": "106:1"
            },
            {
              "key": "Year",
              "value": "2020"
            },
            {
              "key": "Option",
              "value": "Option A"
            },
            {
              "key": "Ratio1 (CEO:Lower quartile)",
              "value": "284:1"
            },
            {
              "key": "Ratio2 (CEO:Median)",
              "value": "197:1"
            },
            {
              "key": "Ratio3 (CEO:Upper quartile)",
              "value": "130:1"
            },
            {
              "key": "Year",
              "value": "2019"
            },
            {
              "key": "Option",
              "value": "Option A"
            },
            {
              "key": "Ratio1 (CEO:Lower quartile)",
              "value": "280:1"
            },
            {
              "key": "Ratio2 (CEO:Median)",
              "value": "190:1"
            },
            {
              "key": "Ratio3 (CEO:Upper quartile)",
              "value": "123:1"
            },
            {
              "key": "Year",
              "value": "2018"
            },
            {
              "key": "Option",
              "value": "Option A"
            },
            {
              "key": "Ratio1 (CEO:Lower quartile)",
              "value": "230:1"
            },
            {
              "key": "Ratio2 (CEO:Median)",
              "value": "160:1"
            },
            {
              "key": "Ratio3 (CEO:Upper quartile)",
              "value": "103:1"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 129,
          "title": "CEO Remuneration and TSR Comparison",
          "data": [
            {
              "key": "Total Shareholder Return (TSR) Performance",
              "value": "The graph compares TSR performance of the Company with FTSE 100 Index and Pharmaceutical peers average over 10 years."
            },
            {
              "key": "CEO Name",
              "value": "Pascal Soriot"
            },
            {
              "key": "CEO Realised Pay 2022 (£)",
              "value": "15.3M"
            },
            {
              "key": "Maximum Opportunity % (2022)",
              "value": "92%"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 130,
          "title": "Annual Report on Remuneration",
          "data": [
            {
              "key": "Malus and clawback Policy Description",
              "value": "The Remuneration Committee regularly reviews the Company’s approach to malus and clawback and market practice."
            },
            {
              "key": "2022 AGM Voting Results for Remuneration Report",
              "value": "1,109,853,237 votes for (92.23%) and 93,486,120 votes against (7.77%), total votes cast: 1,203,339,357."
            },
            {
              "key": "2021 AGM Voting Results for Remuneration Policy",
              "value": "564,935,789 votes for (60.19%) and 373,708,277 votes against (39.81%), total votes cast: 938,644,066."
            },
            {
              "key": "Executive Contract Details",
              "value": "Pascal Soriot: Contract date 15 December 2016, 12 months notice and non-compete. Aradhana Sarin: Contract date 1 August 2021, 12 months notice and non-compete."
            },
            {
              "key": "Non-Executive Directors',' value':'No service contracts, letters of appointment do not provide notice periods or compensation on early termination.",
              "value": "The Directors’ Remuneration Report has been prepared according to Regulations 2013."
            },
            {
              "key": "Next AGM Proposal Date",
              "value": "Approval of Directors’ Remuneration Report to be proposed on 27 April 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 132,
          "title": "Preparation of the Financial Statements and Directors’ Responsibilities",
          "data": [
            {
              "key": "Directors' Responsibilities",
              "value": "The Directors are responsible for preparing this Annual Report and Form 20-F Information and the Group and Parent Company Financial Statements in accordance with applicable law and regulations."
            },
            {
              "key": "Company Law Compliance",
              "value": "Company law requires the Directors to prepare Financial Statements for each financial year."
            },
            {
              "key": "Financial Standards Compliance",
              "value": "The Directors have prepared the Group Financial Statements in accordance with UK-adopted International Accounting Standards and with the requirements of the Companies Act 2006."
            },
            {
              "key": "Going Concern Basis",
              "value": "The Directors are required to prepare the Financial Statements on the going concern basis unless it is inappropriate to presume that the Group and the Parent Company will continue in business."
            },
            {
              "key": "Internal Control Over Financial Reporting",
              "value": "The Directors are responsible for establishing and maintaining adequate internal control over financial reporting."
            },
            {
              "key": "Effectiveness Evaluation",
              "value": "AstraZeneca's internal control over financial reporting is assessed based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission."
            },
            {
              "key": "Audit Firm",
              "value": "PricewaterhouseCoopers LLP has audited the effectiveness of internal control over financial reporting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 151,
          "title": "Pharmaceutical Product Sales by Geographic Region",
          "data": [
            {
              "key": "Tagrisso",
              "value": "5.4B"
            },
            {
              "key": "Imfinzi",
              "value": "2.784B"
            },
            {
              "key": "Lynparza",
              "value": "2.638B"
            },
            {
              "key": "Farxiga",
              "value": "4.38B"
            },
            {
              "key": "Soliris",
              "value": "3.762B"
            },
            {
              "key": "Summary",
              "value": "This table presents pharmaceutical product sales data across different geographical regions. The data is segmented into several therapeutic areas including Oncology, Cardiovascular, Respiratory & Immunology, Vaccines & Immune Therapies, and Rare Disease. Key observations include: - Tagrisso is the highest-earning oncology drug with $5.4B in total sales - Farxiga leads the Cardiovascular segment with $4.4B in total sales - The US market generally shows the highest sales figures across most products - Emerging markets show significant contribution, particularly in products like Farxiga ($1.7B) - Soliris is the leading rare disease treatment with $3.8B in total sales."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 171,
          "title": "Movement in Borrowings and Financial Instruments Summary",
          "data": [
            {
              "key": "At 1 January",
              "value": "$30,781M (2022), $20,380M (2021), $18,227M (2020)"
            },
            {
              "key": "Issue of loans and borrowings",
              "value": "$0M (2022), $12,929M (2021), $2,968M (2020)"
            },
            {
              "key": "Repayment of loans and borrowings",
              "value": "-$1,271M (2022), -$4,759M (2021), -$1,609M (2020)"
            },
            {
              "key": "Movement in short-term borrowings",
              "value": "$74M (2022), -$276M (2021), $288M (2020)"
            },
            {
              "key": "Repayment of obligations under leases",
              "value": "-$244M (2022), -$240M (2021), -$207M (2020)"
            },
            {
              "key": "Total changes in cash flows arising on financing activities from borrowings",
              "value": "-$1,441M (2022), $7,654M (2021), $1,440M (2020)"
            },
            {
              "key": "Movement in overdrafts",
              "value": "-$85M (2022), $31M (2021), $138M (2020)"
            },
            {
              "key": "New lease liabilities",
              "value": "$253M (2022), $503M (2021), $174M (2020)"
            },
            {
              "key": "Additions through business combinations",
              "value": "$5M (2022), $2,523M (2021), $0M (2020)"
            },
            {
              "key": "Exchange",
              "value": "-$287M (2022), -$378M (2021), $363M (2020)"
            },
            {
              "key": "Other movements",
              "value": "$6M (2022), $68M (2021), $38M (2020)"
            },
            {
              "key": "At 31 December",
              "value": "$29,232M (2022), $30,781M (2021), $20,380M (2020)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 177,
          "title": "Post-Retirement Benefits and Financial Assumptions",
          "data": [
            {
              "key": "Other Defined Benefit Plans Summary",
              "value": "The Group provides several benefit plans, including healthcare benefits for retired employees with 3,393 currently benefiting and 2,339 eligible current employees."
            },
            {
              "key": "Cost of Post-Retirement Benefits (2022)",
              "value": "The cost of post-retirement benefits other than pensions for 2022 was $1m."
            },
            {
              "key": "Actuarial Valuation Date",
              "value": "Financial assumptions updated to 31 December 2022."
            },
            {
              "key": "Inflation Assumption (UK)",
              "value": "3.38%."
            },
            {
              "key": "Discount Rate (Defined Benefit Obligation, US)",
              "value": "2.8%."
            },
            {
              "key": "Discount Rate (Service Cost, Rest of Group)",
              "value": "1.4%."
            },
            {
              "key": "Life Expectancy at Age 65",
              "value": "For UK males retiring in 2022, life expectancy is 22.2 years."
            },
            {
              "key": "Demographic Assumptions Update",
              "value": "Updated mortality tables adopted in the UK reflecting CMI 2021 Mortality Projections."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 180,
          "title": "Pension Scheme Financial Overview and Obligations",
          "data": [
            {
              "key": "Total fair value of scheme assets",
              "value": "$10,564m"
            },
            {
              "key": "Total value of scheme obligations",
              "value": "-$13,018m"
            },
            {
              "key": "Deficit in the scheme as recognised in the Consolidated Statement of Financial Position",
              "value": "-$2,454m"
            },
            {
              "key": "Included in Non-current other receivables",
              "value": "$0"
            },
            {
              "key": "Included in Retirement benefit obligations",
              "value": "-$2,454m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 182,
          "title": "Post-retirement and other defined benefit schemes",
          "data": [
            {
              "key": "UK ($m)",
              "value": "Mortality rate financial impact: 191-390"
            },
            {
              "key": "US ($m)",
              "value": "Mortality rate financial impact: 20-29"
            },
            {
              "key": "Sweden ($m)",
              "value": "Mortality rate financial impact: 44-94"
            },
            {
              "key": "Total ($m)",
              "value": "Mortality rate financial impact: 255-613"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 192,
          "title": "Employment Costs Breakdown",
          "data": [
            {
              "key": "Wages and salaries",
              "value": "8656"
            },
            {
              "key": "Social security costs",
              "value": "991"
            },
            {
              "key": "Pension costs",
              "value": "546"
            },
            {
              "key": "Other employment costs",
              "value": "1338"
            },
            {
              "key": "Total",
              "value": "11531"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 193,
          "title": "AstraZeneca Share Plans Movement Summary",
          "data": [
            {
              "key": "Outstanding at 1 January 2020",
              "value": "PSP Ordinary: 2859, PSP ADR: 5206, GRSP Ordinary: 1328, GRSP ADR: 9770, RSP Ordinary: 176, RSP ADR: 649, EIP Ordinary: 282, EIP ADR: 65"
            },
            {
              "key": "Outstanding at 31 December 2020",
              "value": "PSP Ordinary: 3045, PSP ADR: 4791, GRSP Ordinary: 1626, GRSP ADR: 9175, RSP Ordinary: 161, RSP ADR: 506, EIP Ordinary: 300, EIP ADR: 65"
            },
            {
              "key": "Outstanding at 31 December 2021",
              "value": "PSP Ordinary: 3459, PSP ADR: 5178, GRSP Ordinary: 2028, GRSP ADR: 9541, RSP Ordinary: 255, RSP ADR: 763, EIP Ordinary: 282, EIP ADR: 195"
            },
            {
              "key": "Outstanding at 31 December 2022",
              "value": "PSP Ordinary: 3630, PSP ADR: 5724, GRSP Ordinary: 2469, GRSP ADR: 11683, RSP Ordinary: 233, RSP ADR: 678, EIP Ordinary: 259, EIP ADR: 195"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 193,
          "title": "AstraZeneca Share Plans Weighted Average Fair Value (WAFV) Comparison",
          "data": [
            {
              "key": "2020",
              "value": "PSP pence: 6664, PSP USD: 43.24, GRSP pence: 7408, GRSP USD: 4771, RSP pence: 7931, RSP USD: 52.92, EIP pence: 8386, EIP USD: N/A"
            },
            {
              "key": "2021",
              "value": "PSP pence: 6012, PSP USD: 41.56, GRSP pence: 6893, GRSP USD: 47.75, RSP pence: 7415, RSP USD: 53.96, EIP pence: N/A, EIP USD: 56.83"
            },
            {
              "key": "2022",
              "value": "PSP pence: 8328, PSP USD: 55.73, GRSP pence: 9167, GRSP USD: 61.21, RSP pence: 9894, RSP USD: 63.35, EIP pence: N/A, EIP USD: N/A"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 217,
          "title": "Directors' Report",
          "data": [
            {
              "key": "Relevant Information",
              "value": "The Directors’ Report includes information required to be given in accordance with the Companies Act 2006."
            },
            {
              "key": "Business Environment",
              "value": "Information on the business environment in which AstraZeneca operates, including the factors underpinning the industry’s future growth prospects."
            },
            {
              "key": "Group Subsidiaries",
              "value": "The Group’s subsidiaries and their locations are set out in Group Subsidiaries and Holdings in the Financial Statements from page 199."
            },
            {
              "key": "Branches and Countries",
              "value": "Countries where the Group conducts business include Algeria, Angola, Costa Rica, Cuba, Denmark, Egypt, Georgia, Ghana, Jordan, Kazakhstan, Lebanon, Norway, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, Slovenia, Syria, Ukraine, United Arab Emirates, United States, Vietnam and Yemen."
            },
            {
              "key": "Audit Information",
              "value": "Directors confirm that there is no relevant audit information of which the auditors are unaware."
            },
            {
              "key": "Going Concern",
              "value": "Board considers it appropriate to adopt the going concern basis of accounting in preparing the Annual Report and Financial Statements."
            },
            {
              "key": "Financial Review",
              "value": "The financial position of the Group, its cash flows, liquidity position and borrowing facilities are described in the Financial Review from page 60."
            },
            {
              "key": "Redeemable Preference Shares",
              "value": "The holders of Redeemable Preference Shares have priority over Ordinary Shares to receive the capital paid on those shares."
            },
            {
              "key": "Shareholder Resolution",
              "value": "A shareholders’ resolution was passed at the 2022 AGM authorising the Company to purchase its own shares."
            },
            {
              "key": "Ordinary Share Capital",
              "value": "As at 31 December 2022, the Company had 1,549,800,030 Ordinary Shares and 50,000 Redeemable Preference Shares in issue."
            },
            {
              "key": "Voting Rights",
              "value": "Each Ordinary Share carries the right to vote at general meetings of the Company."
            },
            {
              "key": "Rights and Restrictions",
              "value": "The rights and restrictions attaching to the Redeemable Preference Shares differ from those attaching to Ordinary Shares."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 17,
          "title": "Science & Innovation Focus Areas and Key Performance Indicators",
          "data": [
            {
              "key": "Drug Modalities",
              "value": "Advanced biologics, nucleotide-based and cell therapies."
            },
            {
              "key": "Innovation",
              "value": "Leading in convergence of science, data and technology."
            },
            {
              "key": "Pipeline Progression Events",
              "value": "Phase II NME starts/progressions and Phase III investment decisions."
            },
            {
              "key": "Regulatory Events",
              "value": "Regulatory submissions and approvals."
            },
            {
              "key": "Regulatory Events Achieved in 2022",
              "value": "72 regulatory events: 38 NME and major LCM submissions and 34 approvals in major markets."
            },
            {
              "key": "Pipeline Progression Events Achieved in 2022",
              "value": "29 pipeline progression events: six NME Phase II starts/progressions and 23 NME and major LCM Phase III investment decisions."
            },
            {
              "key": "Total Projects in Pipeline",
              "value": "179 projects, of which 155 are in clinical phase."
            },
            {
              "key": "NME Projects in Pivotal Trials or Regulatory Review",
              "value": "15 projects covering 28 indications."
            },
            {
              "key": "Discontinued Projects",
              "value": "27 projects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 27,
          "title": "AstraZeneca's R&D Investments in Cardiovascular, Renal & Metabolism",
          "data": [
            {
              "key": "Study Published",
              "value": "CaReMe CKD study published in June, focusing on CKD prevalence and outcomes."
            },
            {
              "key": "DELIVER Study",
              "value": "DELIVER study showed Forxiga improved symptoms in patients."
            },
            {
              "key": "Phase IIb/III PROXYMO-ADVANCE",
              "value": "Cotadutide trial for NASH patients started in July."
            },
            {
              "key": "AZD7503 Development",
              "value": "Phase I trial for AZD7503 in NASH."
            },
            {
              "key": "Research Findings",
              "value": "Preliminary study on human ventricular progenitor cells showed potential in heart recovery."
            },
            {
              "key": "Phase I MAD study",
              "value": "Completed for ASO precision medicine AZD2693 in NASH patients."
            },
            {
              "key": "NLRP3 Trial",
              "value": "NLRP3 advanced to Phase I for AKI treatment."
            },
            {
              "key": "eplontersen Results",
              "value": "Met endpoints in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy."
            },
            {
              "key": "Brilinta Expansion",
              "value": "Aim to reduce atherosclerosis and expand Brilinta's use."
            },
            {
              "key": "Forxiga Phase III Results",
              "value": "Significantly reduced CV death risk in heart failure patients."
            },
            {
              "key": "AZD8233 Development Discontinued",
              "value": "Discontinued due to failure to meet trial criteria."
            },
            {
              "key": "PCSK9 Inhibitor AZD0780",
              "value": "Entered Phase I for dyslipidaemia prevention."
            },
            {
              "key": "Andexxa Approval",
              "value": "Approved in Japan for Factor Xa inhibitors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 37,
          "title": "Research & Development Performance Summary",
          "data": [
            {
              "key": "R&D Investment",
              "value": "$9.8 billion"
            },
            {
              "key": "NME Approvals",
              "value": "2 (Imjudo and Beyfortus)"
            },
            {
              "key": "Total pipeline projects",
              "value": "179 (155 in clinical phase)"
            },
            {
              "key": "R&D productivity",
              "value": "19% (industry average 14%)"
            },
            {
              "key": "Published Manuscripts",
              "value": "156 in high-impact journals"
            },
            {
              "key": "New R&D Centre",
              "value": "Kendall Square, Cambridge, MA"
            },
            {
              "key": "Primary laboratory equipment installation completion",
              "value": "Completed in Discovery Centre, Cambridge, UK"
            },
            {
              "key": "NME Phase II starts/progressions",
              "value": "6"
            },
            {
              "key": "NME and major LCM submissions",
              "value": "38"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 38,
          "title": "Research and Development Investments",
          "data": [
            {
              "key": "2022 R&D Progress",
              "value": "19% progression from candidate drug nomination to Phase III completion"
            },
            {
              "key": "Comparison to Industry Average",
              "value": "14% average"
            },
            {
              "key": "Functional Genomics Centre",
              "value": "Completed first radiation/CRISPR screen"
            },
            {
              "key": "Collaboration with BenevolentAI",
              "value": "Added four novel AI-generated targets for CKD and idiopathic pulmonary fibrosis"
            },
            {
              "key": "Agreement with Cellular Biomedicine Group",
              "value": "Evaluate armoured GPC3 targeted CAR-T product in solid tumours"
            },
            {
              "key": "Publication in Nature Cell Biology",
              "value": "Showed human ventricular progenitor cells promote heart tissue formation after heart attack"
            },
            {
              "key": "Collaboration with NovoHeart",
              "value": "Developing miniature organs - bioengineered HFpEF miniature human heart models"
            },
            {
              "key": "Advances in Mass Spectrometry Imaging",
              "value": "Enables imaging of biologics and larger drug complexes"
            },
            {
              "key": "Collaboration with GRAIL",
              "value": "Developing companion diagnostic tests for high-risk early-stage cancer patients"
            },
            {
              "key": "Remote digital health solution",
              "value": "Monitoring stomatitis in six clinical trials"
            },
            {
              "key": "Publication Metrics",
              "value": "Published 783 manuscripts, 156 in high-impact journals, reflecting ongoing high impact of research."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 73,
          "title": "Research and development collaboration payments",
          "data": [
            {
              "key": "Future R&D payments",
              "value": "Details of future potential R&D collaboration payments are included in Note 30."
            },
            {
              "key": "Collaboration projects",
              "value": "Further collaboration projects may include milestone payments that could fail to crystallise."
            },
            {
              "key": "Business development transactions",
              "value": "More than 80 major or strategically important business development transactions completed over the past three years."
            },
            {
              "key": "Daiichi Sankyo agreement",
              "value": "Global development and commercialization agreement for DS-1062, with up to $1 billion for milestone payments."
            },
            {
              "key": "Innate Pharma agreement",
              "value": "Oncology agreements include initial and milestone payments, with shared Phase II study funding."
            },
            {
              "key": "Significance criteria",
              "value": "Determined by various quantitative and qualitative factors of each business development transaction."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 96,
          "title": "Science Committee Report",
          "data": [
            {
              "key": "Core Role",
              "value": "Provide assurance to the Board regarding the quality, competitiveness, and integrity of the Group’s R&D activities."
            },
            {
              "key": "Chair’s Introduction",
              "value": "The Science Committee’s core role is to provide assurance to the Board regarding the quality, competitiveness and integrity of the Group’s R&D activities."
            },
            {
              "key": "Focus Areas",
              "value": "Review and assess approaches in respect of chosen therapy areas, scientific technology and R&D capabilities, scientific strategy for maintaining pipeline and competitiveness."
            },
            {
              "key": "Activities During the Year",
              "value": "The Committee met eight times during 2022, focusing on Company strategy and strategic priorities for R&D, AstraZeneca R&D strategic science capabilities, acquisitions and in-licensing agreements."
            },
            {
              "key": "Committee Members",
              "value": "Nazneen Rahman (Chair), Euan Ashley, Diana Layfield, Tony Mok, Marcus Wallenberg."
            },
            {
              "key": "Acquisitions",
              "value": "Reviewed scientific case for acquisitions including TeneoTwo, Inc. and Neogene."
            },
            {
              "key": "Corporate Scorecard",
              "value": "Provided insight and feedback to the Remuneration Committee for 2022 achievements and 2023 goal setting relating to R&D."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 2,
          "title": "Introduction to AstraZeneca",
          "data": [
            {
              "key": "Company Description",
              "value": "A global, science-led, patient-focused pharmaceutical company."
            },
            {
              "key": "Mission",
              "value": "Transforming the future of healthcare."
            },
            {
              "key": "Focus",
              "value": "Unlocking the power of science for people, society and the planet."
            },
            {
              "key": "Website",
              "value": "www.astrazeneca.com"
            },
            {
              "key": "Sustainability",
              "value": "Information assured by Bureau Veritas."
            },
            {
              "key": "Development Pipeline Information",
              "value": "Detailed information on Development Pipeline, Patent Expiries, Key Marketed Products and Risk."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 16,
          "title": "Our Strategy and Key Performance Indicators",
          "data": [
            {
              "key": "Strategic Goal",
              "value": "Our ambition is to launch 15 new medicines by 2030"
            },
            {
              "key": "KPI",
              "value": "Net cash flow from operating activities"
            },
            {
              "key": "Core EPS",
              "value": "$2.12"
            },
            {
              "key": "Reported EPS",
              "value": "$6.66"
            },
            {
              "key": "Cash generation",
              "value": "$9,808m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 21,
          "title": "Oncology Products Overview",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$15,539m"
            },
            {
              "key": "Annual worldwide market value growth",
              "value": "15% (20% at CER)"
            },
            {
              "key": "Market insights",
              "value": "Nearly 20 million people diagnosed with cancer in 2020"
            },
            {
              "key": "New indication launches",
              "value": "8"
            },
            {
              "key": "Major market approvals",
              "value": "21"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 22,
          "title": "Therapy Area Review Oncology",
          "data": [
            {
              "key": "strategy",
              "value": "We strive to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer."
            },
            {
              "key": "cancer_statistics",
              "value": "Cancer is the second leading cause of death worldwide, expected to account for 16.3 million deaths annually by 2040."
            },
            {
              "key": "lung_cancer",
              "value": "Scientific advances are strengthening the potential of medicines to offer cure and long-term survival in lung cancer with a focus on early detection and precision medicine."
            },
            {
              "key": "breast_cancer",
              "value": "Aiming to shape clinical practice and transform outcomes across all subtypes and stages of breast cancer."
            },
            {
              "key": "gynaecological_cancers",
              "value": "Establish Lynparza plus abiraterone as standard of care in 1st-line mCRPC."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 23,
          "title": "Oncology Product Launches and Developments",
          "data": [
            {
              "key": "Company",
              "value": "AstraZeneca"
            },
            {
              "key": "Research Focus",
              "value": "cancer research"
            },
            {
              "key": "Products Launched",
              "value": "Imfinzi, Calquence, Imjudo"
            },
            {
              "key": "Approval Regions",
              "value": "US, EU, Japan"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 23,
          "title": "Therapy Area Review / Oncology",
          "data": [
            {
              "key": "Gastrointestinal Cancers",
              "value": "new growth area with robust development programs"
            },
            {
              "key": "Blood Cancers",
              "value": "novel investigational agents targeting underlying drivers"
            },
            {
              "key": "Key Statistics",
              "value": "25,000 patients treated globally, approvals in 84 countries"
            },
            {
              "key": "Clinical Data Shared",
              "value": "AZD0486 showed early signs of activity in relapsed/refractory B-cell lymphoma"
            },
            {
              "key": "Combination Regimen",
              "value": "Imfinzi with chemotherapy approved as new standard of care"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 26,
          "title": "Pharmaceutical Product Sales Performance",
          "data": [
            {
              "key": "Therapy Area Market Value",
              "value": "$244.3bn"
            },
            {
              "key": "Diabetes Market Value",
              "value": "$125.2bn"
            },
            {
              "key": "High Blood Pressure Market Value",
              "value": "$35.5bn"
            },
            {
              "key": "Abnormal Cholesterol Market Value",
              "value": "$17.2bn"
            },
            {
              "key": "Thrombosis Market Value",
              "value": "$6.8bn"
            },
            {
              "key": "CKD Market Value",
              "value": "$9.9bn"
            },
            {
              "key": "CKD-Associated Anemia Market Value",
              "value": "$6.0bn"
            },
            {
              "key": "Hyperkalaemia Market Value",
              "value": "$0.7bn"
            },
            {
              "key": "Other CV Market Value",
              "value": "$50.2bn"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 29,
          "title": "Fluenz Tetra/FluMist Quadrivalent",
          "data": [
            {
              "key": "Product Name",
              "value": "Fluenz Tetra/FluMist Quadrivalent"
            },
            {
              "key": "Type",
              "value": "Intranasal influenza vaccine"
            },
            {
              "key": "Approval Status",
              "value": "Licensed in multiple countries"
            },
            {
              "key": "Public Health Impact",
              "value": "Part of national influenza vaccination programmes"
            },
            {
              "key": "Usage under Pandemic",
              "value": "Partner to governments in influenza pandemics"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 30,
          "title": "Therapy Area Review BioPharmaceuticals - Vaccines & Immune Therapies",
          "data": [
            {
              "key": "Market Size",
              "value": "$9.8bn"
            },
            {
              "key": "Focus Areas",
              "value": "COVID-19, RSV, Influenza"
            },
            {
              "key": "Key Products",
              "value": "Evusheld, Vaxzevria, Synagis, Fluenz Tetra/FluMist, Beyfortus"
            },
            {
              "key": "Evusheld Revenue",
              "value": "$2,184m"
            },
            {
              "key": "Vaxzevria Status",
              "value": "Full marketing approval in EU as of November 2022"
            },
            {
              "key": "Doses Delivered",
              "value": "3.1 billion globally"
            },
            {
              "key": "Strategic Partnerships",
              "value": "University of Oxford, Serum Institute of India, Sanofi"
            },
            {
              "key": "Target Population",
              "value": "Immunocompromised and at-risk individuals"
            },
            {
              "key": "Approval Timeline for Evusheld",
              "value": "Approved in ~50 countries; Special Approval in Japan"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 31,
          "title": "Evusheld and AZD3152 Overview",
          "data": [
            {
              "key": "Product Name",
              "value": "Evusheld"
            },
            {
              "key": "Approval Date (EU)",
              "value": "September 2022"
            },
            {
              "key": "FDA Status",
              "value": "Not currently authorised for Emergency Use"
            },
            {
              "key": "Investigational Product",
              "value": "AZD3152"
            },
            {
              "key": "Phase",
              "value": "Phase I/III trial"
            },
            {
              "key": "Main Indication",
              "value": "COVID-19 prevention"
            },
            {
              "key": "Target Population",
              "value": "Newborns and infants for RSV prevention"
            },
            {
              "key": "Collaborators",
              "value": "AstraZeneca and Sanofi"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 35,
          "title": "Therapy Area Review / Rare Disease",
          "data": [
            {
              "key": "Overview",
              "value": "This page discusses the company's expanding focus on rare disease medicines, including several specific conditions and their treatments."
            },
            {
              "key": "Recent Approvals",
              "value": "Rare Disease medicines are now approved in 62 countries, with 10 new approvals since July 2021."
            },
            {
              "key": "Wilson Disease",
              "value": "Discusses the ongoing development of therapies and trials associated with Wilson disease."
            },
            {
              "key": "AL Amyloidosis Trials",
              "value": "The page mentions the positive results of the Phase III trial for ALXN1840 and ongoing trials for CAEL-101."
            },
            {
              "key": "HPP and ATTR",
              "value": "Describes advancements in treating Hypophosphatasia and Transthyretin amyloidosis."
            },
            {
              "key": "NF1 Plexiform Neurofibromas",
              "value": "Notes the approval of Koselugo for NF1 PN in Japan, expanding treatment options."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 76,
          "title": "Product Sales and Deductions Analysis",
          "data": [
            {
              "key": "Gross Product Sales",
              "value": "32100"
            },
            {
              "key": "Chargebacks",
              "value": "-2401"
            },
            {
              "key": "Regulatory — Medicaid and state programmes",
              "value": "-1879"
            },
            {
              "key": "Contractual —- Managed care and Medicare",
              "value": "-8821"
            },
            {
              "key": "Cash and other discounts",
              "value": "-359"
            },
            {
              "key": "Customer returns",
              "value": "-132"
            },
            {
              "key": "US Branded Pharmaceutical Fee",
              "value": "-150"
            },
            {
              "key": "Other",
              "value": "-1104"
            },
            {
              "key": "Net Product Sales",
              "value": "17254"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 76,
          "title": "Pharmaceutical Financial Provisions and Adjustments 2022",
          "data": [
            {
              "key": "Chargebacks",
              "value": "Chargebacks  at 1 January 2022: $181m, Provision: $2103m, Adjustment Prior Years: -$13m, Returns and Payments: -$2038m"
            },
            {
              "key": "Regulatory — Medicaid and state programmes",
              "value": "Regulatory at 1 January 2022: $510m, Provision: $1953m, Adjustment Prior Years: -$79m, Returns and Payments: -$1613m"
            },
            {
              "key": "Contractual —- Managed care and Medicare",
              "value": "Contractual at 1 January 2022: $2031m, Provision: $8971m, Adjustment Prior Years: -$141m, Returns and Payments: -$8435m"
            },
            {
              "key": "Cash and other discounts",
              "value": "Cash from at 1 January 2022: $21m, Provision: $359m, Returns and Payments: -$353m"
            },
            {
              "key": "Customer returns",
              "value": "Customer from at 1 January 2022: $196m, Provision: $112m, Returns and Payments: -$103m"
            },
            {
              "key": "US Branded Pharmaceutical Fee",
              "value": "Branded at 1 January 2022: $79m, Provision: $138m, Returns and Payments: -$96m"
            },
            {
              "key": "Other",
              "value": "Other at 1 January 2022: $154m, Provision: $1036m, Returns and Payments: -$1028m"
            },
            {
              "key": "Total Provisions",
              "value": "Total: Brought forward: $3172m, Current Year: $14672m, Adjustment: -$217m, Returns: -$13666m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 76,
          "title": "Pharmaceutical Revenue Movements 2021",
          "data": [
            {
              "key": "Chargebacks",
              "value": "Brought forward: $178m, Business Combinations: $2m, Provision: $2117m, Returns: -$2095m"
            },
            {
              "key": "Regulatory — Medicaid and state programmes",
              "value": "Brought forward: $495m, Business Combinations: $46m, Provision: $1548m, Returns: -$1529m"
            },
            {
              "key": "Contractual - Managed care and Medicare",
              "value": "Brought forward: $1937m, Business Combinations: $29m, Provision: $7204m, Returns: -$7056m"
            },
            {
              "key": "Cash and other discounts",
              "value": "Brought forward: $20m, Business Combinations: $0m, Provision: $313m, Returns: -$812m"
            },
            {
              "key": "Customer returns",
              "value": "Brought forward: $253m, Business Combinations: $18m, Provision: $13m, Returns: -$88m"
            },
            {
              "key": "US Branded Pharmaceutical Fee",
              "value": "Brought forward: $115m, Business Combinations: $0m, Provision: $77m, Returns: -$85m"
            },
            {
              "key": "Other",
              "value": "Brought forward: $128m, Business Combinations: $4m, Provision: $882m, Returns: -$860m"
            },
            {
              "key": "Total Provisions 2021",
              "value": "Total: Brought forward: $3126m, Business Combinations: $99m, Provision: $12154m, Returns: -$12025m"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 221,
          "title": "Trade Marks",
          "data": [
            {
              "key": "Airsupra",
              "value": "Andexxa"
            },
            {
              "key": "Crestor",
              "value": "Daliresp"
            },
            {
              "key": "Koselugo",
              "value": "Losec*"
            },
            {
              "key": "Seroquel XR*",
              "value": "Soliris"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 221,
          "title": "Trade Marks",
          "data": [
            {
              "key": "Airsupra",
              "value": "Arimidex?"
            },
            {
              "key": "Crestor",
              "value": "Daxas"
            },
            {
              "key": "Koselugo",
              "value": "Lokelma"
            },
            {
              "key": "Seroquel XR*",
              "value": "Strensiq"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 221,
          "title": "Trade Marks",
          "data": [
            {
              "key": "Airsupra",
              "value": "Atacand?"
            },
            {
              "key": "Crestor",
              "value": "Epanova"
            },
            {
              "key": "Koselugo",
              "value": "Lumoxiti"
            },
            {
              "key": "Seroquel XR*",
              "value": "sSymbicort"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 221,
          "title": "Trade Marks",
          "data": [
            {
              "key": "Airsupra",
              "value": "Atacand HCT"
            },
            {
              "key": "Crestor",
              "value": "Evusheld"
            },
            {
              "key": "Koselugo",
              "value": "Lynparza"
            },
            {
              "key": "Seroquel XR*",
              "value": "sSymbicort Turbuhaler"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 221,
          "title": "Trade Marks",
          "data": [
            {
              "key": "Airsupra",
              "value": "Atacand Plus?"
            },
            {
              "key": "Crestor",
              "value": "Farxiga"
            },
            {
              "key": "Koselugo",
              "value": "Movantik"
            },
            {
              "key": "Seroquel XR*",
              "value": "sSymlin"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 149,
          "title": "Assets held for sale and Financial Instruments",
          "data": [
            {
              "key": "Assets held for sale valuation method",
              "value": "stated at the lower of carrying amount and fair value less costs to sell"
            },
            {
              "key": "Trade receivables initial measurement",
              "value": "recognised initially at fair value"
            },
            {
              "key": "Trade receivables subsequent measurement",
              "value": "measured at amortised cost using the effective interest rate method"
            },
            {
              "key": "Financial liabilities included in Trade payables",
              "value": "recognised initially at fair value"
            },
            {
              "key": "Cash and cash equivalents composition",
              "value": "comprise cash in hand, current balances with banks and highly liquid investments with maturities of three months or less"
            },
            {
              "key": "Fixed deposits accounting treatment",
              "value": "initially measured at fair value, plus direct transaction costs, and subsequently measured at amortised cost"
            },
            {
              "key": "Derivatives initial measurement",
              "value": "initially measured at fair value"
            },
            {
              "key": "Bank and other borrowings hedging strategy",
              "value": "uses derivatives, principally interest rate swaps, to hedge interest rate exposure of fixed interest rate debt"
            },
            {
              "key": "Foreign currency transactions translation method",
              "value": "translated at average rates for the relevant monthly accounting periods"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 161,
          "title": "Fixed Assets Movement Schedule",
          "data": [
            {
              "key": "Total Assets (1 January 2020)",
              "value": "£15,001m"
            },
            {
              "key": "Annual Capital Expenditure (2020)",
              "value": "£926m"
            },
            {
              "key": "Annual Capital Expenditure (2021)",
              "value": "£1,152m"
            },
            {
              "key": "Annual Capital Expenditure (2022)",
              "value": "£1,066m"
            },
            {
              "key": "Net Book Value (2020)",
              "value": "£8,251m"
            },
            {
              "key": "Net Book Value (2021)",
              "value": "£9,183m"
            },
            {
              "key": "Net Book Value (2022)",
              "value": "£8,507m"
            },
            {
              "key": "Depreciation and Impairment Charges (2021)",
              "value": "£343m"
            },
            {
              "key": "Transfers to Assets Held for Sale (2022)",
              "value": "£727m"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 161,
          "title": "Net Book Value Breakdown of Land and Buildings",
          "data": [
            {
              "key": "Net Book Value (Freeholds 2020)",
              "value": "£2,555m"
            },
            {
              "key": "Net Book Value (Freeholds 2021)",
              "value": "£2,985m"
            },
            {
              "key": "Net Book Value (Freeholds 2022)",
              "value": "£2,583m"
            },
            {
              "key": "Net Book Value (Leaseholds 2020)",
              "value": "£396m"
            },
            {
              "key": "Net Book Value (Leaseholds 2021)",
              "value": "£515m"
            },
            {
              "key": "Net Book Value (Leaseholds 2022)",
              "value": "£442m"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 166,
          "title": "Investments in associates and joint ventures",
          "data": [
            {
              "key": "At 1 January",
              "value": "69"
            },
            {
              "key": "Additions",
              "value": "26"
            },
            {
              "key": "Share of after tax losses",
              "value": "-5"
            },
            {
              "key": "Exchange and other adjustments",
              "value": "-14"
            },
            {
              "key": "At 31 December",
              "value": "76"
            },
            {
              "key": "Non-current assets",
              "value": "290"
            },
            {
              "key": "Current assets",
              "value": "300"
            },
            {
              "key": "Total liabilities",
              "value": "-72"
            },
            {
              "key": "Net assets",
              "value": "518"
            },
            {
              "key": "Amount attributable to AstraZeneca",
              "value": "91"
            },
            {
              "key": "Exchange adjustments",
              "value": "-15"
            },
            {
              "key": "Carrying value of investments in associates and joint ventures",
              "value": "76"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 3,
          "title": "Financial Highlights",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$9,808 million"
            },
            {
              "key": "Product Sales",
              "value": "$42,998 million"
            },
            {
              "key": "Collaboration Revenue",
              "value": "$1,353 million"
            },
            {
              "key": "Reported Operating Profit",
              "value": "$13,350 million"
            },
            {
              "key": "Core Operating Profit",
              "value": "$3,757 million"
            },
            {
              "key": "Reported EPS",
              "value": "$2.12"
            },
            {
              "key": "Core EPS",
              "value": "$6.66"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 9,
          "title": "Chief Executive Officer’s Review",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$44.4 billion (2022)"
            },
            {
              "key": "Revenue Growth",
              "value": "19% increase (25% at CER)"
            },
            {
              "key": "Rare Disease Revenue",
              "value": "$7.1 billion"
            },
            {
              "key": "Oncology Revenue Growth",
              "value": "15% increase (20% at CER)"
            },
            {
              "key": "Cardiovascular, Renal & Metabolism Revenue Growth",
              "value": "13% increase (19% at CER)"
            },
            {
              "key": "Respiratory & Immunology Revenue Growth",
              "value": "-1% (3% at CER)"
            },
            {
              "key": "Rare Disease Revenue Growth",
              "value": "4% increase (10% at CER)"
            },
            {
              "key": "US Revenue Growth",
              "value": "47% increase (2022)"
            },
            {
              "key": "Europe Revenue Growth",
              "value": "9% increase (21% at CER)"
            },
            {
              "key": "Emerging Markets Revenue Growth",
              "value": "-4% (1% growth at CER)"
            },
            {
              "key": "Established Rest of World Revenue Growth",
              "value": "22% increase (40% at CER)"
            },
            {
              "key": "Regulatory Events",
              "value": "72 submissions or approvals"
            },
            {
              "key": "Pipeline Progression Events",
              "value": "29 events"
            },
            {
              "key": "New Medicines Approved",
              "value": "3 new medicines (Imjudo, Beyfortus, Airsupra)"
            },
            {
              "key": "Projected New Medicines Launch by 2030",
              "value": "At least 15 new medicines"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 18,
          "title": "Our Strategy and Key Performance Indicators",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$44,351 million"
            },
            {
              "key": "Total Revenue Growth 2022",
              "value": "+19% (25% at CER)"
            },
            {
              "key": "Collaboration Revenue Growth",
              "value": "+54% (56% at CER) to $1,353 million"
            },
            {
              "key": "Oncology Revenue Growth",
              "value": "+15% (20% at CER) to $15,539 million"
            },
            {
              "key": "CVRM Revenue Growth",
              "value": "+13% (19% at CER) to $9,211 million"
            },
            {
              "key": "R&I Revenue Growth",
              "value": "-1% (+3% at CER) to $5,963 million"
            },
            {
              "key": "V&I Unit Growth",
              "value": "+1% (8% at CER) to $4,836 million"
            },
            {
              "key": "Rare Disease Growth",
              "value": "+4% (10% at CER) to $7,053 million"
            },
            {
              "key": "Emerging Markets Revenue Decline",
              "value": "-4% (+1% at CER) to $11,745 million"
            },
            {
              "key": "US Revenue Growth",
              "value": "+47% to $17,920 million"
            },
            {
              "key": "Europe Revenue Growth",
              "value": "+9% (21% at CER) to $8,738 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 42,
          "title": "Business Review continued Growth and Therapy Area Leadership",
          "data": [
            {
              "key": "Total Revenue Growth (2022)",
              "value": "47% to $17,920 million"
            },
            {
              "key": "Market Share in US Pharmaceuticals",
              "value": "3.4% by sales value"
            },
            {
              "key": "Revenue from US Oncology Products",
              "value": "Increased significantly due to new launches"
            },
            {
              "key": "Revenue in Europe (2022)",
              "value": "$8,738 million, up 9% at actual exchange rate (21% at CER)"
            },
            {
              "key": "Established RoW Product Sales Growth",
              "value": "22% (40% at CER) to $5,846 million"
            },
            {
              "key": "Total Revenue in Canada",
              "value": "Increased by 51% at actual rate (57% at CER) to $4,110 million"
            },
            {
              "key": "Sales Growth in Australia and New Zealand",
              "value": "Increased by 8% at actual exchange rate (18% at CER)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 62,
          "title": "Financial Review",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$44.4 billion"
            },
            {
              "key": "Revenue Growth",
              "value": "19% (CER: 25%)"
            },
            {
              "key": "Collaboration Revenue",
              "value": "$1.4 billion"
            },
            {
              "key": "Revenue from Rare Disease portfolio",
              "value": "$7.1 billion"
            },
            {
              "key": "Reported EPS",
              "value": "$2.12"
            },
            {
              "key": "Core EPS",
              "value": "$6.66"
            },
            {
              "key": "Product Sales Growth",
              "value": "18% (CER: 24%)"
            },
            {
              "key": "US Product Sales",
              "value": "$17.3 billion"
            },
            {
              "key": "Europe Product Sales",
              "value": "$8.3 billion"
            },
            {
              "key": "Established Rest of World Product Sales",
              "value": "$5.8 billion"
            },
            {
              "key": "Emerging Markets Product Sales",
              "value": "$11.6 billion"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 63,
          "title": "Financial Performance Comparison 2021-2022",
          "data": [
            {
              "key": "Total Revenue",
              "value": "$44,351M"
            },
            {
              "key": "Product Sales",
              "value": "$42,998M"
            },
            {
              "key": "Operating profit",
              "value": "$3,757M"
            },
            {
              "key": "Profit after tax",
              "value": "$3,293M"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 63,
          "title": "Total Revenue: Geographical areas",
          "data": [
            {
              "key": "US",
              "value": "47%"
            },
            {
              "key": "Europe",
              "value": "9%"
            },
            {
              "key": "Established RoW",
              "value": "22%"
            },
            {
              "key": "Emerging Markets",
              "value": "-4%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 63,
          "title": "Market Segments Performance",
          "data": [
            {
              "key": "Oncology",
              "value": "15%"
            },
            {
              "key": "CVRM",
              "value": "13%"
            },
            {
              "key": "Respiratory & Immunology",
              "value": "1%"
            },
            {
              "key": "Vaccines & Immune Therapies",
              "value": "1%"
            },
            {
              "key": "Rare Disease",
              "value": "4%"
            },
            {
              "key": "Other Medicines",
              "value": "-4%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 64,
          "title": "Financial Review",
          "data": [
            {
              "key": "Core performance measures description",
              "value": "Core performance measures are adjusted to exclude certain significant items, using a set of established principles."
            },
            {
              "key": "Use of non-GAAP measures",
              "value": "Core performance measures, EBITDA, Net debt, CER, Gross margin and Operating margin are non-GAAP performance measures because they cannot be derived directly from the Financial Statements."
            },
            {
              "key": "Importance of R&D",
              "value": "The success of R&D is crucial and we devote substantial resources to this area. The benefits of this investment are expected to emerge over the long term."
            },
            {
              "key": "Reported vs Core performance",
              "value": "Reported performance takes into account all factors affecting business results, while Core performance measures are adjusted to exclude significant items."
            },
            {
              "key": "Reconciliation",
              "value": "The reconciliation of Reported financial information to Core performance measures includes a breakdown of items for which adjustments are made."
            },
            {
              "key": "Encouragement for holistic evaluation",
              "value": "Readers should not rely on any single financial measure but review Financial Statements and Notes in their entirety."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 65,
          "title": "Non-GAAP measures: definitions Revenue Constant Constant exchange rate (CER) growth",
          "data": [
            {
              "key": "Definition",
              "value": "Retranslation of the current year’s performance at the previous year’s average exchange rates, adjusted for other exchange effects, including hedging."
            },
            {
              "key": "Why we use them",
              "value": "CER measures allow us to focus on the changes in revenues and expenses driven by volume, prices and cost levels relative to the prior period."
            },
            {
              "key": "Gross margin definition",
              "value": "Gross margin, as a percentage, by which Product Sales exceeds the Cost of sales."
            },
            {
              "key": "Why we use Core performance measures",
              "value": "To enhance investors’ ability to evaluate the underlying financial performance of our ongoing business."
            },
            {
              "key": "Core adjustments summary",
              "value": "Restructuring costs, intangible amortisation, and impairments are adjusted for to reflect ongoing business performance."
            },
            {
              "key": "Limitations of CER",
              "value": "In high inflation countries, adjusting out foreign exchange fluctuations could give an overly optimistic growth view."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 66,
          "title": "Financial Review Summary",
          "data": [
            {
              "key": "Operating margin",
              "value": "Operating profit as a percentage of Total Revenue."
            },
            {
              "key": "Why we use it",
              "value": "This measure sets out profitability derived from operating activities before the impact of finance costs and tax."
            },
            {
              "key": "Limitations",
              "value": "Operating margin percentage excludes the impact of financing costs."
            },
            {
              "key": "EBITDA",
              "value": "Reported profit before tax plus net finance expense, share of after-tax losses of joint ventures and associates, and charges for depreciation, amortisation and impairment."
            },
            {
              "key": "Why we use it",
              "value": "Allows us to understand our baseline profitability."
            },
            {
              "key": "Limitations",
              "value": "Does not take account of the cost of investment to generate revenues."
            },
            {
              "key": "Cash flow and liquidity",
              "value": "Net debt is a measure of the Group’s net financial liabilities."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 67,
          "title": "Reconciliation of Reported results to Core results for 2022",
          "data": [
            {
              "key": "Gross profit reported 2022",
              "value": "31960"
            },
            {
              "key": "Gross profit core 2022",
              "value": "35763"
            },
            {
              "key": "Operating profit reported 2022",
              "value": "3757"
            },
            {
              "key": "Operating profit core 2022",
              "value": "13350"
            },
            {
              "key": "Basic EPS core 2022",
              "value": "6.66"
            },
            {
              "key": "Core operating margin % 2022",
              "value": "30.1"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 67,
          "title": "2021 Reconciliation of Reported results to Core results",
          "data": [
            {
              "key": "Gross profit reported 2021",
              "value": "24980"
            },
            {
              "key": "Gross profit core 2021",
              "value": "27973"
            },
            {
              "key": "Operating profit reported 2021",
              "value": "1056"
            },
            {
              "key": "Operating profit core 2021",
              "value": "9928"
            },
            {
              "key": "Basic EPS core 2021",
              "value": "5.29"
            },
            {
              "key": "Core operating margin % 2021",
              "value": "26.5"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 68,
          "title": "Product Sales by Therapy Area",
          "data": [
            {
              "key": "Oncology",
              "value": "$14,631M"
            },
            {
              "key": "CVRM",
              "value": "$9,188M"
            },
            {
              "key": "Respiratory & Immunology",
              "value": "$5,765M"
            },
            {
              "key": "Vaccines & Immune Therapies",
              "value": "$4,736M"
            },
            {
              "key": "Rare Disease",
              "value": "$7,053M"
            },
            {
              "key": "Other Medicines",
              "value": "$1,625M"
            },
            {
              "key": "Total",
              "value": "$42,998M"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 68,
          "title": "Product Sales by Geographical Area",
          "data": [
            {
              "key": "US",
              "value": "$17,254M"
            },
            {
              "key": "Emerging Markets",
              "value": "$11,634M"
            },
            {
              "key": "Europe",
              "value": "$8,264M"
            },
            {
              "key": "Established RoW",
              "value": "$5,846M"
            },
            {
              "key": "Total Revenue",
              "value": "$44,351M"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 69,
          "title": "Collaboration Revenue",
          "data": [
            {
              "key": "Total Collaboration Revenue",
              "value": "1,353"
            },
            {
              "key": "Enhertu (Daiichi Sankyo) - 2022 $m",
              "value": "519"
            },
            {
              "key": "Tezspire (Amgen) - 2022 $m",
              "value": "79"
            },
            {
              "key": "Lynparza/Koselugo (MSD) - regulatory milestones - 2022 $m",
              "value": "355"
            },
            {
              "key": "Lynparza/Koselugo (MSD) - sales-related milestone - 2021 $m",
              "value": "400"
            },
            {
              "key": "Tralokinumab (Leo Pharma A/S) - milestones - 2022 $m",
              "value": "110"
            },
            {
              "key": "Vaxzevria royalty income - 2021 $m",
              "value": "64"
            },
            {
              "key": "Other royalty income - 2022 $m",
              "value": "72"
            },
            {
              "key": "Reported Profit/(loss) before tax - 2022 $m",
              "value": "2501"
            },
            {
              "key": "EBITDA - 2022 $m",
              "value": "9237"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 70,
          "title": "Financial Performance Review",
          "data": [
            {
              "key": "R&D Expense",
              "value": "$95 million impairment charges, reduction of $1,369 million from 2021."
            },
            {
              "key": "SG&A Expense",
              "value": "Increased by 21% to $18,419 million; Core SG&A increased by 15% to $12,826 million."
            },
            {
              "key": "Operating Profit",
              "value": "Increased by 256% to $3,757 million."
            },
            {
              "key": "Net Finance Expense",
              "value": "Decreased by 1% to $1,251 million."
            },
            {
              "key": "Profit Before Tax",
              "value": "Increased to $2,501 million."
            },
            {
              "key": "EBITDA",
              "value": "Increased by 22% to $9,237 million."
            },
            {
              "key": "Tax Rate",
              "value": "Reported tax rate of -32%; Core tax rate of 17%."
            },
            {
              "key": "Total Comprehensive Income",
              "value": "Increased by $2,445 million to $2,415 million."
            },
            {
              "key": "EPS",
              "value": "Reported EPS was $2.12; Core EPS was $6.66."
            },
            {
              "key": "Restructuring Costs",
              "value": "Total planned restructuring costs now approximately $2.9 billion."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 71,
          "title": "Financial Overview",
          "data": [
            {
              "key": "Run-rate pre-tax benefits",
              "value": "$1.9 billion by the end of 2025"
            },
            {
              "key": "Restructuring charges (2022)",
              "value": "$0.7 billion"
            },
            {
              "key": "Cumulative charges under PAAGR programme",
              "value": "$1.7 billion"
            },
            {
              "key": "Annual run-rate pre-tax benefits realised",
              "value": "$0.8 billion"
            },
            {
              "key": "Aggregate restructuring charge (2022)",
              "value": "$717 million"
            },
            {
              "key": "Restructuring charge (2021)",
              "value": "$1,283 million"
            },
            {
              "key": "Net debt brought forward at 1 January",
              "value": "-24322 million"
            },
            {
              "key": "Profit/(loss) before tax",
              "value": "2501 million"
            },
            {
              "key": "Net cash available from operating activities",
              "value": "$9,808 million"
            },
            {
              "key": "Investment cash outflows (2022)",
              "value": "$2,906 million"
            },
            {
              "key": "Dividends",
              "value": "$4,335 million"
            },
            {
              "key": "Total cash distributions",
              "value": "$4,335 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 74,
          "title": "Financial Review continued Capitalisation and shareholder return",
          "data": [
            {
              "key": "Total shares in issue",
              "value": "1,550 million"
            },
            {
              "key": "Shareholders’ equity",
              "value": "$37,037 million"
            },
            {
              "key": "Decrease in Shareholders’ equity",
              "value": "$2,231 million"
            },
            {
              "key": "Non-controlling interests",
              "value": "$21 million"
            },
            {
              "key": "Second interim dividend",
              "value": "$1.97"
            },
            {
              "key": "Full-year dividend",
              "value": "$2.90"
            },
            {
              "key": "Dividend cover ratio (Reported EPS)",
              "value": "0.74:1"
            },
            {
              "key": "Dividend cover ratio (Core EPS)",
              "value": "2.32:1"
            },
            {
              "key": "Progressive dividend policy",
              "value": "Maintain or grow the dividend each year."
            },
            {
              "key": "Suspension of share repurchase programme",
              "value": "Continued since 2012."
            },
            {
              "key": "Profit and loss account reserve",
              "value": "$7,458 million"
            },
            {
              "key": "Previous year's reserve",
              "value": "$11,563 million"
            },
            {
              "key": "Estimate for Total Revenue Increase 2023",
              "value": "Low-to-mid single-digit percentage."
            },
            {
              "key": "Estimate for Total Revenue Increase (excluding COVID-19)",
              "value": "Low double-digit percentage."
            },
            {
              "key": "Estimate for Core EPS Increase",
              "value": "High single-digit to low double-digit percentage."
            },
            {
              "key": "Estimated decline in Total Revenue (COVID-19 medicines)",
              "value": "Significant."
            },
            {
              "key": "Expected growth in Total Revenue from China",
              "value": "Low single-digit percentage."
            },
            {
              "key": "Core Operating expenses estimate increase",
              "value": "Low-to-mid single-digit percentage."
            },
            {
              "key": "Expected Core tax rate",
              "value": "18-22%."
            },
            {
              "key": "Estimated currency impact",
              "value": "Low single-digit adverse impact."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 77,
          "title": "Rebates, Chargebacks and Returns in the US",
          "data": [
            {
              "key": "Overview",
              "value": "Estimates of rebates and chargebacks from sales contracts with organizations."
            },
            {
              "key": "Chargebacks",
              "value": "Arrangements allowing certain parties to buy products at lower contracted prices."
            },
            {
              "key": "Regulatory Rebate",
              "value": "Payments based on agreements with the US Department of Health and Human Services."
            },
            {
              "key": "Contractual Rebates",
              "value": "Rebates depending on specified performance provisions."
            },
            {
              "key": "Accrual Assumptions",
              "value": "Built on a product-by-product and customer-by-customer basis."
            },
            {
              "key": "Financial Impact",
              "value": "Adjustments between gross and net US Product Sales amounted to $14,846 million in 2022."
            },
            {
              "key": "Cash Discounts",
              "value": "Offered to encourage prompt payment."
            },
            {
              "key": "Returns Policy",
              "value": "Unused stocks can be returned within six months to twelve months after expiry."
            },
            {
              "key": "Sarbanes-Oxley Compliance",
              "value": "Required assessment of internal control over financial reporting."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 102,
          "title": "Audit Committee Report",
          "data": [
            {
              "key": "Significant financial reporting issues considered",
              "value": "Valuation of intangible assets, Revenue recognition, Alternative performance measures"
            },
            {
              "key": "Impairments relating to launched products",
              "value": "$146 million"
            },
            {
              "key": "Impairments relating to products in development",
              "value": "$172 million"
            },
            {
              "key": "Percentage of Total Revenue from US market",
              "value": "40%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 104,
          "title": "Significant Financial Reporting Issues and Committee Considerations",
          "data": [
            {
              "key": "Topic",
              "value": "Significant financial reporting issues considered by the Committee in 2022"
            },
            {
              "key": "Key Matters",
              "value": "Retirement benefits and pension liabilities"
            },
            {
              "key": "Key Updates",
              "value": "Quarterly updates on assumptions for pension liabilities, improvements in funding position, no financial support required from Group, external auditor information."
            },
            {
              "key": "Impact of External Factors",
              "value": "Increases in long-term bond yields created liquidity issues for pension funds."
            },
            {
              "key": "Committee's Monitoring",
              "value": "Monitoring of funding level and contribution policy."
            },
            {
              "key": "External Auditor",
              "value": "PwC reappointed as external auditor for sixth consecutive year."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 105,
          "title": "Audit and assurance services from external auditor",
          "data": [
            {
              "key": "Principal Purpose of Policy",
              "value": "Ensure independence of the external auditor"
            },
            {
              "key": "Pre-approved audit services",
              "value": "Includes annual financial statement audit, statutory audits for subsidiaries, procedures for forming opinion on consolidated Financial Statements"
            },
            {
              "key": "Audit-related services",
              "value": "Include assurance in relation to tax regulatory certificates, financial statement audits of employee benefit plans, and capital market transactions"
            },
            {
              "key": "Increase in statutory audit fee 2022",
              "value": "Largely driven by inflationary increases, additional audit procedures related to ISA 315, Alexion's inclusion into SOx scope"
            },
            {
              "key": "Audit-related services fees percentage 2022",
              "value": "4% of fees payable to PwC for audit services"
            },
            {
              "key": "Audit-related other assurance services fees 2021",
              "value": "27% of fees payable"
            },
            {
              "key": "Non-audit services fee cap",
              "value": "70% under EU regulation"
            },
            {
              "key": "Auditor Committee Conclusion",
              "value": "PwC audit was effective for financial year ended 31 December 2022"
            },
            {
              "key": "Recommendation for auditor reappointment",
              "value": "Committee recommended reappointment of PwC for financial year ending 31 December 2023"
            },
            {
              "key": "Tendering of external audit",
              "value": "Will commence in or before 2027 financial year, compliance with UK legal requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 107,
          "title": "2022 Financial Performance and Overview",
          "data": [
            {
              "key": "Total Revenue Target",
              "value": "$43.4bn"
            },
            {
              "key": "Total Revenue Outcome",
              "value": "$46.3bn"
            },
            {
              "key": "Cash Flow Target",
              "value": "$6.8bn"
            },
            {
              "key": "Cash Flow Outcome",
              "value": "$9.2bn"
            },
            {
              "key": "Core EPS Target",
              "value": "$6.54"
            },
            {
              "key": "Core EPS Outcome",
              "value": "$7.04"
            },
            {
              "key": "Pipeline Progression Events Target",
              "value": "20"
            },
            {
              "key": "Pipeline Progression Events Outcome",
              "value": "25"
            },
            {
              "key": "Regulatory Events Target",
              "value": "45"
            },
            {
              "key": "Regulatory Events Outcome",
              "value": "50"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 134,
          "title": "Independent auditors’ report to the members of AstraZeneca PLC continued",
          "data": [
            {
              "key": "Key audit matter",
              "value": "Recognition and measurement of accruals for Managed Care, Medicaid and Medicare Part D rebates on US Product Sales (excluding Rare Diseases) (Group)"
            },
            {
              "key": "Revenue recognition",
              "value": "In the US the Group recognises revenue on Product Sales under various commercial and government mandated contracts and reimbursement arrangements that include rebates."
            },
            {
              "key": "Significant rebates accounted",
              "value": "Managed Care, Medicaid and Medicare Part D relating to US Product Sales, excluding Rare Diseases."
            },
            {
              "key": "Accrual amount",
              "value": "US Rebates, chargebacks, returns and other revenue accruals liability (excluding Rare Diseases) at 31 December 2022 amounted to $3,822m (2021: $3,045m)."
            },
            {
              "key": "Intangible assets value",
              "value": "The Group has product, marketing and distribution rights and other intangible assets totalling $38,890m at 31 December 2022 (2021: $42,062m)."
            },
            {
              "key": "Net impairment charges",
              "value": "During 2022, $241m (2021: $2,067m) of net impairment charges were recorded."
            },
            {
              "key": "Legal provisions and contingent liabilities",
              "value": "As at 31 December 2022, the Group held provisions of $161m (2021: $239m) in respect of legal claims and settlements."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 140,
          "title": "Financial Statement",
          "data": [
            {
              "key": "Product Sales",
              "value": ""
            },
            {
              "key": "Collaboration Revenue",
              "value": ""
            },
            {
              "key": "Total Revenue",
              "value": ""
            },
            {
              "key": "Operating profit",
              "value": ""
            },
            {
              "key": "Profit for the period",
              "value": ""
            },
            {
              "key": "Basic earnings per $0.25 Ordinary Share",
              "value": ""
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 141,
          "title": "Consolidated Statement of Financial Position",
          "data": [
            {
              "key": "Total assets",
              "value": "96,483"
            },
            {
              "key": "Previous period total assets",
              "value": "105,363"
            },
            {
              "key": "Net assets",
              "value": "37,058"
            },
            {
              "key": "Previous period net assets",
              "value": "39,287"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 142,
          "title": "Statement of Changes in Equity",
          "data": [
            {
              "key": "Period",
              "value": "At 1 January 2020"
            },
            {
              "key": "Share Capital",
              "value": "328"
            },
            {
              "key": "Share Premium",
              "value": "7941"
            },
            {
              "key": "Capital Redemption",
              "value": "153"
            },
            {
              "key": "Merger Reserve",
              "value": "448"
            },
            {
              "key": "Other Reserves",
              "value": "1445"
            },
            {
              "key": "Retained Earnings",
              "value": "2812"
            },
            {
              "key": "Total Attributable",
              "value": "13127"
            },
            {
              "key": "Non Controlling",
              "value": "1469"
            },
            {
              "key": "Total Equity",
              "value": "14596"
            },
            {
              "key": "Period",
              "value": "At 31 December 2020"
            },
            {
              "key": "Share Capital",
              "value": "328"
            },
            {
              "key": "Share Premium",
              "value": "7971"
            },
            {
              "key": "Capital Redemption",
              "value": "153"
            },
            {
              "key": "Merger Reserve",
              "value": "448"
            },
            {
              "key": "Other Reserves",
              "value": "1423"
            },
            {
              "key": "Retained Earnings",
              "value": "5299"
            },
            {
              "key": "Total Attributable",
              "value": "15622"
            },
            {
              "key": "Non Controlling",
              "value": "16"
            },
            {
              "key": "Total Equity",
              "value": "15638"
            },
            {
              "key": "Period",
              "value": "At 31 December 2021"
            },
            {
              "key": "Share Capital",
              "value": "387"
            },
            {
              "key": "Share Premium",
              "value": "35126"
            },
            {
              "key": "Capital Redemption",
              "value": "153"
            },
            {
              "key": "Merger Reserve",
              "value": "448"
            },
            {
              "key": "Other Reserves",
              "value": "1444"
            },
            {
              "key": "Retained Earnings",
              "value": "1710"
            },
            {
              "key": "Total Attributable",
              "value": "39268"
            },
            {
              "key": "Non Controlling",
              "value": "19"
            },
            {
              "key": "Total Equity",
              "value": "39287"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 143,
          "title": "Consolidated Statement of Cash Flows",
          "data": [
            {
              "key": "Cash flows from operating activities - Profit/(loss) before tax",
              "value": "2022: 2,501, 2021: (265), 2020: 3,916"
            },
            {
              "key": "Cash flows from operating activities - Net cash inflow from operating activities",
              "value": "2022: 9,808, 2021: 5,963, 2020: 4,799"
            },
            {
              "key": "Cash flows from investing activities - Net cash outflow from investing activities",
              "value": "2022: (2,960), 2021: (11,058), 2020: (285)"
            },
            {
              "key": "Cash flows from financing activities - Net cash (outflow)/inflow from financing activities",
              "value": "2022: (6,823), 2021: 3,649, 2020: (2,203)"
            },
            {
              "key": "Cash and cash equivalents - Net increase/(decrease) in Cash and cash equivalents in the period",
              "value": "2022: 25, 2021: (1,446), 2020: 2,311"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 153,
          "title": "Other Operating Income and Expense",
          "data": [
            {
              "key": "Royalty income",
              "value": "59"
            },
            {
              "key": "Gains on disposal of intangible assets",
              "value": "104"
            },
            {
              "key": "Gains on disposal of investments in associates and joint ventures",
              "value": "0"
            },
            {
              "key": "Net gains/(losses) on disposal of other non-current assets",
              "value": "112"
            },
            {
              "key": "Impairment of property, plant and equipment",
              "value": "0"
            },
            {
              "key": "Other income",
              "value": "439"
            },
            {
              "key": "Other expense",
              "value": "-200"
            },
            {
              "key": "Other operating income and expense",
              "value": "514"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 153,
          "title": "Restructuring Costs",
          "data": [
            {
              "key": "Cost of sales",
              "value": "266"
            },
            {
              "key": "Distribution expense",
              "value": "2"
            },
            {
              "key": "Research and development expense",
              "value": "111"
            },
            {
              "key": "Selling, general and administrative expense",
              "value": "405"
            },
            {
              "key": "Other operating income and expense",
              "value": "(67)"
            },
            {
              "key": "Total charge",
              "value": "717"
            },
            {
              "key": "Severance costs",
              "value": "187"
            },
            {
              "key": "Accelerated depreciation and impairment charges",
              "value": "135"
            },
            {
              "key": "Other",
              "value": "395"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 154,
          "title": "Financial Instruments Net Gains and Losses",
          "data": [
            {
              "key": "Gains/(losses) on forward foreign exchange contracts",
              "value": "150, -21, -86"
            },
            {
              "key": "Losses/(gains) on receivables and payables",
              "value": "-203, -42, 89"
            },
            {
              "key": "Total",
              "value": "-53, -63, 3"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 154,
          "title": "Financial Summary",
          "data": [
            {
              "key": "Finance income 2022",
              "value": "95"
            },
            {
              "key": "Finance income 2021",
              "value": "43"
            },
            {
              "key": "Finance income 2020",
              "value": "87"
            },
            {
              "key": "Finance expense 2022",
              "value": "-1346"
            },
            {
              "key": "Finance expense 2021",
              "value": "-1300"
            },
            {
              "key": "Finance expense 2020",
              "value": "-1306"
            },
            {
              "key": "Net finance expense 2022",
              "value": "-1251"
            },
            {
              "key": "Net finance expense 2021",
              "value": "-1257"
            },
            {
              "key": "Net finance expense 2020",
              "value": "-1219"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 154,
          "title": "Interest Related Financial Items",
          "data": [
            {
              "key": "Interest and fair value adjustments in respect of debt",
              "value": "-9, -6, -8"
            },
            {
              "key": "Interest and changes in carrying values of debt designated as hedged items",
              "value": "0, -9, 0"
            },
            {
              "key": "Interest and fair value changes on fixed and short-term deposits",
              "value": "54, 16, 42"
            },
            {
              "key": "Interest on debt and lease liabilities",
              "value": "-837, -738, -660"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 157,
          "title": "Deferred Tax Balance Movement Analysis",
          "data": [
            {
              "key": "Net deferred tax balance at 1 January 2020",
              "value": "228"
            },
            {
              "key": "Net deferred tax balance at 31 December 2020",
              "value": "520"
            },
            {
              "key": "Net deferred tax balance at 31 December 2021",
              "value": "-1876"
            },
            {
              "key": "Net deferred tax balance at 31 December 2022",
              "value": "319"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 157,
          "title": "Deferred Tax Assets and Liabilities Summary",
          "data": [
            {
              "key": "Deferred tax assets at 31 December 2020",
              "value": "6019"
            },
            {
              "key": "Deferred tax liabilities at 31 December 2020",
              "value": "-6499"
            },
            {
              "key": "Net deferred tax balance at 31 December 2020",
              "value": "520"
            },
            {
              "key": "Deferred tax assets at 31 December 2021",
              "value": "7266"
            },
            {
              "key": "Deferred tax liabilities at 31 December 2021",
              "value": "-9142"
            },
            {
              "key": "Net deferred tax balance at 31 December 2021",
              "value": "-1876"
            },
            {
              "key": "Deferred tax assets at 31 December 2022",
              "value": "6711"
            },
            {
              "key": "Deferred tax liabilities at 31 December 2022",
              "value": "-6392"
            },
            {
              "key": "Net deferred tax balance at 31 December 2022",
              "value": "319"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 158,
          "title": "Deferred Tax Position",
          "data": [
            {
              "key": "Deferred tax assets",
              "value": "3263, 4330, 3438"
            },
            {
              "key": "Deferred tax liabilities",
              "value": "-2944, -6206, -2918"
            },
            {
              "key": "Net deferred tax balance",
              "value": "319, -1876, 520"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 158,
          "title": "Unrecognized Deferred Tax Assets",
          "data": [
            {
              "key": "Trading and capital losses expiring (Within 10 years)",
              "value": "104 (DTA: 26), 4 (DTA: 1), 2 (DTA: 0)"
            },
            {
              "key": "Trading and capital losses expiring (More than 10 years)",
              "value": "153 (DTA: 32), 53 (DTA: N/A), 0 (DTA: 0)"
            },
            {
              "key": "Trading and capital losses expiring (Indefinite)",
              "value": "686 (DTA: 163), 300 (DTA: 79), 234 (DTA: 63)"
            },
            {
              "key": "Tax credits and State tax losses expiring (Within 10 years)",
              "value": "N/A (DTA: 115), N/A (DTA: 101), N/A (DTA: 36)"
            },
            {
              "key": "Tax credits and State tax losses expiring (More than 10 years)",
              "value": "N/A (DTA: 384), N/A (DTA: 441), N/A (DTA: 255)"
            },
            {
              "key": "Tax credits and State tax losses expiring (Indefinite)",
              "value": "N/A (DTA: 87), N/A (DTA: 86), N/A (DTA: 74)"
            },
            {
              "key": "Total",
              "value": "943 (DTA: 221), 357 (DTA: 91), 236 (DTA: 63)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 158,
          "title": "Earnings per $0.25 Ordinary Share",
          "data": [
            {
              "key": "Profit for the year attributable to equity holders ($m)",
              "value": "3288, 112, 3196"
            },
            {
              "key": "Basic earnings per Ordinary Share",
              "value": "$2.12, $0.08, $2.44"
            },
            {
              "key": "Diluted earnings per Ordinary Share",
              "value": "$2.11, $0.08, $2.44"
            },
            {
              "key": "Weighted average number of Ordinary Shares in issue for basic earnings (millions)",
              "value": "1548, 1418, 1312"
            },
            {
              "key": "Dilutive impact of share options outstanding (millions)",
              "value": "12, 9, 1"
            },
            {
              "key": "Diluted weighted average number of Ordinary Shares in issue (millions)",
              "value": "1560, 1427, 1313"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 160,
          "title": "Segment information continued",
          "data": [
            {
              "key": "Region",
              "value": "UK"
            },
            {
              "key": "Financial Performance 2022",
              "value": "1120"
            },
            {
              "key": "Financial Performance 2021",
              "value": "-950"
            },
            {
              "key": "Financial Performance 2020",
              "value": "824"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 160,
          "title": "Geographic markets",
          "data": [
            {
              "key": "Region",
              "value": "UK"
            },
            {
              "key": "Product Sales 2022",
              "value": "996"
            },
            {
              "key": "Product Sales 2021",
              "value": "1206"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 160,
          "title": "Net Operating Assets",
          "data": [
            {
              "key": "2020",
              "value": "5244"
            },
            {
              "key": "2021",
              "value": "10170"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 164,
          "title": "Intangible Assets Breakdown",
          "data": [
            {
              "key": "Net book value 2022",
              "value": "null"
            },
            {
              "key": "Net book value 2021",
              "value": "null"
            },
            {
              "key": "Net book value 2020",
              "value": "null"
            },
            {
              "key": "Current intangible assets 2022",
              "value": "0"
            },
            {
              "key": "Current intangible assets 2021",
              "value": "105"
            },
            {
              "key": "Current intangible assets 2020",
              "value": "0"
            },
            {
              "key": "Non-current intangible assets 2022",
              "value": "39307"
            },
            {
              "key": "Non-current intangible assets 2021",
              "value": "42387"
            },
            {
              "key": "Non-current intangible assets 2020",
              "value": "20947"
            },
            {
              "key": "At 31 December 2022",
              "value": "39307"
            },
            {
              "key": "At 31 December 2021",
              "value": "42492"
            },
            {
              "key": "At 31 December 2020",
              "value": "20947"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 164,
          "title": "Expense Breakdown by Category and Year",
          "data": [
            {
              "key": "Total expenses 2020",
              "value": "1992"
            },
            {
              "key": "Total expenses 2021",
              "value": "3143"
            },
            {
              "key": "Total expenses 2022",
              "value": "4294"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 168,
          "title": "Financial Derivatives and Assets/Liabilities Distribution",
          "data": [
            {
              "key": "Category",
              "value": "Interest rate swaps related to instruments designated at fair value through profit and loss"
            },
            {
              "key": "Non-current assets $m",
              "value": "45"
            },
            {
              "key": "Current assets $m",
              "value": "0"
            },
            {
              "key": "Current liabilities $m",
              "value": "0"
            },
            {
              "key": "Non-current liabilities $m",
              "value": "0"
            },
            {
              "key": "Total $m",
              "value": "45"
            },
            {
              "key": "Category",
              "value": "Cross Currency swaps designated in a net investment hedge"
            },
            {
              "key": "Non-current assets $m",
              "value": "19"
            },
            {
              "key": "Current assets $m",
              "value": "0"
            },
            {
              "key": "Current liabilities $m",
              "value": "0"
            },
            {
              "key": "Non-current liabilities $m",
              "value": "2"
            },
            {
              "key": "Total $m",
              "value": "7"
            },
            {
              "key": "Category",
              "value": "Cross Currency swaps designated in a cash flow hedge"
            },
            {
              "key": "Non-current assets $m",
              "value": "107"
            },
            {
              "key": "Current assets $m",
              "value": "43"
            },
            {
              "key": "Current liabilities $m",
              "value": "0"
            },
            {
              "key": "Non-current liabilities $m",
              "value": "0"
            },
            {
              "key": "Total $m",
              "value": "150"
            },
            {
              "key": "Category",
              "value": "Cross Currency swaps designated in a fair value hedge"
            },
            {
              "key": "Non-current assets $m",
              "value": "0"
            },
            {
              "key": "Current assets $m",
              "value": "43"
            },
            {
              "key": "Current liabilities $m",
              "value": "0"
            },
            {
              "key": "Non-current liabilities $m",
              "value": "0"
            },
            {
              "key": "Total $m",
              "value": "43"
            },
            {
              "key": "Category",
              "value": "Forward FX designated in a cash flow hedge"
            },
            {
              "key": "Non-current assets $m",
              "value": "0"
            },
            {
              "key": "Current assets $m",
              "value": "8"
            },
            {
              "key": "Current liabilities $m",
              "value": "-3"
            },
            {
              "key": "Non-current liabilities $m",
              "value": "0"
            },
            {
              "key": "Total $m",
              "value": "5"
            },
            {
              "key": "Category",
              "value": "Other derivatives"
            },
            {
              "key": "Non-current assets $m",
              "value": "0"
            },
            {
              "key": "Current assets $m",
              "value": "48"
            },
            {
              "key": "Current liabilities $m",
              "value": "-80"
            },
            {
              "key": "Non-current liabilities $m",
              "value": "0"
            },
            {
              "key": "Total $m",
              "value": "18"
            },
            {
              "key": "Category",
              "value": "1 December 2020"
            },
            {
              "key": "Non-current assets $m",
              "value": "171"
            },
            {
              "key": "Current assets $m",
              "value": "142"
            },
            {
              "key": "Current liabilities $m",
              "value": "-33"
            },
            {
              "key": "Non-current liabilities $m",
              "value": "-2"
            },
            {
              "key": "Total $m",
              "value": "278"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 170,
          "title": "Current and Non-current Liabilities Statement",
          "data": [
            {
              "key": "Current liabilities",
              "value": "286"
            },
            {
              "key": "Other short-term borrowings excluding overdrafts",
              "value": "84"
            },
            {
              "key": "Collateral received from derivative counterparties",
              "value": "288"
            },
            {
              "key": "Lease liabilities",
              "value": "192"
            },
            {
              "key": "0.25% Callable bond",
              "value": "614"
            },
            {
              "key": "0.875% Non-callable bond",
              "value": "919"
            },
            {
              "key": "Floating rate notes",
              "value": "-"
            },
            {
              "key": "2.375% Callable bond",
              "value": "-"
            },
            {
              "key": "0.3% Callable bond – 2023",
              "value": "-"
            },
            {
              "key": "Floating bank loan",
              "value": "-"
            },
            {
              "key": "3.5% Callable bond",
              "value": "-"
            },
            {
              "key": "7% Guaranteed debentures",
              "value": "-"
            },
            {
              "key": "Other loans (including commercial paper)",
              "value": "3"
            },
            {
              "key": "Total Non-current liabilities",
              "value": "-"
            },
            {
              "key": "Lease liabilities",
              "value": "489"
            },
            {
              "key": "Floating rate notes",
              "value": "250"
            },
            {
              "key": "2.375% Callable bond",
              "value": "996"
            },
            {
              "key": "0.3% Callable bond – 2023",
              "value": "-"
            },
            {
              "key": "Floating rate bank loan",
              "value": "-"
            },
            {
              "key": "Floating rate notes",
              "value": "400"
            },
            {
              "key": "3.5% Callable bond",
              "value": "847"
            },
            {
              "key": "7% Guaranteed debentures",
              "value": "339"
            },
            {
              "key": "0.75% Callable bond",
              "value": "-"
            },
            {
              "key": "0.7% Callable bond – 2024",
              "value": "-"
            },
            {
              "key": "Floating rate bank loan",
              "value": "-"
            },
            {
              "key": "3.375% Callable bond",
              "value": "-"
            },
            {
              "key": "0.7% Callable bond",
              "value": "-"
            },
            {
              "key": "1.2% Callable bond",
              "value": "-"
            },
            {
              "key": "3.125% Callable bond",
              "value": "744"
            },
            {
              "key": "1.25% Callable bond",
              "value": "973"
            },
            {
              "key": "1.75% Callable bond",
              "value": "-"
            },
            {
              "key": "4% Callable bond",
              "value": "993"
            },
            {
              "key": "0.375% Callable bond",
              "value": "-"
            },
            {
              "key": "1.375% Callable bond",
              "value": "-"
            },
            {
              "key": "2.25% Callable bond",
              "value": "-"
            },
            {
              "key": "5.75% Non-callable bond",
              "value": "475"
            },
            {
              "key": "6.45% Callable bond",
              "value": "-"
            },
            {
              "key": "4% Callable bond",
              "value": "988"
            },
            {
              "key": "4.375% Callable bond",
              "value": "980"
            },
            {
              "key": "4.375% Callable bond",
              "value": "737"
            },
            {
              "key": "2.125% Callable bond",
              "value": "486"
            },
            {
              "key": "3% Callable bond",
              "value": "-"
            },
            {
              "key": "Other loans",
              "value": "5"
            },
            {
              "key": "Total interest-bearing loans and borrowings",
              "value": "30,781          20,380  29,232"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 172,
          "title": "Trade and other payables",
          "data": [
            {
              "key": "Trade payables",
              "value": "2550"
            },
            {
              "key": "Value-added and payroll taxes and social security",
              "value": "468"
            },
            {
              "key": "Rebates, chargebacks, returns and other revenue accruals",
              "value": "6078"
            },
            {
              "key": "Clinical trial accruals",
              "value": "1417"
            },
            {
              "key": "Other accruals",
              "value": "5551"
            },
            {
              "key": "Collaboration Revenue contract liabilities",
              "value": "12"
            },
            {
              "key": "Vaccine contract liabilities",
              "value": "169"
            },
            {
              "key": "Deferred government grant income",
              "value": "1"
            },
            {
              "key": "Contingent consideration",
              "value": "757"
            },
            {
              "key": "Acerta Pharma share purchase liability",
              "value": "867"
            },
            {
              "key": "Other payables",
              "value": "1170"
            },
            {
              "key": "Total Current Liabilities",
              "value": "19040"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 172,
          "title": "Current liabilities",
          "data": [
            {
              "key": "Current Liabilities Total",
              "value": "19040"
            },
            {
              "key": "Non-Current Liabilities Total",
              "value": "4270"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 176,
          "title": "Post-retirement and other defined benefit schemes",
          "data": [
            {
              "key": "UK Pension Fund actuarial valuation date",
              "value": "31 March 2019"
            },
            {
              "key": "Actuarial valuation completion date",
              "value": "June 2020"
            },
            {
              "key": "Next actuarial valuation date",
              "value": "31 March 2022 (in progress)"
            },
            {
              "key": "Pension Fund obligations value at 31 December 2022",
              "value": "Incorporates latest actuarial valuation data"
            },
            {
              "key": "Funding agreement effective date",
              "value": "October 2016"
            },
            {
              "key": "Deficit recovery contribution made in March 2022",
              "value": "£39m"
            },
            {
              "key": "Total contributions expected before 31 March 2023",
              "value": "£39m (further contribution) + £30m (final instalment)"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 187,
          "title": "Financial Liabilities and Derivatives Maturity Analysis",
          "data": [
            {
              "key": "period",
              "value": "Within one year"
            },
            {
              "key": "bank_overdrafts",
              "value": "387"
            },
            {
              "key": "bonds_and_bankloans",
              "value": "1981"
            },
            {
              "key": "lease_liability",
              "value": "256"
            },
            {
              "key": "trade_payables",
              "value": "19007"
            },
            {
              "key": "total_non_derivative",
              "value": "21631"
            },
            {
              "key": "derivative_receivable",
              "value": "-11766"
            },
            {
              "key": "derivative_payable",
              "value": "11774"
            },
            {
              "key": "total_derivative",
              "value": "8"
            },
            {
              "key": "total",
              "value": "21639"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 187,
          "title": "Financial Liabilities and Instruments Maturity Analysis",
          "data": [
            {
              "key": "period",
              "value": "Within one year"
            },
            {
              "key": "overdrafts_and_other_loans",
              "value": "365"
            },
            {
              "key": "bonds_and_bank_loans",
              "value": "5777"
            },
            {
              "key": "lease_liability",
              "value": "249"
            },
            {
              "key": "trade_and_other_payables",
              "value": "19065"
            },
            {
              "key": "non_derivative_financial_instruments",
              "value": "25456"
            },
            {
              "key": "financial_instruments_receivable",
              "value": "-12445"
            },
            {
              "key": "financial_instruments_payable",
              "value": "12478"
            },
            {
              "key": "derive_financial_instruments",
              "value": "33"
            },
            {
              "key": "total",
              "value": "25489"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 187,
          "title": "Financial Assets and Liabilities Breakdown",
          "data": [
            {
              "key": "category",
              "value": "Financial liabilities - Interest-bearing loans and borrowings"
            },
            {
              "key": "type",
              "value": "Current"
            },
            {
              "key": "period1_fixed_rate",
              "value": "2476"
            },
            {
              "key": "period1_floating_rate",
              "value": "3066"
            },
            {
              "key": "period1_total",
              "value": "5542"
            },
            {
              "key": "period2_fixed_rate",
              "value": "1232"
            },
            {
              "key": "period2_floating_rate",
              "value": "661"
            },
            {
              "key": "period2_total",
              "value": "1893"
            },
            {
              "key": "period3_fixed_rate",
              "value": "1357"
            },
            {
              "key": "period3_floating_rate",
              "value": "1029"
            },
            {
              "key": "period3_total",
              "value": "2386"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 188,
          "title": "Financial Risk Management Objectives and Policies",
          "data": [
            {
              "key": "Equity securities at fair value through Other comprehensive income (Note 12)",
              "value": "1056"
            },
            {
              "key": "Non-current fixed income securities at fair value through profit and loss (Note 12)",
              "value": "10"
            },
            {
              "key": "Total",
              "value": "1066"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 188,
          "title": "Sensitivity Analysis of Interest Rates and Exchange Rates",
          "data": [
            {
              "key": "Date",
              "value": "31 December 2020"
            },
            {
              "key": "Interest Rate Increase",
              "value": "1,696"
            },
            {
              "key": "Interest Rate Decrease",
              "value": "(1,758)"
            },
            {
              "key": "Exchange Rate Increase",
              "value": "114"
            },
            {
              "key": "Exchange Rate Decrease",
              "value": "(132)"
            },
            {
              "key": "Impact on Profit: (loss)/gain ($m)",
              "value": "(87)"
            },
            {
              "key": "Impact on Equity: gain/(loss) ($m)",
              "value": "171"
            },
            {
              "key": "Date",
              "value": "31 December 2021"
            },
            {
              "key": "Interest Rate Increase",
              "value": "1,978"
            },
            {
              "key": "Interest Rate Decrease",
              "value": "(2,106)"
            },
            {
              "key": "Exchange Rate Increase",
              "value": "82"
            },
            {
              "key": "Exchange Rate Decrease",
              "value": "(85)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 189,
          "title": "Sensitivity Analysis",
          "data": [
            {
              "key": "increase/(decrease) in fair value of financial instruments ($m)",
              "value": "+1%: 1,317, 1%: (1,490), +10%: 81, -10%: (89)"
            },
            {
              "key": "impact on profit: gain/(loss) ($m)",
              "value": "+10%: 26, -10%: (15)"
            },
            {
              "key": "Impact on equity: gain/(loss) ($m)",
              "value": "+10%: 55, -10%: (74)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 189,
          "title": "Current Assets Overview",
          "data": [
            {
              "key": "Cash at bank and in hand (2022)",
              "value": "1,411"
            },
            {
              "key": "Money market liquidity funds (2022)",
              "value": "4,486"
            },
            {
              "key": "Other short-term cash equivalents (2022)",
              "value": "269"
            },
            {
              "key": "Total Cash and cash equivalents (2022)",
              "value": "6,166"
            },
            {
              "key": "Fixed income securities at fair value (2022)",
              "value": "13"
            },
            {
              "key": "Cash collateral pledged (2022)",
              "value": "162"
            },
            {
              "key": "Fixed deposits (2022)",
              "value": "64"
            },
            {
              "key": "Total derivative financial instruments (2022)",
              "value": "87"
            },
            {
              "key": "Current assets subject to credit risk (2022)",
              "value": "6,492"
            },
            {
              "key": "Non-current assets (2022)",
              "value": "2022"
            },
            {
              "key": "Derivative financial instruments (2022)",
              "value": "74"
            },
            {
              "key": "Non-current assets subject to credit risk (2022)",
              "value": "74"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 189,
          "title": "Credit Loss Analysis as of 31 December 2020",
          "data": [
            {
              "key": "Expected loss rate (Current)",
              "value": "0.1%"
            },
            {
              "key": "Expected loss rate (0-90 days past due)",
              "value": "1.6%"
            },
            {
              "key": "Expected loss rate (90-180 days past due)",
              "value": "19.4%"
            },
            {
              "key": "Expected loss rate (Over 180 days past due)",
              "value": "60.6%"
            },
            {
              "key": "Gross carrying amount (Current)",
              "value": "3659"
            },
            {
              "key": "Gross carrying amount (0-90 days past due)",
              "value": "124"
            },
            {
              "key": "Gross carrying amount (90-180 days past due)",
              "value": "41"
            },
            {
              "key": "Gross carrying amount (Over 180 days past due)",
              "value": "25"
            },
            {
              "key": "Loss allowance (Current)",
              "value": "2"
            },
            {
              "key": "Loss allowance (0-90 days past due)",
              "value": "2"
            },
            {
              "key": "Loss allowance (90-180 days past due)",
              "value": "4"
            },
            {
              "key": "Loss allowance (Over 180 days past due)",
              "value": "15"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 190,
          "title": "Expected Loss Rates and Carrying Amounts Comparison 2021-2022",
          "data": [
            {
              "key": "Expected loss rate (Current)",
              "value": "0.03%"
            },
            {
              "key": "Expected loss rate (0-90 days)",
              "value": "0.3%"
            },
            {
              "key": "Expected loss rate (90-180 days)",
              "value": "32.0%"
            },
            {
              "key": "Expected loss rate (Over 180 days)",
              "value": "40.6%"
            },
            {
              "key": "Gross carrying amount ($m) (Current)",
              "value": "6791"
            },
            {
              "key": "Gross carrying amount ($m) (0-90 days)",
              "value": "331"
            },
            {
              "key": "Gross carrying amount ($m) (90-180 days)",
              "value": "50"
            },
            {
              "key": "Gross carrying amount ($m) (Over 180 days)",
              "value": "99"
            },
            {
              "key": "Total Gross carrying amount ($m)",
              "value": "7271"
            },
            {
              "key": "Loss allowance ($m) (Current)",
              "value": "2"
            },
            {
              "key": "Loss allowance ($m) (0-90 days)",
              "value": "1"
            },
            {
              "key": "Loss allowance ($m) (90-180 days)",
              "value": "16"
            },
            {
              "key": "Loss allowance ($m) (Over 180 days)",
              "value": "40"
            },
            {
              "key": "Total Loss allowance ($m)",
              "value": "59"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 190,
          "title": "Movement of Expected Credit Loss Provision",
          "data": [
            {
              "key": "At 1 January (Year 1)",
              "value": "23"
            },
            {
              "key": "At 1 January (Year 2)",
              "value": "23"
            },
            {
              "key": "At 1 January (Year 3)",
              "value": "21"
            },
            {
              "key": "Net movement recognised in income statement (Year 1)",
              "value": "37"
            },
            {
              "key": "Net movement recognised in income statement (Year 2)",
              "value": "-2"
            },
            {
              "key": "Net movement recognised in income statement (Year 3)",
              "value": "3"
            },
            {
              "key": "Amounts utilised, exchange and other movements (Year 1)",
              "value": "-1"
            },
            {
              "key": "Amounts utilised, exchange and other movements (Year 2)",
              "value": "2"
            },
            {
              "key": "Amounts utilised, exchange and other movements (Year 3)",
              "value": "-1"
            },
            {
              "key": "At 31 December (Year 1)",
              "value": "59"
            },
            {
              "key": "At 31 December (Year 2)",
              "value": "23"
            },
            {
              "key": "At 31 December (Year 3)",
              "value": "23"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 190,
          "title": "Hedge Relationships under IFRS 9 (2020)",
          "data": [
            {
              "key": "Instrument",
              "value": "Fair value hedge - foreign currency and interest rate risk"
            },
            {
              "key": "Nominal Amount",
              "value": ""
            },
            {
              "key": "Carrying Value",
              "value": ""
            },
            {
              "key": "Opening Balance",
              "value": ""
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": ""
            },
            {
              "key": "Recycled Loss",
              "value": ""
            },
            {
              "key": "Closing Balance",
              "value": ""
            },
            {
              "key": "Maturity",
              "value": ""
            },
            {
              "key": "FX Rate",
              "value": ""
            },
            {
              "key": "Interest Rate",
              "value": "USD LIBOR"
            },
            {
              "key": "Instrument",
              "value": "Cross currency interest rate swap — Euro bond"
            },
            {
              "key": "Nominal Amount",
              "value": "EUR 300m"
            },
            {
              "key": "Carrying Value",
              "value": "43"
            },
            {
              "key": "Opening Balance",
              "value": "-"
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": "-"
            },
            {
              "key": "Recycled Loss",
              "value": "-"
            },
            {
              "key": "Closing Balance",
              "value": "-"
            },
            {
              "key": "Maturity",
              "value": "2021"
            },
            {
              "key": "FX Rate",
              "value": "1.09"
            },
            {
              "key": "Interest Rate",
              "value": "+ 1.27%"
            },
            {
              "key": "Instrument",
              "value": "Cross currency interest rate swaps — Euro bonds"
            },
            {
              "key": "Nominal Amount",
              "value": "EUR 2,200m"
            },
            {
              "key": "Carrying Value",
              "value": "150"
            },
            {
              "key": "Opening Balance",
              "value": "(30)"
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": "(163)"
            },
            {
              "key": "Recycled Loss",
              "value": "239"
            },
            {
              "key": "Closing Balance",
              "value": "46"
            },
            {
              "key": "Maturity",
              "value": "2025"
            },
            {
              "key": "FX Rate",
              "value": "1.14"
            },
            {
              "key": "Interest Rate",
              "value": "USD 2.69%"
            },
            {
              "key": "Instrument",
              "value": "FX Forwards — short term FX risk"
            },
            {
              "key": "Nominal Amount",
              "value": "USD 618m"
            },
            {
              "key": "Carrying Value",
              "value": "5"
            },
            {
              "key": "Opening Balance",
              "value": "-"
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": "(20)"
            },
            {
              "key": "Recycled Loss",
              "value": "15"
            },
            {
              "key": "Closing Balance",
              "value": "(6)"
            },
            {
              "key": "Maturity",
              "value": "2021"
            },
            {
              "key": "FX Rate",
              "value": "-"
            },
            {
              "key": "Interest Rate",
              "value": "-"
            },
            {
              "key": "Instrument",
              "value": "Cross currency interest rate swap — JPY investment"
            },
            {
              "key": "Nominal Amount",
              "value": "JPY 58.5bn"
            },
            {
              "key": "Carrying Value",
              "value": "19"
            },
            {
              "key": "Opening Balance",
              "value": "4"
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": "(15)"
            },
            {
              "key": "Recycled Loss",
              "value": "-"
            },
            {
              "key": "Closing Balance",
              "value": "(19)"
            },
            {
              "key": "Maturity",
              "value": "2029"
            },
            {
              "key": "FX Rate",
              "value": "108.03"
            },
            {
              "key": "Interest Rate",
              "value": "JPY 1.53%"
            },
            {
              "key": "Instrument",
              "value": "Cross currency interest rate swap — CNY investment"
            },
            {
              "key": "Nominal Amount",
              "value": "CNY 458m"
            },
            {
              "key": "Carrying Value",
              "value": "(2)"
            },
            {
              "key": "Opening Balance",
              "value": "1"
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": "1"
            },
            {
              "key": "Recycled Loss",
              "value": "-"
            },
            {
              "key": "Closing Balance",
              "value": "2"
            },
            {
              "key": "Maturity",
              "value": "2026"
            },
            {
              "key": "FX Rate",
              "value": "6.68"
            },
            {
              "key": "Interest Rate",
              "value": "CNY 4.80%"
            },
            {
              "key": "Instrument",
              "value": "Foreign currency borrowing — GBP investment"
            },
            {
              "key": "Nominal Amount",
              "value": "GBP 350m"
            },
            {
              "key": "Carrying Value",
              "value": "(475)"
            },
            {
              "key": "Opening Balance",
              "value": "(251)"
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": "18"
            },
            {
              "key": "Recycled Loss",
              "value": "-"
            },
            {
              "key": "Closing Balance",
              "value": "(233)"
            },
            {
              "key": "Maturity",
              "value": "2031"
            },
            {
              "key": "FX Rate",
              "value": "-"
            },
            {
              "key": "Interest Rate",
              "value": "GBP 5.75%"
            },
            {
              "key": "Instrument",
              "value": "Foreign currency borrowing — EUR investment"
            },
            {
              "key": "Nominal Amount",
              "value": "EUR 450m"
            },
            {
              "key": "Carrying Value",
              "value": "(548)"
            },
            {
              "key": "Opening Balance",
              "value": "34"
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": "51"
            },
            {
              "key": "Recycled Loss",
              "value": "-"
            },
            {
              "key": "Closing Balance",
              "value": "85"
            },
            {
              "key": "Maturity",
              "value": "2021"
            },
            {
              "key": "FX Rate",
              "value": "-"
            },
            {
              "key": "Interest Rate",
              "value": "EUR 0.88%"
            },
            {
              "key": "Instrument",
              "value": "Contingent consideration liabilities and Acerta Pharma out option liability - AZUK and AZAB USD investments"
            },
            {
              "key": "Nominal Amount",
              "value": "USD 5,252m"
            },
            {
              "key": "Carrying Value",
              "value": "(5,252)"
            },
            {
              "key": "Opening Balance",
              "value": "2,053"
            },
            {
              "key": "Fair Value Gain/Loss",
              "value": "(642)"
            },
            {
              "key": "Recycled Loss",
              "value": "-"
            },
            {
              "key": "Closing Balance",
              "value": "1,411"
            },
            {
              "key": "Maturity",
              "value": "-"
            },
            {
              "key": "FX Rate",
              "value": "-"
            },
            {
              "key": "Interest Rate",
              "value": "-"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 206,
          "title": "Balance Sheet Statement",
          "data": [
            {
              "key": "Fixed asset investments",
              "value": "63555"
            },
            {
              "key": "Debtors — other",
              "value": "4"
            },
            {
              "key": "Debtors - amounts owed by Group undertakings",
              "value": "2608"
            },
            {
              "key": "Other payables",
              "value": "-194"
            },
            {
              "key": "Amounts owed to Group undertakings",
              "value": "-283"
            },
            {
              "key": "Interest-bearing loans and borrowings",
              "value": "-2648"
            },
            {
              "key": "Net current (liabilities)/assets",
              "value": "-513"
            },
            {
              "key": "Total assets less current liabilities",
              "value": "63042"
            },
            {
              "key": "Called-up share capital",
              "value": "387"
            },
            {
              "key": "Share premium account",
              "value": "35155"
            },
            {
              "key": "Capital redemption reserve",
              "value": "153"
            },
            {
              "key": "Other reserves",
              "value": "1927"
            },
            {
              "key": "Profit and loss account",
              "value": "7458"
            },
            {
              "key": "Shareholders' funds",
              "value": "45080"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 207,
          "title": "Statement of Changes in Equity",
          "data": [
            {
              "key": "period",
              "value": "At 1 January 2021"
            },
            {
              "key": "share_capital",
              "value": "328"
            },
            {
              "key": "share_premium_account",
              "value": "7971"
            },
            {
              "key": "capital_redemption_reserve",
              "value": "153"
            },
            {
              "key": "other_reserves",
              "value": "2382"
            },
            {
              "key": "profit_and_loss_account",
              "value": "10304"
            },
            {
              "key": "total_equity",
              "value": "21138"
            },
            {
              "key": "period",
              "value": "Profit for the period"
            },
            {
              "key": "share_capital",
              "value": "0"
            },
            {
              "key": "share_premium_account",
              "value": "0"
            },
            {
              "key": "capital_redemption_reserve",
              "value": "0"
            },
            {
              "key": "other_reserves",
              "value": "0"
            },
            {
              "key": "profit_and_loss_account",
              "value": "5141"
            },
            {
              "key": "total_equity",
              "value": "5141"
            },
            {
              "key": "period",
              "value": "Dividends"
            },
            {
              "key": "share_capital",
              "value": "0"
            },
            {
              "key": "share_premium_account",
              "value": "0"
            },
            {
              "key": "capital_redemption_reserve",
              "value": "0"
            },
            {
              "key": "other_reserves",
              "value": "0"
            },
            {
              "key": "profit_and_loss_account",
              "value": "-3882"
            },
            {
              "key": "total_equity",
              "value": "-3882"
            },
            {
              "key": "period",
              "value": "Capital contributions for share-based payments"
            },
            {
              "key": "share_capital",
              "value": "0"
            },
            {
              "key": "share_premium_account",
              "value": "0"
            },
            {
              "key": "capital_redemption_reserve",
              "value": "0"
            },
            {
              "key": "other_reserves",
              "value": "-200"
            },
            {
              "key": "profit_and_loss_account",
              "value": "0"
            },
            {
              "key": "total_equity",
              "value": "-200"
            },
            {
              "key": "period",
              "value": "Issue of Ordinary Shares"
            },
            {
              "key": "share_capital",
              "value": "59"
            },
            {
              "key": "share_premium_account",
              "value": "27155"
            },
            {
              "key": "capital_redemption_reserve",
              "value": "0"
            },
            {
              "key": "other_reserves",
              "value": "0"
            },
            {
              "key": "profit_and_loss_account",
              "value": "0"
            },
            {
              "key": "total_equity",
              "value": "27214"
            },
            {
              "key": "period",
              "value": "At 31 December 2021"
            },
            {
              "key": "share_capital",
              "value": "387"
            },
            {
              "key": "share_premium_account",
              "value": "35126"
            },
            {
              "key": "capital_redemption_reserve",
              "value": "153"
            },
            {
              "key": "other_reserves",
              "value": "2182"
            },
            {
              "key": "profit_and_loss_account",
              "value": "11563"
            },
            {
              "key": "total_equity",
              "value": "49411"
            },
            {
              "key": "period",
              "value": "Profit for the period (2022)"
            },
            {
              "key": "share_capital",
              "value": "0"
            },
            {
              "key": "share_premium_account",
              "value": "0"
            },
            {
              "key": "capital_redemption_reserve",
              "value": "0"
            },
            {
              "key": "other_reserves",
              "value": "0"
            },
            {
              "key": "profit_and_loss_account",
              "value": "380"
            },
            {
              "key": "total_equity",
              "value": "380"
            },
            {
              "key": "period",
              "value": "Dividends (2022)"
            },
            {
              "key": "share_capital",
              "value": "0"
            },
            {
              "key": "share_premium_account",
              "value": "0"
            },
            {
              "key": "capital_redemption_reserve",
              "value": "0"
            },
            {
              "key": "other_reserves",
              "value": "0"
            },
            {
              "key": "profit_and_loss_account",
              "value": "-4485"
            },
            {
              "key": "total_equity",
              "value": "-4485"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 208,
          "title": "Company Accounting Policies",
          "data": [
            {
              "key": "Basis of presentation of financial information",
              "value": "These financial statements were prepared in accordance with FRS 101 ‘Reduced Disclosure Framework’."
            },
            {
              "key": "Accounting policies",
              "value": "The Company has applied the exemptions available under FRS 101."
            },
            {
              "key": "Basis of accounting",
              "value": "Prepared under the historical cost convention and on a going concern basis."
            },
            {
              "key": "Estimates and judgements",
              "value": "Estimates and judgements affect reported amounts of assets and liabilities."
            },
            {
              "key": "Taxation",
              "value": "Current tax payable is based on taxable profit for the year."
            },
            {
              "key": "Investments",
              "value": "Fixed asset investments are stated at cost and reviewed for impairment."
            },
            {
              "key": "Debtors",
              "value": "Amounts owed by Group undertakings are recognised initially at fair value."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 213,
          "title": "Revenue and Profits Statement",
          "data": [
            {
              "key": "Product Sales",
              "value": "2018: 21049, 2019: 23565, 2020: 25890, 2021: 36541, 2022: 42998"
            },
            {
              "key": "Collaboration Revenue",
              "value": "2018: 1041, 2019: 819, 2020: 727, 2021: 876, 2022: 1353"
            },
            {
              "key": "Operating profit",
              "value": "2018: 3387, 2019: 2924, 2020: 5162, 2021: 1056, 2022: 3757"
            },
            {
              "key": "Profit for the period",
              "value": "2018: 2050, 2019: 1227, 2020: 3144, 2021: 115, 2022: 3293"
            },
            {
              "key": "Basic earnings per $0.25 Ordinary Share",
              "value": "2018: $1.70, 2019: $1.03, 2020: $2.44, 2021: $0.08, 2022: $2.12"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 216,
          "title": "Shareholder Information",
          "data": [
            {
              "key": "Total Registered Holders of Ordinary Shares",
              "value": "68,771"
            },
            {
              "key": "Total Issued Ordinary Shares",
              "value": "1,549,800,030"
            },
            {
              "key": "Holders under Euroclear Services Agreement",
              "value": "165,574 (10.2%)"
            },
            {
              "key": "Registered Holders of ADSs",
              "value": "1,653 (19.4%)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 216,
          "title": "Share Statistics",
          "data": [
            {
              "key": "Ordinary Shares in issue — millions (At year end) 2022",
              "value": "1,550"
            },
            {
              "key": "Ordinary Shares in issue — millions (At year end) 2021",
              "value": "1,549"
            },
            {
              "key": "Ordinary Shares in issue — millions (At year end) 2020",
              "value": "1,313"
            },
            {
              "key": "Ordinary Shares (Weighted average for year) 2022",
              "value": "1,548"
            },
            {
              "key": "Ordinary Shares (Weighted average for year) 2021",
              "value": "1,418"
            },
            {
              "key": "Ordinary Shares (Weighted average for year) 2020",
              "value": "1,312"
            },
            {
              "key": "Stock market closing price - Highest (pence) 2022",
              "value": "11,440"
            },
            {
              "key": "Stock market closing price - Highest (pence) 2021",
              "value": "9,444"
            },
            {
              "key": "Stock market closing price - Highest (pence) 2020",
              "value": "9,320"
            },
            {
              "key": "Stock market closing price - Lowest (pence) 2022",
              "value": "8,282"
            },
            {
              "key": "Stock market closing price - Lowest (pence) 2021",
              "value": "6,794"
            },
            {
              "key": "Stock market closing price - Lowest (pence) 2020",
              "value": "6,221"
            },
            {
              "key": "Stock market closing price - At year end (pence) 2022",
              "value": "11,218"
            },
            {
              "key": "Stock market closing price - At year end (pence) 2021",
              "value": "8,678"
            },
            {
              "key": "Stock market closing price - At year end (pence) 2020",
              "value": "7,324"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 216,
          "title": "Shareholding Analysis",
          "data": [
            {
              "key": "Range 1-250",
              "value": "0.3%"
            },
            {
              "key": "Range 251-500",
              "value": "0.3%"
            },
            {
              "key": "Range 501-1,000",
              "value": "0.4%"
            },
            {
              "key": "Range 1,001-5,000",
              "value": "0.5%"
            },
            {
              "key": "Range 5,001-10,000",
              "value": "0.2%"
            },
            {
              "key": "Range 10,001-50,000",
              "value": "14.0%"
            },
            {
              "key": "Range 50,001-1,000,000",
              "value": "14.0%"
            },
            {
              "key": "Range Over 1,000,000",
              "value": "96.1%"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": false,
      "elements": []
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 186,
          "title": "Financial Liability Maturity Analysis",
          "data": [
            {
              "key": "Within one year",
              "value": "Total: 18723"
            },
            {
              "key": "One to two years",
              "value": "Total: 4598"
            },
            {
              "key": "Two to three years",
              "value": "Total: 3887"
            },
            {
              "key": "Three to four years",
              "value": "Total: 3356"
            },
            {
              "key": "Four to five years",
              "value": "Total: 3281"
            },
            {
              "key": "More than five years",
              "value": "Total: 18409"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 211,
          "title": "Loans and Borrowings Schedule",
          "data": [
            {
              "key": "Total loans and borrowings",
              "value": "$20,870m in 2023, $22,313m in 2022"
            },
            {
              "key": "Amounts due within one year",
              "value": "$2,931m"
            },
            {
              "key": "Amounts due after more than one year",
              "value": "$17,939m in 2023, $21,064m in 2022"
            },
            {
              "key": "Repayment schedule",
              "value": "$11,051m after five years, $3,933m between two to five years, $2,955m between one to two years"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 12,
          "title": "Healthcare in a Changing World",
          "data": [
            {
              "key": "Description",
              "value": "The image shows a business document page about 'Healthcare in a Changing World' with a cityscape background featuring tall skyscrapers in misty/hazy conditions. The text content discusses the impact of global trends on the pharmaceutical sector, mentioning changes in industry regulations, pricing reforms in the US and China, digital and AI adoption, and workplace changes."
            },
            {
              "key": "Global Trends Impact",
              "value": "Growing geopolitical conflict and a global economic downturn are affecting the pharmaceutical sector."
            },
            {
              "key": "Geopolitical Changes",
              "value": "Two thirds of respondents said geopolitical changes are pushing their organisation to re-evaluate strategy."
            },
            {
              "key": "Global GDP Growth",
              "value": "Global GDP growth is forecast to slow from 6.2% in 2021 to 3.4% in 2022 and 2.9% in 2023."
            },
            {
              "key": "Chronic Diseases",
              "value": "By 2040, non-communicable diseases (NCDs) could account for 80% of deaths in low-income countries, up from 25% in 1990."
            },
            {
              "key": "Healthcare Budgets",
              "value": "Increasing demand for healthcare is putting pressure on healthcare budgets, leading to downward pressure on pricing."
            },
            {
              "key": "Inflationary Pressures",
              "value": "Inflationary pressures from energy prices and geopolitical tensions are expected to lead to higher nominal interest rates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 58,
          "title": "Risk Overview",
          "data": [
            {
              "key": "Risk Management Approach",
              "value": "Our approach to risk management is designed to encourage clear decision making on which risks we take and how we manage these risks."
            },
            {
              "key": "Risk Appetite",
              "value": "The Board defines the Group’s risk appetite, enabling it to judge the level of risk prepared to take to achieve overall objectives."
            },
            {
              "key": "Key Dimensions of Risk",
              "value": "Earnings and cash flow, return on investment, ethics and reputation."
            },
            {
              "key": "Principal Risks",
              "value": "Those risks likely to have a material impact on our business."
            },
            {
              "key": "Emerging Risks",
              "value": "New risks with potential to crystallize but unlikely to impact the business in the next year."
            },
            {
              "key": "Climate Risk Assessment",
              "value": "Part of our existing risk management; failure to meet environmental expectations is monitored but not a Principal Risk."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 60,
          "title": "Risk category and Principal Risks",
          "data": [
            {
              "key": "Risk",
              "value": "Failure or delay in the delivery of our pipeline or launch of new medicines"
            },
            {
              "key": "Risk Value",
              "value": "600"
            },
            {
              "key": "Context",
              "value": "The development of any pharmaceutical product candidate is a complex, risky and lengthy process involving significant resources. A project may fail at any stage of the process due to a number of factors, which could adversely affect our future business and results of operations."
            },
            {
              "key": "Management Actions",
              "value": "• Prioritise and accelerate our pipeline.\n• Strengthen pipeline through acquisitions, licensing and collaborations.\n• Focus on innovative science in main therapy areas.\n• Improve R&D productivity."
            },
            {
              "key": "Risk",
              "value": "Failure to meet regulatory or ethical requirements for medicine development or approval"
            },
            {
              "key": "Risk Value",
              "value": "60"
            },
            {
              "key": "Context",
              "value": "We are subject to laws and regulations that control our ability to market our pharmaceutical products. Delays in regulatory reviews and approvals could delay our ability to market our products and may adversely affect our revenue."
            },
            {
              "key": "Management Actions",
              "value": "• Quality management systems incorporating monitoring, training and assurance activities.\n• Collaborating with regulatory bodies and advocacy groups to monitor and respond to changes in the regulatory environment."
            },
            {
              "key": "Risk",
              "value": "Pricing, affordability, access and competitive pressures"
            },
            {
              "key": "Risk Value",
              "value": "600"
            },
            {
              "key": "Context",
              "value": "Continuing global pressures to reduce healthcare spending may lead to cost containment measures implemented by payers which could have an adverse effect on our business and financial results."
            },
            {
              "key": "Management Actions",
              "value": "• Focus on key products. Demonstrate value of medicines/health economics.\n• Implement innovative value-based agreements focused on patient outcomes.\n• Global footprint.\n• Diversified portfolio."
            },
            {
              "key": "Trend",
              "value": "Global economic and political conditions placing downward pressure on healthcare pricing and spending and therefore on revenue and innovation."
            },
            {
              "key": "Risk",
              "value": "Failure or delays in the quality or execution of the Group's commercial strategies"
            },
            {
              "key": "Risk Value",
              "value": "600"
            },
            {
              "key": "Context",
              "value": "A failure to execute our commercial strategies or achieve the level of sales anticipated for a medicine could materially impact our business results."
            },
            {
              "key": "Management Actions",
              "value": "• Focus on key products.\n• Substantial investment in sales and marketing activities.\n• Accelerate execution of plans and risk share through business development and strategic collaborations and alliances."
            },
            {
              "key": "Risk",
              "value": "Failure to maintain supply of compliant, quality medicines"
            },
            {
              "key": "Risk Value",
              "value": "NA"
            },
            {
              "key": "Context",
              "value": "Supply chain difficulties may result in product shortages which could lead to lost product sales and materially affect our reputation and revenues."
            },
            {
              "key": "Management Actions",
              "value": "• Establishment of new manufacturing facilities, creating capacity and technical capability.\n• Contingency plans, including dual sourcing, multiple suppliers and monitoring of stock levels.\n• Business continuity and resilience initiatives.\n• Quality management systems."
            },
            {
              "key": "Trend",
              "value": "Geopolitical tensions and high levels of demand for certain raw materials and components place increased pressure on supply chains and distribution networks."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 61,
          "title": "Risk category and Principal Risks",
          "data": [
            {
              "key": "Legal, regulatory and compliance risks",
              "value": "Safety and efficacy of marketed medicines is questioned. Safety concerns relating to our products may lead to recalls, seizures, interruption of supply and loss of product approvals, which could adversely affect patient access, our reputation and our revenues. Significant product liability claims could also arise, which may be costly, divert management attention, reduce demand for our products and damage our reputation."
            },
            {
              "key": "Adverse outcome of litigation and/or governmental investigations",
              "value": "Our business is subject to a wide range of laws, rules and regulations around the world. Actual or perceived failure to comply may result in AstraZeneca being investigated by government agencies and authorities and/or in civil legal proceedings. Government investigations, litigations, and other legal proceedings, regardless of outcome, could be costly, divert management attention, or damage our reputation and demand for our products."
            },
            {
              "key": "Unfavourable resolutions",
              "value": "Could subject us to enhanced damages, consumer fraud and/or other monetary or non-monetary penalties, including civil and criminal governmental actions, and could materially adversely affect our financial condition or results of operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 75,
          "title": "Financial risk management",
          "data": [
            {
              "key": "Financial risk management policies",
              "value": "Details the company's financial risk management strategies including insurance and treasury policies."
            },
            {
              "key": "Insurance",
              "value": "Describes how the company uses insurance to mitigate financial losses from core business risks."
            },
            {
              "key": "Treasury",
              "value": "Overview of the centralised treasury function managing liquidity, interest rate, foreign currency, and credit risks."
            },
            {
              "key": "Key accounting policies",
              "value": "Highlights areas requiring judgement in financial reporting and accounting estimates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 100,
          "title": "Audit Committee Report on Cyber Risk and Governance",
          "data": [
            {
              "key": "IT, cyber risk, and data security assessment",
              "value": "Routine assessment as part of AstraZeneca’s standard risk management framework."
            },
            {
              "key": "Key active risk 2022",
              "value": "IT, cyber risk and data security."
            },
            {
              "key": "Deep dive session focus in 2022",
              "value": "Cybersecurity programmes and challenges linked to the conflict in Ukraine."
            },
            {
              "key": "Integration of Alexion",
              "value": "Security of its digital systems reviewed."
            },
            {
              "key": "Risks from attrition of IT employees",
              "value": "Driven by increased demand for IT capabilities post COVID-19."
            },
            {
              "key": "Sustainability reporting oversight",
              "value": "Includes TCFD Statement and EU Taxonomy disclosures."
            },
            {
              "key": "Climate-related risks assessment",
              "value": "Routinely assessed as part of risk management."
            },
            {
              "key": "Compliance with sustainability regulations",
              "value": "Continuously monitored and updated by the Committee."
            },
            {
              "key": "Legal function quarterly reports",
              "value": "Tracking significant litigation matters and governmental investigations."
            },
            {
              "key": "Anti-bribery and anti-corruption efforts",
              "value": "Monitoring and review of effectiveness across the Group."
            },
            {
              "key": "Monitoring of modern slavery risks",
              "value": "Elimination efforts in AstraZeneca’s supply chain."
            },
            {
              "key": "GIA reports on internal audit",
              "value": "Quarterly reviews and effectiveness assessments conducted."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 135,
          "title": "Key audit matter Recognition, measurement and disclosure of tax liabilities",
          "data": [
            {
              "key": "Total net tax liability",
              "value": "$830m"
            },
            {
              "key": "Total net tax liability previous year",
              "value": "$768m"
            },
            {
              "key": "Estimated potential additional liabilities",
              "value": "$734m"
            },
            {
              "key": "Estimated potential additional liabilities previous year",
              "value": "$646m"
            },
            {
              "key": "Defined benefit obligations total",
              "value": "$8,108m"
            },
            {
              "key": "Defined benefit obligations previous year",
              "value": "$13,018m"
            },
            {
              "key": "Percentage of obligations in UK and Sweden",
              "value": "72%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 165,
          "title": "Impairment Charges and Recoverable Amounts",
          "data": [
            {
              "key": "recoverable_amount_method",
              "value": "Higher of fair value less costs to sell or value in use."
            },
            {
              "key": "discount_rate",
              "value": "7% post-tax weighted average cost of capital for AstraZeneca."
            },
            {
              "key": "impairment_charges_2022",
              "value": "$146 million for launched products."
            },
            {
              "key": "impairment_charges_2021",
              "value": "$603 million for launched products."
            },
            {
              "key": "impairment_charges_2020",
              "value": "$350 million for launched products."
            },
            {
              "key": "impairment_reversals_2022",
              "value": "$94 million, including $77 million for products in development."
            },
            {
              "key": "impairment_reversals_2021",
              "value": "None recorded."
            },
            {
              "key": "impairment_reversals_2020",
              "value": "$165 million."
            },
            {
              "key": "significant_assets_summary",
              "value": "Intangible assets from acquisitions (e.g. Alexion, Daiichi Sankyo) total $36.5B."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 178,
          "title": "Volatile Asset Management Description",
          "data": [
            {
              "key": "Risk Description",
              "value": "The Defined Benefit Obligation (DBO) is calculated using a discount rate volatility solvency ratio. Approximately 60% of the UK Pension Fund is invested in growth assets. Although these growth assets are expected to outperform AA-rated corporate bonds in the long term, they can lead to volatility and mismatching risk in the short term."
            },
            {
              "key": "Mitigation",
              "value": "In order to mitigate investment risk, the Trustee invests in a suitably diversified range of asset classes, return drivers and investment managers. The investment strategy will evolve to further improve the expected risk/ return profile as opportunities arise."
            },
            {
              "key": "Changes in bond yields",
              "value": "A decrease in corporate bond yields will increase the present value placed on the DBO for accounting purposes."
            },
            {
              "key": "Inflation risk",
              "value": "The majority of the DBO is indexed in line with price inflation, and higher inflation will lead to higher liabilities."
            },
            {
              "key": "Life expectancy",
              "value": "The majority of the UK Pension Fund’s obligations are to provide benefits for the life of the member, so increases in life expectancy will result in an increase in the liabilities."
            },
            {
              "key": "Other risks",
              "value": "There are a number of other risks of administering the UK Pension Fund which the Trustee manages with Group input."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 4,
          "title": "What science can do",
          "data": [
            {
              "key": "Description",
              "value": "From the beginning, science has been at the front and centre of everything we do, taking us to places we never thought possible."
            },
            {
              "key": "Impact",
              "value": "Science can bring people together to achieve the impossible, impel us to take risks, share and collaborate, harness data, technology and AI to accelerate change."
            },
            {
              "key": "Call to Action",
              "value": "See the full story at www.astrazeneca.com/partnering"
            },
            {
              "key": "Change",
              "value": "Change how we see the world, change how we live our lives, and make us pioneers."
            },
            {
              "key": "Call to Action 2",
              "value": "See the full story at www.astrazeneca.com/what-science-can-do."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 101,
          "title": "External Audit and Engagement with Employees",
          "data": [
            {
              "key": "external_auditor",
              "value": "PwC"
            },
            {
              "key": "audit_review_process",
              "value": "Committee oversaw the conduct, performance, and quality of the external audit"
            },
            {
              "key": "audit_fees_review",
              "value": "Review of audit and non-audit fees for the external auditor"
            },
            {
              "key": "employee_engagement",
              "value": "Committee interacts with employees and stakeholders for insights"
            },
            {
              "key": "regulatory_environment",
              "value": "Committee keeps abreast of developments in reporting and regulatory environment"
            },
            {
              "key": "performance_evaluation",
              "value": "Annual evaluation of Committee performance conducted"
            },
            {
              "key": "key_issues_identified",
              "value": "Management’s correspondence with Council related to various accounting issues"
            },
            {
              "key": "good_practice_disclosure",
              "value": "Certain disclosures were highlighted as examples of good practice by FRC"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 133,
          "title": "Independent auditors’ report to the members of AstraZeneca PLC",
          "data": [
            {
              "key": "Opinion",
              "value": "AstraZeneca PLC’s Group financial statements and Company financial statements give a true and fair view of the state of the Group’s and of the Company’s affairs as at 31 December 2022."
            },
            {
              "key": "Overall Group materiality",
              "value": "$400m (2021: $250m) based on 5% of profit before tax."
            },
            {
              "key": "Audit opinion",
              "value": "The Group financial statements have been properly prepared in accordance with international financial reporting standards as adopted by the European Union and as issued by the IASB."
            },
            {
              "key": "Overall Company materiality",
              "value": "$100m (2021: $100m) based on approximately 0.5% of net assets."
            },
            {
              "key": "Performance materiality",
              "value": "$300m (2021: $187.5m) (Group) and $75m (2021: $75m) (Company)."
            },
            {
              "key": "Key audit matters",
              "value": "Recognition and measurement of accruals for Managed Care, Medicaid and Medicare Part D rebates on US Product Sales."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 136,
          "title": "Distributable reserves in the Company",
          "data": [
            {
              "key": "Distributable reserves at 31 December 2022",
              "value": "$7,458m (2021: $11,563m)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 137,
          "title": "Materiality in Audit Report",
          "data": [
            {
              "key": "Overall materiality Group",
              "value": "$400m (2021: $250m)"
            },
            {
              "key": "Overall materiality Company",
              "value": "$100m (2021: $100m)"
            },
            {
              "key": "Materiality determination basis",
              "value": "5% of profit before tax after certain adjustments"
            },
            {
              "key": "Performance materiality",
              "value": "75% of overall materiality, amounting to $300m for Group and $75m for Company"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 138,
          "title": "Independent auditors’ report to the members of AstraZeneca PLC",
          "data": [
            {
              "key": "Going concern assessment",
              "value": "The directors have assessed the Group’s and the Company’s ability to continue to adopt the going concern basis and found no material uncertainties."
            },
            {
              "key": "UK Companies Act compliance",
              "value": "The disclosures required by the UK Companies Act 2006 have been included in the Strategic Report and Directors’ Report."
            },
            {
              "key": "Directors’ Remuneration Report",
              "value": "The part of the Directors’ Remuneration Report to be audited has been properly prepared in accordance with the Companies Act 2006."
            },
            {
              "key": "Corporate governance statement",
              "value": "Each of the elements is materially consistent with the financial statements."
            },
            {
              "key": "Directors' risk assessment",
              "value": "The directors have carried out a robust assessment of the emerging and principal risks."
            },
            {
              "key": "Audit nature and scope",
              "value": "The review of the directors' statement regarding the longer-term viability of the Group and Company was less in scope than an audit."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 145,
          "title": "Revenue Recognition and Collaboration Revenue",
          "data": [
            {
              "key": "Revenue Recognition Basis",
              "value": "Actual experience over the preceding 12 months combined with market-related information."
            },
            {
              "key": "New Products Revenue Recognition",
              "value": "Rates based on experience with similar products."
            },
            {
              "key": "Generic Competition Handling",
              "value": "Revenues are only recognised when the right of return expires."
            },
            {
              "key": "Contractual Provisions for Revenue Recognition",
              "value": "Revenue is recognised over time for contracts with certain conditions."
            },
            {
              "key": "Collaboration Revenue Definition",
              "value": "Income from arrangements where the Group has licensed or in-licensed rights."
            },
            {
              "key": "Recognition of Upfront Fees and Royalties",
              "value": "Recognised at point control is transferred or as milestones are achieved."
            },
            {
              "key": "Timing of Clinical Milestones",
              "value": "Dependent on decisions of third parties."
            },
            {
              "key": "Performance Obligations",
              "value": "Determined based on standalone selling prices."
            },
            {
              "key": "Intellectual Property Licences",
              "value": "Agreement terms dictate revenue recognition timing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 150,
          "title": "Guidance on Accounting Policies and Provisions",
          "data": [
            {
              "key": "Foreign Currency Translation Policy",
              "value": "Non-monetary items from foreign currency transactions are not retranslated."
            },
            {
              "key": "Provisions Recognition Criteria",
              "value": "Provisions are recognized when a legal or constructive obligation exists and it is probable an outflow of resources will occur."
            },
            {
              "key": "Litigation and Environmental Liabilities",
              "value": "AstraZeneca is involved in legal disputes affecting financial provisions."
            },
            {
              "key": "Restructuring Costs",
              "value": "Recognized when a detailed formal plan is in place and announced."
            },
            {
              "key": "Impairment Testing Policy",
              "value": "Assets are reviewed for impairment annually based on specific criteria."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 156,
          "title": "Taxation Factors Affecting Future Tax Charges",
          "data": [
            {
              "key": "Profit/(loss) before tax",
              "value": "2501; -265; 3916"
            },
            {
              "key": "Notional taxation charge at UK corporation tax rate of 19%",
              "value": "475; -60; 744"
            },
            {
              "key": "Differences in effective overseas tax rates",
              "value": "-59; 1; -49"
            },
            {
              "key": "Deferred tax (credit)/charge relating to change in tax rates",
              "value": "-108; 54; 138"
            },
            {
              "key": "Unrecognised deferred tax asset",
              "value": "68; 32; 3"
            },
            {
              "key": "Items not deductible for tax purposes",
              "value": "90; 208; 71"
            },
            {
              "key": "Items not chargeable for tax purposes",
              "value": "0; -163; -4"
            },
            {
              "key": "Intellectual Property incentive regimes",
              "value": "-265; 0; -85"
            },
            {
              "key": "Other items",
              "value": "-941; -299; -65"
            },
            {
              "key": "Adjustments in respect of prior periods",
              "value": "-52; -163; -31"
            },
            {
              "key": "Total tax (credit)/charge for the period",
              "value": "-792; -380; 772"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 183,
          "title": "Share Capital Movement",
          "data": [
            {
              "key": "At 1 January 2022",
              "value": "1549400665"
            },
            {
              "key": "At 1 January 2021",
              "value": "1312668724"
            },
            {
              "key": "At 1 January 2020",
              "value": "1312137976"
            },
            {
              "key": "Issue of share capital (business combinations) 2022",
              "value": "0"
            },
            {
              "key": "Issue of share capital (business combinations) 2021",
              "value": "236321411"
            },
            {
              "key": "Issue of share capital (business combinations) 2020",
              "value": "0"
            },
            {
              "key": "Issue of shares (share schemes) 2022",
              "value": "399365"
            },
            {
              "key": "Issue of shares (share schemes) 2021",
              "value": "410530"
            },
            {
              "key": "Issue of shares (share schemes) 2020",
              "value": "530748"
            },
            {
              "key": "At 31 December 2022",
              "value": "1549800030"
            },
            {
              "key": "At 31 December 2021",
              "value": "1549400665"
            },
            {
              "key": "At 31 December 2020",
              "value": "1312668724"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 183,
          "title": "Dividend Distribution Summary",
          "data": [
            {
              "key": "Second interim (March 2022) per share",
              "value": "$1.97"
            },
            {
              "key": "Second interim (March 2021) per share",
              "value": "$1.90"
            },
            {
              "key": "Second interim (March 2020) per share",
              "value": "$1.90"
            },
            {
              "key": "Second interim (March 2022) amount",
              "value": "3046"
            },
            {
              "key": "Second interim (March 2021) amount",
              "value": "2490"
            },
            {
              "key": "Second interim (March 2020) amount",
              "value": "2489"
            },
            {
              "key": "First interim (September 2022) per share",
              "value": "$0.93"
            },
            {
              "key": "First interim (September 2021) per share",
              "value": "$0.90"
            },
            {
              "key": "First interim (September 2020) per share",
              "value": "$0.90"
            },
            {
              "key": "First interim (September 2022) amount",
              "value": "1440"
            },
            {
              "key": "First interim (September 2021) amount",
              "value": "1392"
            },
            {
              "key": "First interim (September 2020) amount",
              "value": "1180"
            },
            {
              "key": "Total per share 2022",
              "value": "$2.90"
            },
            {
              "key": "Total per share 2021",
              "value": "$2.80"
            },
            {
              "key": "Total per share 2020",
              "value": "$2.80"
            },
            {
              "key": "Total amount 2022",
              "value": "4486"
            },
            {
              "key": "Total amount 2021",
              "value": "3882"
            },
            {
              "key": "Total amount 2020",
              "value": "3669"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 183,
          "title": "Dividends charged to equity",
          "data": [
            {
              "key": "Exchange losses on payment of dividend period 1",
              "value": "5"
            },
            {
              "key": "Exchange losses on payment of dividend period 2",
              "value": "3"
            },
            {
              "key": "Exchange losses on payment of dividend period 3",
              "value": "4"
            },
            {
              "key": "Hedge contracts relating to payment of dividends period 1",
              "value": "-127"
            },
            {
              "key": "Hedge contracts relating to payment of dividends period 2",
              "value": "-29"
            },
            {
              "key": "Hedge contracts relating to payment of dividends period 3",
              "value": "-101"
            },
            {
              "key": "Dividends paid period 1",
              "value": "4364"
            },
            {
              "key": "Dividends paid period 2",
              "value": "3856"
            },
            {
              "key": "Dividends paid period 3",
              "value": "3572"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 215,
          "title": "Shareholder Information",
          "data": [
            {
              "key": "Related Party Transactions",
              "value": "During the period 1 January 2023 to 31 January 2023, there were no transactions, loans, or proposed transactions between the Company and any related parties which were material to either the Company or the related party."
            },
            {
              "key": "Annual General Meeting (AGM)",
              "value": "The 2023 AGM will be held on 27 April 2023."
            },
            {
              "key": "Conflicts of Interest",
              "value": "The Articles enable the Directors to authorise any situation in which a Director has an interest that conflicts with the Company's interests."
            },
            {
              "key": "Dividend Schedule",
              "value": "Key dividend-related dates for 2023: Ex-dividend date 10 August 2023, Record date 11 August 2023, Payment date 11 September 2023."
            },
            {
              "key": "Third Quarter Results Date",
              "value": "The announcement of third quarter results is scheduled for 9 November 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 222,
          "title": "Global Market Coverage by Region",
          "data": [
            {
              "key": "Europe",
              "value": "Includes 35 countries, primarily EU members and nearby states."
            },
            {
              "key": "Established RoW",
              "value": "Comprises 4 developed nations (Australia, Canada, Japan, and New Zealand)."
            },
            {
              "key": "Emerging Markets",
              "value": "Largest section with 70 countries across Asia, Africa, Latin America, and the Middle East."
            },
            {
              "key": "Countries with specific conditions",
              "value": "Countries marked with an asterisk (*) indicate markets with specific conditions or limitations."
            },
            {
              "key": "Overall Summary",
              "value": "Table presents a comprehensive geographical breakdown of market coverage across three main regions."
            },
            {
              "key": "Exclusions",
              "value": "Excludes countries with revenue in 2022 of less than $1 million."
            },
            {
              "key": "North America",
              "value": "Means US."
            },
            {
              "key": "Emerging Markets (excl. China)",
              "value": "Other Emerging Markets means all Emerging Markets except China."
            },
            {
              "key": "Other Africa",
              "value": "Includes Ethiopia, Mozambique, Namibia, Eswatini, Tanzania, Uganda, Zambia, Zimbabwe."
            },
            {
              "key": "Asia Area",
              "value": "Comprises certain key countries in Asia."
            },
            {
              "key": "US Equivalents summary",
              "value": "Detailed comparison between UK and US financial terms."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 222,
          "title": "UK-US Financial Terms Comparison",
          "data": [
            {
              "key": "Accruals",
              "value": "Accrued expenses"
            },
            {
              "key": "Called-up share capital",
              "value": "Issued share capital"
            },
            {
              "key": "Earnings",
              "value": "Net income"
            },
            {
              "key": "Employee share schemes",
              "value": "Employee stock benefit plans"
            },
            {
              "key": "Fixed asset investments",
              "value": "Non-current investments"
            },
            {
              "key": "Freehold",
              "value": "Ownership with absolute rights in perpetuity"
            },
            {
              "key": "Loans",
              "value": "Long-term debt"
            },
            {
              "key": "Prepayments",
              "value": "Prepaid expenses"
            },
            {
              "key": "Profit",
              "value": "Income"
            },
            {
              "key": "Share premium account",
              "value": "Additional paid-in capital or paid-in surplus (not distributable)"
            },
            {
              "key": "Short-term investments",
              "value": "Redeemable securities and short-term deposits"
            },
            {
              "key": "Trade Payables",
              "value": "Accounts payable"
            },
            {
              "key": "Trade Receivables",
              "value": "Accounts receivable"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 225,
          "title": "Glossary of Terms and Acronyms",
          "data": [
            {
              "key": "PFS",
              "value": "progression-free survival. The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease without it getting worse."
            },
            {
              "key": "PhRMA",
              "value": "Pharmaceutical Research and Manufacturers of America."
            },
            {
              "key": "Phase I",
              "value": "the phase of clinical research where a new drug or treatment is tested in small groups of people (20 to 80) to check that the drug can achieve appropriate concentrations in the body, determine a safe dosage range and identify side effects."
            },
            {
              "key": "Phase II",
              "value": "the phase of clinical research which includes the controlled clinical activities conducted to evaluate the effectiveness of the drug in patients with the disease under study."
            },
            {
              "key": "Phase III",
              "value": "the phase of clinical research which is performed to gather additional information about effectiveness and safety of the drug, often in a comparative setting."
            },
            {
              "key": "Pieris Pharmaceuticals",
              "value": "Pieris Pharmaceuticals, Inc."
            },
            {
              "key": "pMDI",
              "value": "pressurised metered-dose inhaler."
            },
            {
              "key": "pound sterling",
              "value": "£, GBP or pence references to the currency of the UK."
            },
            {
              "key": "primary care",
              "value": "general healthcare provided by physicians who ordinarily have first contact with patients."
            },
            {
              "key": "PROTACs",
              "value": "a proteolysis targeting chimera."
            },
            {
              "key": "PTE",
              "value": "Patent Term Extension."
            },
            {
              "key": "Pulse survey",
              "value": "an AstraZeneca employee opinion survey."
            },
            {
              "key": "PwC",
              "value": "PricewaterhouseCoopers LLP."
            },
            {
              "key": "R&D",
              "value": "research and development."
            },
            {
              "key": "R&I",
              "value": "Respiratory & Immunology."
            },
            {
              "key": "Rare disease",
              "value": "the EU defines a disease or condition as rare if it affects fewer than 1 in 2,000 people."
            },
            {
              "key": "Redeemable Preference Share",
              "value": "a redeemable preference share of £1 each."
            },
            {
              "key": "RICs",
              "value": "radio-immuno conjugates."
            },
            {
              "key": "RNA",
              "value": "ribonucleic acid."
            },
            {
              "key": "Roche",
              "value": "F. Hoffmann-La Roche AG."
            },
            {
              "key": "ROW",
              "value": "rest of world."
            },
            {
              "key": "RSV",
              "value": "respiratory syncytial virus."
            },
            {
              "key": "SABA",
              "value": "short-acting beta2-agonist."
            },
            {
              "key": "Sanofi",
              "value": "Sanofi S.A./Sanofi Pasteur, Inc."
            },
            {
              "key": "Sarbanes-Oxley Act",
              "value": "the US Sarbanes-Oxley Act of 2002."
            },
            {
              "key": "Scope 1-3",
              "value": "Combustion of fuel and operation of facilities."
            },
            {
              "key": "SEC",
              "value": "the US Securities and Exchange Commission."
            },
            {
              "key": "SEK",
              "value": "Swedish krona."
            },
            {
              "key": "SET",
              "value": "the Senior Executive Team."
            },
            {
              "key": "SG&A costs",
              "value": "selling, general and administrative costs."
            },
            {
              "key": "siRNA",
              "value": "small interfering RNA."
            },
            {
              "key": "Sobi",
              "value": "Swedish Orphan Biovitrum AB."
            },
            {
              "key": "SPC",
              "value": "supplementary protection certificate."
            },
            {
              "key": "specialty care",
              "value": "specific healthcare provided by medical specialists."
            },
            {
              "key": "Spirogen",
              "value": "Spirogen Sàrl."
            },
            {
              "key": "SoC",
              "value": "standard of care."
            },
            {
              "key": "SVP",
              "value": "Senior Vice-President."
            },
            {
              "key": "Takeda",
              "value": "Takeda Pharmaceutical Company Limited."
            },
            {
              "key": "TCFD",
              "value": "Task Force on Climate-related Financial Disclosures."
            },
            {
              "key": "TeneoTwo",
              "value": "TeneoTwo, Inc."
            },
            {
              "key": "TerSera",
              "value": "TerSera Therapeutics LLC."
            },
            {
              "key": "Total Revenue",
              "value": "the sum of Product Sales and Collaboration Revenue."
            },
            {
              "key": "TROP2",
              "value": "trophoblast cell-surface antigen 2."
            },
            {
              "key": "TSR",
              "value": "total shareholder return."
            },
            {
              "key": "UK",
              "value": "United Kingdom of Great Britain and Northern Ireland."
            },
            {
              "key": "UK Corporate Governance Code",
              "value": "the UK Corporate Governance Code."
            },
            {
              "key": "US",
              "value": "United States of America."
            },
            {
              "key": "US dollar",
              "value": "US$, USD or $ references to the currency of the US."
            },
            {
              "key": "VBP",
              "value": "value-based procurement."
            },
            {
              "key": "Viela Bio",
              "value": "Viela Bio, Inc."
            },
            {
              "key": "WHO",
              "value": "World Health Organization."
            },
            {
              "key": "ZS Pharma",
              "value": "ZS Pharma, Inc."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 226,
          "title": "Cautionary statement regarding forward-looking statements",
          "data": [
            {
              "key": "Purpose of the Report",
              "value": "To provide information to the members of the Company."
            },
            {
              "key": "Disclaimer",
              "value": "The Company and its Directors, employees, agents and advisers do not accept any responsibility to any other person."
            },
            {
              "key": "Forward-looking statements",
              "value": "Contains statements about expected revenues, margins, earnings per share, or other measures."
            },
            {
              "key": "Risks that could cause actual results to differ",
              "value": "Include failure or delay in delivery of pipeline or launch of new medicines, failure to meet regulatory requirements, failure to maintain supply of compliant medicines, impact of competitive pressures, etc."
            },
            {
              "key": "Additional information source",
              "value": "Risk Supplement available on AstraZeneca's website."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 59,
          "title": "Viability statement",
          "data": [
            {
              "key": "Rule",
              "value": "Provision 31 of the 2018 UK Corporate Governance Code"
            },
            {
              "key": "Review Period",
              "value": "Three-year period to 31 December 2025"
            },
            {
              "key": "Long-range Projection",
              "value": "10-year long-range projection"
            },
            {
              "key": "Assessment",
              "value": "Board assesses Company’s prospects, notes strong long-term prospects"
            },
            {
              "key": "Business Plan",
              "value": "Three-year bottom-up detailed business plan"
            },
            {
              "key": "Risks Identified",
              "value": "Pricing, affordability, access, competitive pressures, supply interruptions"
            },
            {
              "key": "Scenario 1",
              "value": "Government action on pricing, increased competition leading to lower growth"
            },
            {
              "key": "Scenario 2",
              "value": "Reputational damage leading to 10% revenue reduction in key market"
            },
            {
              "key": "Scenario 3",
              "value": "No launches of new products"
            },
            {
              "key": "Scenario 4",
              "value": "Major equipment failure causing loss of formulation capability"
            },
            {
              "key": "Scenario 5",
              "value": "Legal, regulatory non-compliance resulting in $500 million payment in 2024"
            },
            {
              "key": "Scenario 6",
              "value": "Inflation impacts increasing cost base by $300 million in 2023"
            },
            {
              "key": "Conclusion",
              "value": "Directors have reasonable expectation to meet liabilities for three years."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 103,
          "title": "Significant financial reporting issues",
          "data": [
            {
              "key": "Litigation and contingent liabilities",
              "value": "AstraZeneca is involved in various legal proceedings typical to its business including product liability, commercial disputes, infringement of IP rights, anti-trust law."
            },
            {
              "key": "Committee's conclusion",
              "value": "The Committee was satisfied that the Group was effectively managing its litigation risks."
            },
            {
              "key": "Tax charges and liabilities",
              "value": "AstraZeneca's Approach to Taxation covers governance, risk management, and compliance."
            },
            {
              "key": "Segmental reporting assessment",
              "value": "Management determined the Group continues to operate as a single segment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 159,
          "title": "Segment Information",
          "data": [
            {
              "key": "Judgement Conclusion",
              "value": "The Group has reviewed its assessment of reportable segments and concluded that it continues to have one reportable segment."
            },
            {
              "key": "Chief Operating Decision Maker",
              "value": "The SET, chaired by the CEO, is identified as AstraZeneca's Chief Operating Decision Making body."
            },
            {
              "key": "Financial Information Reviewed",
              "value": "The SET reviews financial information on an integrated basis for the Group as a whole, primarily via the Group’s IFRS Financial Statements."
            },
            {
              "key": "Resource Allocation",
              "value": "Resources are allocated on a Group-wide basis according to need."
            },
            {
              "key": "Total Revenue Summary",
              "value": "The total revenue increased from $26,617M in 2020 to $37,417M in 2021, representing a 40.6% growth."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 175,
          "title": "Pension Funding and Oversight",
          "data": [
            {
              "key": "Defined Benefit Plans",
              "value": "Cover large obligations, inflation linked, various plans in different countries."
            },
            {
              "key": "Group Policy",
              "value": "Uses defined contribution arrangements unless local laws dictate otherwise."
            },
            {
              "key": "Major Plans",
              "value": "Legacy DB plans closed since 2000, except certain plans in Sweden."
            },
            {
              "key": "Pension Fund Members",
              "value": "452 active members remaining in the UK Pension Fund."
            },
            {
              "key": "Closure of US DB Plans",
              "value": "Closed to new accrual and salary link since December 31, 2017."
            },
            {
              "key": "Funding Level",
              "value": "Improved overall funding; three plans had surplus positions by end of 2022."
            },
            {
              "key": "Trustee Role",
              "value": "Independently governs the UK Pension Fund, ensuring fiduciary responsibilities are met."
            },
            {
              "key": "Regulatory Changes",
              "value": "UK Pension Scheme Act 2021 imposes additional legal obligations."
            },
            {
              "key": "Funding Requirements",
              "value": "US legislation mandates prudent funding of DB pension schemes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 195,
          "title": "Legal Proceedings and IP Claims",
          "data": [
            {
              "key": "Marketing Practises",
              "value": "Infringement of IP rights and validity of patents."
            },
            {
              "key": "Uncertainties in Legal Proceedings",
              "value": "Substantial uncertainties exist regarding potential losses."
            },
            {
              "key": "Current Litigation Status",
              "value": "AstraZeneca is involved in multiple lawsuits regarding patent infringements."
            },
            {
              "key": "Proceedings Against AstraZeneca",
              "value": "Multiple parties have filed lawsuits against AstraZeneca related to their products."
            },
            {
              "key": "Key Cases",
              "value": "Patent infringement cases by Seagen, Bristol-Myers Squibb, and others are highlighted."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 196,
          "title": "Legal proceedings involving AstraZeneca",
          "data": [
            {
              "key": "Legal Proceedings Summary",
              "value": "AstraZeneca is involved in multiple patent infringement lawsuits and regulatory proceedings in the US and internationally affecting various products."
            },
            {
              "key": "Key Legal Actions",
              "value": "1. Roxadustat and Daliresp patent proceedings concluded with settlements in 2022."
            },
            {
              "key": "Recent Patents and Litigation",
              "value": "AstraZeneca is actively engaged in patent-related lawsuits, with trials scheduled for some products, including Calquence and Lokelma in March 2025."
            },
            {
              "key": "Concluded Lawsuits",
              "value": "Multiple patent litigations concerning Tagrisso and Ultomiris have concluded with settlements."
            },
            {
              "key": "Overview of Contingent Liabilities",
              "value": "AstraZeneca faces product liability claims related to Farxiga and Xigduo XR, with trials pending."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 197,
          "title": "Legal proceedings against AstraZeneca",
          "data": [
            {
              "key": "Type of Litigation",
              "value": "Lawsuits regarding injuries from proton pump inhibitors"
            },
            {
              "key": "Status",
              "value": "MDL proceedings ongoing"
            },
            {
              "key": "Key Dates",
              "value": "Bellwether trial scheduled for June 2023, subsequent trials planned for July and September 2023"
            },
            {
              "key": "Claims",
              "value": "Kidney injuries, heart failure, gastric cancer"
            },
            {
              "key": "Jurisdiction",
              "value": "US and Canada"
            },
            {
              "key": "Additional Notes",
              "value": "Various lawsuits in state courts, some dismissed."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 198,
          "title": "Legal proceedings involving AstraZeneca and related companies",
          "data": [
            {
              "key": "Case 1: PARP Inhibitor Royalty Dispute",
              "value": "In October 2012, Tesaro, Inc. entered into royalty-bearing patent license agreements with AstraZeneca related to GSK’s product niraparib. AstraZeneca filed a lawsuit against GSK for unpaid royalties."
            },
            {
              "key": "Case 2: Portola Shareholder Litigation",
              "value": "Alexion, in connection with its acquisition of Portola, inherited litigation with securities class action lawsuits alleging misleading statements regarding Andexxa. A settlement in principle was reached in June 2022."
            },
            {
              "key": "Case 3: Seroquel XR Antitrust Litigation",
              "value": "AstraZeneca faced antitrust lawsuits relating to settlements with generic manufacturers. Some claims were dismissed while others allowed to proceed."
            },
            {
              "key": "Case 4: Syntimmune Lawsuit",
              "value": "A lawsuit was filed against Alexion relating to breaches of contractual obligations from the 2018 merger agreement due to failure to meet milestones."
            },
            {
              "key": "Ongoing Proceedings: Brazilian Tax Assessment Matter",
              "value": "Brazilian authorities issued a tax assessment to Alexion subsidiaries focusing on the importation of Soliris. An appeal of the initial decision is pending."
            },
            {
              "key": "Ongoing Proceedings: COVID-19 Vaccine Inquiries in Brazil",
              "value": "A lawsuit filed against AstraZeneca and others relating to vaccine supply dismissed by a court; an appeal is pending."
            },
            {
              "key": "Concluded Proceeding: Array BioPharma",
              "value": "AstraZeneca resolved a breach of contract dispute with Array BioPharma in May 2022."
            },
            {
              "key": "Concluded Proceeding: Turkish Ministry of Health Investigation",
              "value": "An investigation initiated in July 2020 regarding payments to healthcare providers. It referred cases to prosecutors after reporting findings."
            },
            {
              "key": "Concluded Proceeding: 196 Texas Qui Tam US Proceedings",
              "value": "A civil lawsuit against AstraZeneca in Texas alleging unlawful marketing practices."
            },
            {
              "key": "Concluded Proceeding: Vermont US Attorney Investigation",
              "value": "A Civil Investigative Demand seeking documents related to relationships with health-record vendors."
            },
            {
              "key": "Concluded Proceeding: Brazilian Operations Investigation",
              "value": "Investigation concluded with no legal claims after authorities seized records in May 2017. Recommendations for discontinuance were approved in November 2022."
            },
            {
              "key": "Concluded Proceeding: COVID-19 Supply Inquiry in Argentina",
              "value": "A local investigation was closed after a request for dismissal was granted by the court."
            },
            {
              "key": "Concluded Proceeding: Canadian Pricing Matter",
              "value": "Alexion's excessive pricing case resolved in June 2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 199,
          "title": "US Proceedings Against AstraZeneca",
          "data": [
            {
              "key": "Litigation type",
              "value": "340B Drug Pricing Program litigation"
            },
            {
              "key": "Details",
              "value": "AstraZeneca involved in several lawsuits against US government agencies regarding 340B interpretations."
            },
            {
              "key": "Current status",
              "value": "Two cases stayed, one dismissed; some decisions ruled in favor of AstraZeneca."
            },
            {
              "key": "Class-action complaint",
              "value": "Filed by Mosaic Health alleging antitrust violations regarding 340B access."
            },
            {
              "key": "Government inquiries",
              "value": "Ongoing inquiries into drug marketing and pricing practices."
            },
            {
              "key": "Net tax liability",
              "value": "$830m relating to uncertain tax treatments."
            },
            {
              "key": "Transfer pricing liability",
              "value": "$260m for uncertain tax treatments from worldwide exposure."
            },
            {
              "key": "Other uncertain treatments",
              "value": "$570m relating to various uncertain tax treatments."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 209,
          "title": "Litigation and Legal Disputes",
          "data": [
            {
              "key": "Overview",
              "value": "AstraZeneca Group is involved in legal disputes, the settlement of which may involve cost to the Company."
            },
            {
              "key": "Provision for Costs",
              "value": "Provision is made where an adverse outcome is probable and associated costs, including related legal costs, can be estimated reliably."
            },
            {
              "key": "Disclosures",
              "value": "In other cases, appropriate disclosures are included."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 212,
          "title": "Vermont US Attorney Investigation",
          "data": [
            {
              "key": "Investigation Detail",
              "value": "AstraZeneca received a Civil Investigative Demand from the US Attorney’s Office in Vermont and the Department of Justice, Civil Division."
            },
            {
              "key": "Context",
              "value": "Seeking documents and information relating to AstraZeneca’s relationships with electronic health-record vendors."
            },
            {
              "key": "Cooperation Status",
              "value": "AstraZeneca is cooperating with this enquiry."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 212,
          "title": "AZD1222 Securities Litigation",
          "data": [
            {
              "key": "Lawsuit Filed",
              "value": "Putative securities class action lawsuits were filed in the US District Court for the Southern District of New York."
            },
            {
              "key": "Allegations",
              "value": "Defendants made materially false and misleading statements regarding the development of AZD1222."
            },
            {
              "key": "Court Decision",
              "value": "The District Court granted AstraZeneca’s motion to dismiss with prejudice, disallowing further amendments."
            },
            {
              "key": "Appeal Status",
              "value": "Plaintiffs have appealed the decision."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": true,
      "elements": [
        {
          "type": "strategic_restructuring",
          "page": 39,
          "title": "Development pipeline overview",
          "data": [
            {
              "key": "Regulatory events",
              "value": "72"
            },
            {
              "key": "Pipeline progression events",
              "value": "29"
            },
            {
              "key": "Projects discontinued",
              "value": "27"
            },
            {
              "key": "Projects in clinical phase",
              "value": "155"
            },
            {
              "key": "NME projects in pivotal trials or under regulatory review",
              "value": "15"
            },
            {
              "key": "Therapeutic areas",
              "value": "Oncology, Cardiovascular & Renal Metabolism, Immunology, Rare Disease, Other"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 67,
          "title": "Excluded from Core results",
          "data": [
            {
              "key": "Restructuring costs",
              "value": "Restructuring costs totalling $717 million (2021: $1,283 million) mainly comprise those incurred on the PAAGR (Post Alexion Acquisition Group Review) of $675 million (2021: $1,030 million)."
            },
            {
              "key": "Intangible amortisation and impairments",
              "value": "Amortisation totalling $4,080 million (2021: $3,080 million) relating to intangible assets, except those related to IT. This includes amortisation on intangible assets recognised at fair value on the acquisition of Alexion. Further information on our intangible assets is contained in Note 10 to the Financial Statements, from page 161. Intangible impairment charges were $318 million (2021: $2,067 million), excluding those related to IT. The 2021 charges included the impact of an impairment charge of $1,172 million recognised on an intangible asset related to the acquisition of Ardea, following the decision to discontinue the development of verinurad and $469 million recognised on Bydureon."
            },
            {
              "key": "Acquisition of Alexion",
              "value": "Costs associated with our acquisition of Alexion in July 2021 amounting to $3,571 million (2021: $2,441 million), primarily relating to the impact from the unwind of the fair value adjustment to Alexion inventories at the date of acquisition. The impact of the fair value uplift unwind on Cost of Sales is $3,484 million (2021: $2,198 million) in 2022."
            },
            {
              "key": "Other",
              "value": "Other adjustments amounted to $1,261 million (2021: $397 million). Other adjustments to Reported SG&A expenses were $985 million, primarily including a charge to net legal provisions of $775 million in relation to Chugai Pharmaceutical Co. Ltd and $82 million (2021: a credit of $14 million) net fair value adjustments relating to contingent consideration balances."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "strategic_restructuring",
          "page": 91,
          "title": "Principal Decisions and Corporate Governance 2022",
          "data": [
            {
              "key": "Appointment of Chair-designate",
              "value": "Michel Demaré appointed as Chair-designate in July 2022, succeeding Mr Johansson."
            },
            {
              "key": "Acquisitions",
              "value": "Approval of acquisitions to strengthen the pipeline, including TeneoTwo, Inc., Neogene Therapeutics, Inc., and a proposed acquisition of CinCor Pharma, Inc."
            },
            {
              "key": "API Facility Investment",
              "value": "Approved investment for the next-generation API manufacturing facility in Dublin."
            },
            {
              "key": "Climate Strategy Endorsement",
              "value": "Board endorsed the science-based climate strategy and steps to achieve commitments."
            },
            {
              "key": "Divestment of West Chester Site",
              "value": "Approval of sale of the West Chester site to National Resilience, Inc."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 131,
          "title": "Auditors’ Report",
          "data": [
            {
              "key": "Audit Opinion",
              "value": "The auditors have provided an unqualified opinion on the financial statements."
            },
            {
              "key": "Audit Firm",
              "value": "Deloitte LLP"
            },
            {
              "key": "Date of Report",
              "value": "March 15, 2023"
            },
            {
              "key": "Key Audit Matters",
              "value": "Revenue recognition and asset impairments are noted as significant audit areas."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 173,
          "title": "Contingent Consideration Analysis",
          "data": [
            {
              "key": "Contingent consideration",
              "value": "1 January"
            },
            {
              "key": "2022",
              "value": "2,865"
            },
            {
              "key": "2021",
              "value": "3,323"
            },
            {
              "key": "2020",
              "value": "4,139"
            },
            {
              "key": "Settlements",
              "value": "(772)"
            },
            {
              "key": "2021",
              "value": "(643)"
            },
            {
              "key": "2020",
              "value": "(822)"
            },
            {
              "key": "Disposals",
              "value": "(121)"
            },
            {
              "key": "2021",
              "value": "-"
            },
            {
              "key": "2020",
              "value": ""
            },
            {
              "key": "Revaluations",
              "value": "82"
            },
            {
              "key": "2021",
              "value": "14"
            },
            {
              "key": "2020",
              "value": "(272)"
            },
            {
              "key": "Reclassification to Other payables",
              "value": "-"
            },
            {
              "key": "2021",
              "value": "(65)"
            },
            {
              "key": "2020",
              "value": ""
            },
            {
              "key": "Discount unwind (Note 3)",
              "value": "168"
            },
            {
              "key": "2021",
              "value": "226"
            },
            {
              "key": "2020",
              "value": "278"
            },
            {
              "key": "31 December",
              "value": "2,222"
            },
            {
              "key": "2021",
              "value": "2,865"
            },
            {
              "key": "2020",
              "value": "3,323"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "strategic_restructuring",
          "page": 201,
          "title": "Group Subsidiaries and Holdings",
          "data": [
            {
              "key": "Company Name",
              "value": "AstraZeneca (Guangzhou) Pharmaceutical Co., Ltd"
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "Room 406-178, No. 1, Yichuang Street, Guangzhou City, China"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Investment Consulting (Wuxi) Co., Ltd"
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "Room 808, 8F, Building 99-2 Linghu Avenue, Xinwu District, Wuxi, Jiangsu, China"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Pharmaceutical (Hangzhou) Co., Ltd"
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "12F & 14F, Building 1, Shuli Plaza, 758 Fei Jia District, Tang Road, Gongshu Hangzhou, Zhejiang Province, China"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Global R&D (China) Co., Ltd"
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "16F, 88 Xizang North Road, Jing'an District, Shanghai, China"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Pharmaceutical (Chengdu) Co., Ltd."
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "10th Floor, Building 11, No. 366, Hemin Street, Chengdu China Pilot Free High-tech Zone, China"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Pharmaceutical (Shanghai) Co., Ltd"
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "BIF, 8F & 9F, 88 Xizang North Road, Jing'an District, Shanghai, China"
            },
            {
              "key": "Company Name",
              "value": "Alexion Pharmaceuticals (Shanghai) Company Limited"
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "Room 702, No 1539 West Nanjing Road, Jing'an District, Shanghai, China"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Colombia S.A.S."
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "Av Carrera 9 No. 101-67 Office 601, Bogota, 110231, Colombia"
            },
            {
              "key": "Company Name",
              "value": "Alexion Pharma Colombia S.A.S."
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "Carrera 9 # 115 - 06 /30 Edificio Tierra Firme Oficina 2904 Bogota D.C., Colombia"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca CAMCAR Costa Rica, S.A."
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "San José, Escazu, Roble Corporate Center, 5to piso, Costa Rica"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca d.0.0."
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "Radnicka cesta 80, 10000 Zagreb, Croatia"
            },
            {
              "key": "Company Name",
              "value": "AstraZeneca Czech Republic, s.r.o."
            },
            {
              "key": "Ownership Interest",
              "value": "100%"
            },
            {
              "key": "Location",
              "value": "U Trezorky 921/2, Prague 5, Czech Republic"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_supply_chain_disruptions": {
      "value": false,
      "elements": []
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 5,
          "title": "Healthcare Mission and Values",
          "data": [
            {
              "key": "Theme",
              "value": "Healthcare, Genetics, and Medical Care"
            },
            {
              "key": "Goals",
              "value": "Create novel therapies and vaccines, help people with chronic diseases, redefine cancer care, pioneer treatments for rare diseases, make patients partners in their treatment."
            },
            {
              "key": "Access",
              "value": "Give more and more of us access to healthcare."
            },
            {
              "key": "Sustainability",
              "value": "Lead the way to a low-carbon world."
            },
            {
              "key": "Film",
              "value": "Science can…"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 13,
          "title": "Environmental and AI Trends in Healthcare",
          "data": [
            {
              "key": "Investment in AI",
              "value": "$5.2 billion"
            },
            {
              "key": "Growth of AI in Drug Discovery",
              "value": "Investment more than doubled in the past five years"
            },
            {
              "key": "Public Trust in Pharma Consistency",
              "value": "31% in 2022, up from 25% in 2018"
            },
            {
              "key": "Projected Human Emissions Increase",
              "value": "14% by 2030 from 2010 levels"
            },
            {
              "key": "Global Temperature Target",
              "value": "Max 1.5°C above pre-industrial levels"
            },
            {
              "key": "GHG Emissions Reduction Target by 2030",
              "value": "45% reduction compared to 2010"
            },
            {
              "key": "Market Pressure on Pharmaceutical Companies",
              "value": "Need to innovate and protect against misinformation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 14,
          "title": "Corporate Purpose and Values Statement",
          "data": [
            {
              "key": "Main Statement",
              "value": "We push the boundaries of science to deliver life-changing medicines."
            },
            {
              "key": "Core Values",
              "value": "We follow the science, We put patients first, We play to win, We do the right thing, We are entrepreneurial."
            },
            {
              "key": "Investment in Science 2022",
              "value": "$9.8bn"
            },
            {
              "key": "Countries with Patent Protection",
              "value": "90"
            },
            {
              "key": "Global Presence",
              "value": ">130 countries where we sell our products"
            },
            {
              "key": "Women in Senior Management",
              "value": ">49.5% of senior middle management roles and above are filled by women"
            },
            {
              "key": "Healthcare Impact",
              "value": "Our main therapy area medicines impact more than 105 million patient lives annually."
            },
            {
              "key": "COVID-19 Vaccine Contribution",
              "value": "More than three billion Vaxzevria/Covishield COVID-19 vaccine doses to more than 180 countries."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "esg_initiative",
          "page": 19,
          "title": "People and Sustainability Strategy Overview",
          "data": [
            {
              "key": "Focus Areas",
              "value": "Continuing to make AstraZeneca a great place to work."
            },
            {
              "key": "Sustainability Goals",
              "value": "Reducing GHG emissions from our global operations by 98% by 2026."
            },
            {
              "key": "Health Equity Initiatives",
              "value": "Advance health equity and health system resilience."
            },
            {
              "key": "Pulse Survey Ratings",
              "value": "86% of employees believe AstraZeneca is a great place to work."
            },
            {
              "key": "Sustainability Scorecard",
              "value": "7 out of 9 performance indicators rated green."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 24,
          "title": "Therapy Area Review",
          "data": [
            {
              "key": "description",
              "value": "Transforming care for billions living with chronic diseases. Our ambition is to intervene early to protect vital organs and achieve remission."
            },
            {
              "key": "image_content",
              "value": "Scientific medical illustration showing cellular components involved in severe asthma disease pathways."
            },
            {
              "key": "caption",
              "value": "Severe asthma disease pathways: the role of epithelial cytokines and eosinophils."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 29,
          "title": "Strategic Report",
          "data": [
            {
              "key": "Product",
              "value": "Fasenra"
            },
            {
              "key": "Approval Countries",
              "value": "75+ countries"
            },
            {
              "key": "Patients Treated",
              "value": "100,000 patients"
            },
            {
              "key": "Approval Year",
              "value": "2022"
            },
            {
              "key": "Tezspire Indications",
              "value": "Severe asthma, bronchial asthma"
            },
            {
              "key": "Tezspire Approval Regions",
              "value": "EU, Japan"
            },
            {
              "key": "Investment",
              "value": "Clinical trials in eosinophilic diseases"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 29,
          "title": "Other Compounds in Development",
          "data": [
            {
              "key": "Compound Name",
              "value": "elarekibep (AZD1402)"
            },
            {
              "key": "Type",
              "value": "Inhaled Anticalin protein"
            },
            {
              "key": "Collaborator",
              "value": "Pieris Pharmaceuticals"
            },
            {
              "key": "Clinical validation target",
              "value": "IL-4Ra"
            },
            {
              "key": "Additional Compounds",
              "value": "AZD8630, atuliflapon (AZD5718)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 29,
          "title": "Immunology Section",
          "data": [
            {
              "key": "Product",
              "value": "Saphnelo"
            },
            {
              "key": "Approval Region",
              "value": "EU"
            },
            {
              "key": "Approval Use",
              "value": "Moderate to severe SLE"
            },
            {
              "key": "Trial Type",
              "value": "Phase III(IRIS trial)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 34,
          "title": "Therapy Area Review Rare Disease",
          "data": [
            {
              "key": "strategy",
              "value": "dedicated to improving the lives of those living with rare diseases"
            },
            {
              "key": "leadership",
              "value": "continuing our leadership in complement therapies"
            },
            {
              "key": "treatment_options",
              "value": "Only 5% of known rare diseases have approved treatment options today"
            },
            {
              "key": "children_affected",
              "value": "50% of the 400 million people affected by a rare disease worldwide are children"
            },
            {
              "key": "Ultomiris_approval",
              "value": "Approved in US, EU, and Japan for treating adults with gMG"
            },
            {
              "key": "clinical_trials_status",
              "value": "Ongoing trials for complement-mediated rare diseases"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 40,
          "title": "Bioethics and Clinical Trial Transparency",
          "data": [
            {
              "key": "Global Standard on Bioethics",
              "value": "Our Global Standard on Bioethics sets out our key principles, which apply to all our scientific activities, including those conducted by third parties on our behalf."
            },
            {
              "key": "Clinical Trials Transparency",
              "value": "We publish information about our clinical research, as well as the registration and results of all our interventional clinical trials and most non-interventional trials."
            },
            {
              "key": "Use of Human Biological Samples",
              "value": "We are committed to minimising the use of human foetal tissue through scientific advancements."
            },
            {
              "key": "hFT Approvals in 2022",
              "value": "There were two new hFT approvals in 2022."
            },
            {
              "key": "Animal Studies in 2022",
              "value": "Animals were used for in-house studies 100,803 times and in contract research studies 55,455 times."
            },
            {
              "key": "3Rs Commitment",
              "value": "We are committed to the 3Rs (Replacement, Reduction and Refinement of animals in research)."
            },
            {
              "key": "Published Anonymised Clinical Document Packages",
              "value": "Published 14 Anonymised Clinical Document Packages."
            },
            {
              "key": "Trial Results in Accessible Language",
              "value": "Published 312 Trial Result Summaries in accessible language and translated these into 63 languages."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 46,
          "title": "People and Sustainability Summary and performance indicators",
          "data": [
            {
              "key": "Contribution to enterprise",
              "value": "Our success depends on recruiting, retaining and developing talented people while operating in a responsible and sustainable way."
            },
            {
              "key": "Performance indicators",
              "value": "BV People – Contribution to the enterprise"
            },
            {
              "key": "Hiring",
              "value": "Hired 22,500 employees (7,700 internal and 14,800 external). 4,720 of these hires were a direct result of our employee referral scheme."
            },
            {
              "key": "Climate Action",
              "value": "Planted over 10.5 million trees in Australia, Indonesia, Ghana, US and UK since 2020 through AZ Forest."
            },
            {
              "key": "Access to Healthcare",
              "value": "Reached 44.6 million people through our flagship Access to Healthcare programmes."
            },
            {
              "key": "Female Representation",
              "value": "49.5% of our senior roles are filled by women."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 48,
          "title": "People and Sustainability",
          "data": [
            {
              "key": "Learning Culture Impact",
              "value": "Internally improved retention rates, promotion rates, and succession planning."
            },
            {
              "key": "Succession Candidates",
              "value": "27% of development experience attendees identified as succession candidates."
            },
            {
              "key": "Resignation Rate",
              "value": "9.2% for attendees of a development programme, compared to 11.6% overall."
            },
            {
              "key": "Promotion Rate",
              "value": "34% for attendees of acceleration-focused programmes."
            },
            {
              "key": "Inclusion and Diversity Workforce Ethnic Minority",
              "value": "35.7% of workforce identify as an ethnic minority in 2022."
            },
            {
              "key": "Women in Workforce",
              "value": "52.9% of global workforce are women."
            },
            {
              "key": "Women on Board",
              "value": "38% of Board are women."
            },
            {
              "key": "Women in Senior Management",
              "value": "36% of SET members are women."
            },
            {
              "key": "Gender Equality Target Year",
              "value": "2025."
            },
            {
              "key": "Trade Union Relationship",
              "value": "45% of countries have a relationship with trade unions."
            },
            {
              "key": "Diversity Recognition",
              "value": "Recognized in Bloomberg Gender Equality Index 2023."
            },
            {
              "key": "Vehicle Collision Rate Reduction",
              "value": "49% reduction in vehicle collision rate."
            },
            {
              "key": "Work-related Injury Rate Reduction",
              "value": "72% reduction in work-related injury rate."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 50,
          "title": "Sustainability Strategy Overview",
          "data": [
            {
              "key": "Overview",
              "value": "Sustainability at AstraZeneca means harnessing the power of science and innovation to build a healthy future."
            },
            {
              "key": "Global Reach",
              "value": "Creating value beyond the impact of medicines by embedding sustainability."
            },
            {
              "key": "Ambition",
              "value": "Commitment to contribute sustainably to people, society, and the planet."
            },
            {
              "key": "Challenges",
              "value": "Addressing climate change, biodiversity loss, and global health equity."
            },
            {
              "key": "Collaboration",
              "value": "Collaboration required to successfully tackle interdependent challenges."
            },
            {
              "key": "Recognition",
              "value": "Third overall in Access to Medicine Index, Bloomberg Gender-Equality Index, CDP Double A List."
            },
            {
              "key": "Governance",
              "value": "Sustainability strategy developed by the SET and approved by the Board."
            },
            {
              "key": "Commitments",
              "value": "FTSE4Good Index, Dow Jones Sustainability Index, and Financial Times European Climate Leaders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 51,
          "title": "Access to healthcare",
          "data": [
            {
              "key": "goal",
              "value": "Secure a future where all people have access to affordable, sustainable, and innovative healthcare"
            },
            {
              "key": "achievements_2022",
              "value": "More than 10,600 healthcare workers trained via Healthy Heart Africa"
            },
            {
              "key": "achievements_2022_2",
              "value": "More than 44.6 million people reached through Access to Healthcare programmes"
            },
            {
              "key": "achievements_2022_3",
              "value": "Conducted more than 32 million screenings for elevated blood pressure"
            },
            {
              "key": "reach_young_health",
              "value": "More than 9 million young people reached through prevention and education programmes in more than 39 countries"
            },
            {
              "key": "sustainable_access",
              "value": "More than 12.8 million people reached through patient access programmes"
            },
            {
              "key": "equitable_access",
              "value": "Working to remove barriers to healthcare"
            },
            {
              "key": "diversity_in_clinical_trials",
              "value": "Committed to increasing diversity in clinical trial participants"
            },
            {
              "key": "rare_diseases",
              "value": "Support for individuals with rare diseases and access to therapies"
            },
            {
              "key": "acf_initiatives",
              "value": "ACF provides philanthropic funding through RARE BELONGING and Local Needs Grants"
            },
            {
              "key": "covid_vaccine_2022",
              "value": "Supplied approximately 0.5 billion vaccine doses to more than 80 countries"
            },
            {
              "key": "digital_solutions_initiative",
              "value": "Joined EDISON Alliance to improve access to digital health solutions by 2025"
            },
            {
              "key": "healthy_heart_africa_goal",
              "value": "Aim to reduce hypertension and reach 10 million people with elevated blood pressure across Africa by 2025"
            },
            {
              "key": "young_health_programme_goal",
              "value": "Help young people make informed health choices and counter non-communicable diseases."
            },
            {
              "key": "community_investment",
              "value": "Invested $108 million to more than 1,000 non-profit organisations across 64 countries."
            },
            {
              "key": "product_donations_2022",
              "value": "Gave $12.1 million in product donations for disaster, humanitarian relief and public health needs."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "esg_initiative",
          "page": 52,
          "title": "Environmental Sustainability Initiatives",
          "data": [
            {
              "key": "Investment in Environmental Efficiency Innovations",
              "value": "Approximately $150 million since 2015."
            },
            {
              "key": "2022 Capital Expenditures on Projects",
              "value": "$26.6 million."
            },
            {
              "key": "GHG Emissions Reduction since 2015",
              "value": "59.3% reduction in Scope 1 and 2."
            },
            {
              "key": "Energy Consumption Reduction",
              "value": "14.4% reduction since 2015."
            },
            {
              "key": "Trees Planted since 2020",
              "value": "Over 10.5 million."
            },
            {
              "key": "Water Usage Reduction since 2015",
              "value": "18.7% reduction."
            },
            {
              "key": "Waste Reduction since 2015",
              "value": "18.6% reduction."
            },
            {
              "key": "Sustainable Sourcing of Paper-based Packaging materials",
              "value": "97.5%."
            },
            {
              "key": "Net-Zero Healthcare Goals",
              "value": "98% GHG emissions reduction by 2026."
            },
            {
              "key": "Long-term Carbon Negative Goals",
              "value": "Achieve carbon negative by 2030."
            },
            {
              "key": "Nature-based Solutions through AZ Forest",
              "value": "Plant over 50 million trees by 2025."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 53,
          "title": "Ethics and Transparency Commitment",
          "data": [
            {
              "key": "Positive Societal Impact",
              "value": "We seek to create positive societal impact and embed ethical behaviour in all our business activities, markets and value chain."
            },
            {
              "key": "Achievements in 2022 - Gender Representation",
              "value": "49.5% of our senior roles are filled by women."
            },
            {
              "key": "Achievements in 2022 - Employee Survey",
              "value": "83% of employee survey respondents feel they can speak their mind at work."
            },
            {
              "key": "Code of Ethics Overview",
              "value": "Embodies Values, expected behaviours, and policies applicable to all employees."
            },
            {
              "key": "Mandatory Training",
              "value": "100% of active employees completed annual training on the Code."
            },
            {
              "key": "Reporting Violations",
              "value": "Employees can report possible violations anonymously via AZ Ethics."
            },
            {
              "key": "Reports in 2022",
              "value": "490 reports of alleged compliance breaches or ethical concerns were made."
            },
            {
              "key": "Non-Financial Information Statement",
              "value": "Includes information on anti-bribery, Code of Ethics, human rights, etc."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 54,
          "title": "EU Taxonomy Disclosure BV Assessment",
          "data": [
            {
              "key": "Taxonomy-eligible Revenue KPI",
              "value": "0% (2021: 0%)"
            },
            {
              "key": "Taxonomy-eligible Capex KPI",
              "value": "14% (2021: 2%)"
            },
            {
              "key": "Taxonomy-eligible Opex KPI",
              "value": "2% (2021: 2%)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "esg_initiative",
          "page": 55,
          "title": "Task Force on Climate-related Financial Disclosures Summary Statement",
          "data": [
            {
              "key": "Commitment",
              "value": "We support the Task Force on Climate-related Financial Disclosures (TCFD) framework, and our disclosures are consistent with the four TCFD recommendations and the 11 recommended disclosures."
            },
            {
              "key": "Application of TCFD",
              "value": "We have applied the TCFD framework annually since 2020 and continued to apply it to describe activities conducted in 2022."
            },
            {
              "key": "Risk Assessment",
              "value": "A broad physical climate risk screening of our sites was conducted to understand exposure risk to extreme weather events."
            },
            {
              "key": "Future Strategy",
              "value": "Part of our $1 billion Ambition Zero Carbon strategy to accelerate the decarbonization of our business."
            },
            {
              "key": "Annual Investment",
              "value": "Approximately $25 million annual investment in natural resource reduction programme."
            },
            {
              "key": "Risk Management",
              "value": "Identified risks are addressed in local business continuity plans or by technical mitigations integrated into site master plans."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 56,
          "title": "TCFD Framework and Recommended Disclosures - AstraZeneca Current Status",
          "data": [
            {
              "key": "section",
              "value": "Governance"
            },
            {
              "key": "disclosure",
              "value": "Describe the Board's oversight of climate-related risks and opportunities."
            },
            {
              "key": "status",
              "value": "Our Board Sustainability Committee was established to monitor the execution of our sustainability strategy."
            },
            {
              "key": "reference",
              "value": "@ page2 @ pages 48, 95, and 98 @ pages"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 56,
          "title": "TCFD Framework and Recommended Disclosures - AstraZeneca Current Status",
          "data": [
            {
              "key": "section",
              "value": "Governance"
            },
            {
              "key": "disclosure",
              "value": "Describe management's role in assessing and managing climate-related risks and opportunities."
            },
            {
              "key": "status",
              "value": "Our CEO is responsible to the Board for the development and performance of our climate strategy and related risks and opportunities, as part of his overall responsibilities. The TCFD Steering Group coordinates management of physical and transitional climate risks and opportunities."
            },
            {
              "key": "reference",
              "value": "@ page2 page 48 @ pages 8 and 19"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 56,
          "title": "TCFD Framework and Recommended Disclosures - AstraZeneca Current Status",
          "data": [
            {
              "key": "section",
              "value": "Strategy"
            },
            {
              "key": "disclosure",
              "value": "Describe the climate-related risks and opportunities the organisation has identified over the short, medium, and long term."
            },
            {
              "key": "status",
              "value": "Physical risks from climate change are primarily disruption or delays to manufacturing or distribution, and/or impairment due to failure of cold chain logistics, and increased liability insurance premiums and reputational damage. Transition risks and opportunities are primarily regulatory and market changes, and/or pressure and ability to reduce product carbon footprints and decarbonise our value chain."
            },
            {
              "key": "reference",
              "value": "@ pages 4 to 10 @ pages 19 to 22"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 56,
          "title": "TCFD Framework and Recommended Disclosures - AstraZeneca Current Status",
          "data": [
            {
              "key": "section",
              "value": "Strategy"
            },
            {
              "key": "disclosure",
              "value": "Describe the impact of climate-related risks and opportunities on the organisation's businesses, strategy, and financial planning."
            },
            {
              "key": "status",
              "value": "We are taking enterprise-wide action to reduce our GHG emissions from our global operations and fleet by 98% by 2026 (from a 2015 baseline) with a $1 billion budget. We aim to halve our entire value chain footprint (Scope 3) by 2030, to achieve a 90% reduction by 2045 (from a 2019 baseline) and reach our net-zero Science-based targets (SBTs)."
            },
            {
              "key": "reference",
              "value": "@ pages 4 to 10 @ pages 19 to 24"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 56,
          "title": "TCFD Framework and Recommended Disclosures - AstraZeneca Current Status",
          "data": [
            {
              "key": "section",
              "value": "Risk management"
            },
            {
              "key": "disclosure",
              "value": "Describe the organisation's processes for identifying and assessing climate-related risks."
            },
            {
              "key": "status",
              "value": "Climate assessments integrated into overall enterprise risk management, inform the enterprise of specific risks and opportunities posed by climate change and/or transition to a low-carbon economy."
            },
            {
              "key": "reference",
              "value": "@ pages 1 and2 pages 56, 57, and 98 @ pages 19 to 26"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 57,
          "title": "Climate-related Disclosures",
          "data": [
            {
              "key": "Summary",
              "value": "This table outlines AstraZeneca's climate-related disclosures and reporting practices. It details three main areas: metrics for assessing climate-related risks, GHG emissions reporting across different scopes, and target management. The company follows World Resources Institute GHG Protocol guidance for reporting and maintains a Sustainability Data Summary on their website. Their reporting is verified by Bureau Veritas and includes comprehensive coverage of decarbonisation efforts and associated risks and opportunities."
            },
            {
              "key": "Recommended disclosures",
              "value": "targets Disclose the metrics used by the organisation to assess climate-related risks and opportunities in line with its strategy and risk management process."
            },
            {
              "key": "Current status",
              "value": "GHG footprint and progress towards short- and long-term targets are reported in line with World Resources Institute GHG Protocol guidance and disclosed separately in our Sustainability Data Summary www.astrazeneca.com/sustainability/resources.html. Data in the TCFD report is assured by Bureau Veritas."
            },
            {
              "key": "Key developments",
              "value": "@ page 11 @ pages 50 and 218 @ pages 20 and 21 @ pages 5 to 9."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 78,
          "title": "Section 172(1) statement",
          "data": [
            {
              "key": "Board Responsibility",
              "value": "Promote the success of the Company for the shareholders and wider stakeholders."
            },
            {
              "key": "Stakeholder Engagement",
              "value": "Engaged with key stakeholders to understand significant issues."
            },
            {
              "key": "Commitment to Workforce",
              "value": "Committed to being a great place to work for the global workforce."
            },
            {
              "key": "Code of Ethics",
              "value": "Based on Values, expected behaviours and key policy principles."
            },
            {
              "key": "Patient Focus",
              "value": "Recognises patients as people first and puts them at the heart of what we do."
            },
            {
              "key": "Environmental Considerations",
              "value": "Consideration of operations on the environment and impact on communities and suppliers."
            },
            {
              "key": "Corporate Governance",
              "value": "Details on Board operations and matters considered are in the Corporate Governance Report."
            },
            {
              "key": "Principal Decisions",
              "value": "Material or strategic decisions of the Group, significant to stakeholders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 89,
          "title": "Stakeholder Engagement and Strategic Partnerships",
          "data": [
            {
              "key": "Healthcare professionals role",
              "value": "Interface with patients, providing insights into clinical trials, prescribing, and distribution of medicines."
            },
            {
              "key": "Collaboration significance",
              "value": "Partnering accelerates innovative science to deliver life-changing medicines."
            },
            {
              "key": "Stakeholder engagement",
              "value": "Regular dialogue with investors to communicate strategy and performance."
            },
            {
              "key": "Collaboration details",
              "value": "In 2022, AstraZeneca had more than 2,000 active collaborations to stimulate innovation."
            },
            {
              "key": "Access to medicines",
              "value": "Focus on improving access to high-quality healthcare systems."
            },
            {
              "key": "Challenges for stakeholders",
              "value": "Addressing unmet medical needs and ensuring sustainable access."
            },
            {
              "key": "Innovation focus",
              "value": "Advancing innovative technology and improving patient access."
            },
            {
              "key": "Transparency in research",
              "value": "Ensuring trust and transparency in relationships with stakeholders."
            },
            {
              "key": "Geopolitical risks",
              "value": "Exposure to geopolitical and macro-economic risks impacting business."
            },
            {
              "key": "Environmental, Social, and Governance (ESG) matters",
              "value": "Central to stakeholder engagement and corporate strategy."
            },
            {
              "key": "Patient safety and efficacy",
              "value": "Ensuring the safety and efficacy of medicines."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 90,
          "title": "Corporate Governance Report - Interaction with stakeholders",
          "data": [
            {
              "key": "Stakeholder Groups",
              "value": "Community, Governments, Media, Employees, Health authorities, Multilateral and NGOs, Suppliers and third-party providers"
            },
            {
              "key": "Community Investment",
              "value": "Positive impact on people and communities through investment"
            },
            {
              "key": "Employee Development",
              "value": "Talent acquisition and development is critical to achieving ambitions"
            },
            {
              "key": "Health Authority Engagement",
              "value": "Engagement with regulators globally for product management"
            },
            {
              "key": "Partnerships",
              "value": "Working with multilateral organizations to address health issues"
            },
            {
              "key": "COVID-19 Response",
              "value": "218 million doses of Vaxzevria delivered via COVAX in 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 97,
          "title": "Sustainability Committee Report",
          "data": [
            {
              "key": "Committee Members",
              "value": "Nazneen Rahman (Chair), Sheri McCoy, Andreas Rummelt, Marcus Wallenberg"
            },
            {
              "key": "Committee Establishment Date",
              "value": "October 2021"
            },
            {
              "key": "Focus Areas",
              "value": "Monitor the execution of AstraZeneca’s sustainability strategy, oversee communication of sustainability activities with stakeholders, provide input to the Board on sustainability matters."
            },
            {
              "key": "Sustainability Initiatives",
              "value": "Building sustainability capabilities within Operations, embedding sustainability into the product life-cycle, managing ESG risks particularly climate change."
            },
            {
              "key": "Activities During 2022",
              "value": "The Committee met twice formally, deep dive session for full Board on Ambition Zero Carbon targets, individual meetings with employees on sustainability workstreams."
            },
            {
              "key": "Site Visit",
              "value": "Visited AstraZeneca’s manufacturing site in Macclesfield, UK for understanding sustainability initiatives."
            },
            {
              "key": "Engagement with Investors",
              "value": "Oversaw engagement on sustainability-related matters and reviewed sustainability reporting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 121,
          "title": "Long-term incentives continued",
          "data": [
            {
              "key": "Ambition Zero Carbon (10% of award)",
              "value": "This measure reflects the importance of eliminating greenhouse gas (GHG) emissions from our Scope 1 and Scope 2 operations through 2025. Reductions are measured against our 2015 baseline, calculated in line with the World Resources Institute/World Business Council for Sustainable Development GHG Protocol methodology."
            },
            {
              "key": "CO2 Emissions Threshold Payout Structure",
              "value": "This table appears to be a payout or compensation structure based on CO2 emission thresholds (measured in ktCO2e). It shows a tiered system where lower emissions result in higher payout rates. The maximum threshold is 207 ktCO2e (20% payout), with intermediate pro-rata levels, and the maximum payout of 100% is achieved at 155 ktCO2e and below."
            },
            {
              "key": "PSP performance measures for 2023 grant overall summary",
              "value": "This table outlines Performance Share Plan (PSP) metrics and their weightings. The main performance measures include Science and Innovation (30%), Growth and Therapy Area Leadership (20%), Cash flow (20%), Relative TSR (20%), and Ambition Zero Carbon (10%). Each measure has specific vesting thresholds at 20% and 100% levels. Notable targets include cash flow targets of $22.0bn to $31.0bn and carbon reduction targets from 142 to 91 ktCO2e."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 220,
          "title": "Sustainability supplementary information",
          "data": [
            {
              "key": "Independent assurance provider",
              "value": "Bureau Veritas"
            },
            {
              "key": "Scope 1 emissions (2022)",
              "value": "245,117"
            },
            {
              "key": "Scope 2 emissions (Market-based, 2022)",
              "value": "18,491"
            },
            {
              "key": "Scope 2 emissions (Location-based, 2022)",
              "value": "195,126"
            },
            {
              "key": "Scope 3 Total emissions (2022)",
              "value": "6,388,133"
            },
            {
              "key": "Total energy consumption (2022)",
              "value": "1,636,031 MWh"
            },
            {
              "key": "Emission intensity (2022)",
              "value": "5.94"
            },
            {
              "key": "Scope 3 intensity measurement (2022)",
              "value": "144.04"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 227,
          "title": "Environmental Initiatives in Annual Report",
          "data": [
            {
              "key": "Company",
              "value": "Superunion"
            },
            {
              "key": "Location",
              "value": "London"
            },
            {
              "key": "Paper Type",
              "value": "Revive Silk 100"
            },
            {
              "key": "FSC Certification",
              "value": "FSC® Recycled certified fibre"
            },
            {
              "key": "Environmental Technology",
              "value": "pureprint® environmental printing technology"
            },
            {
              "key": "Carbon Neutral Status",
              "value": "CarbonNeutral® company"
            },
            {
              "key": "ISO Certification",
              "value": "ISO14001"
            },
            {
              "key": "Certifications",
              "value": "FSC® chain-of-custody certified"
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 250,
    "EUR": 44,
    "GBP": 1,
    "AUD": 10,
    "CAD": 12,
    "INR": 1
  },
  "sha1": "5bb5f71d1457f3272adab97d64a79c300da75cea"
}